WO2008083354A1 - N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors - Google Patents

N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors Download PDF

Info

Publication number
WO2008083354A1
WO2008083354A1 PCT/US2007/089153 US2007089153W WO2008083354A1 WO 2008083354 A1 WO2008083354 A1 WO 2008083354A1 US 2007089153 W US2007089153 W US 2007089153W WO 2008083354 A1 WO2008083354 A1 WO 2008083354A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
group
heteroaryl
heterocyclyl
diamine
Prior art date
Application number
PCT/US2007/089153
Other languages
French (fr)
Inventor
Dane Goff
Jing Zhang
Rajinder Singh
Sacha Holland
Jiaxin Yu
Thilo Heckrodt
Pingyu Ding
Joane Litvak
Original Assignee
Rigel Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rigel Pharmaceuticals, Inc. filed Critical Rigel Pharmaceuticals, Inc.
Priority to AU2007342005A priority Critical patent/AU2007342005A1/en
Priority to EP07866122.0A priority patent/EP2074115B1/en
Priority to CA2710046A priority patent/CA2710046C/en
Priority to ES07866122.0T priority patent/ES2672172T3/en
Priority to JP2009544313A priority patent/JP5567837B2/en
Priority to CN2007800489092A priority patent/CN101622248B/en
Publication of WO2008083354A1 publication Critical patent/WO2008083354A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Definitions

  • This invention is directed to ⁇ -heteroaryl substituted triazoles and ⁇ -heteroaryl substituted triazoles and pharmaceutical compositions thereof which are useful as inhibitors of the receptor protein tyrosine kinase known as AxI.
  • This invention is also directed to methods of using the compounds and compositions in treating diseases and conditions associated with AxI activity, particularly in treating diseases and conditions associated with angiogenesis and/or cell proliferation.
  • AxI (also known as UFO, ARK, and Tyro7; nucleotide accession numbers NM_021913 and NM_001699; protein accession numbers NP_068713 and NP_001690) is a receptor protein tyrosine kinase (RTK) that comprises a C-terminal extracellular ligand-binding domain and N-terminal cytoplasmic region containing the catalytic domain.
  • RTK receptor protein tyrosine kinase
  • the extracellular domain of AxI has a unique structure that juxtaposes immunoglobulin and fibronectin Type III repeats and is reminiscent of the structure of neural cell adhesion molecules.
  • Gas6 growth arrest specific-6
  • Protein S Protein S.
  • the AxI extracellular domain has been shown to undergo homophilic interactions that mediate cell aggregation, suggesting that one important function of AxI may be to mediate cell-cell adhesion.
  • AxI is predominantly expressed in the vasculature in both endothelial cells (EC's) and vascular smooth muscle cells (VSMCs) and in cells of the myeloid lineage and is also detected in breast epithelial cells, chondrocytes, Sertoli cells and neurons.
  • EC's endothelial cells
  • VSMCs vascular smooth muscle cells
  • Several functions including protection from apoptosis induced by serum starvation, TNF- ⁇ or the viral protein E1A, as well as migration and cell differentiation have been ascribed to AxI signaling in cell culture.
  • AxI-/- mice exhibit no overt developmental phenotype and the physiological function of AxI in vivo is not clearly established in the literature.
  • Angiogenesis (the formation of new blood vessels) is limited to functions such as wound healing and the female reproductive cycle in healthy adults. This physiological process has been co-opted by tumors, thus securing an adequate blood supply that feeds tumor growth and facilitates metastasis.
  • Deregulated angiogenesis also a feature of many other diseases (for example, psoriasis, rheumatoid arthritis, endometriosis and blindness due to age-related macular degeneration (AMD), retinopathy of prematurity and diabetes) and often contributes to the progression or pathology of the condition.
  • AxI and/or its ligand has also been reported in a wide variety of solid tumor types including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma, and uveal melanoma as well as in myeloid leukemia's. Furthermore, it possesses transforming activity in NIH3T3 and 32D cells. It has been demonstrated that loss of AxI expression in tumor cells blocks the growth of solid human neoplasms in an in vivo MDA-MB-231 breast carcinoma xenograft model. Taken together, these data suggest AxI signaling can independently regulate EC angiogenesis and tumor growth and thus represents a novel target class for tumor therapeutic development.
  • AxI and Gas6 proteins are upregulated in a variety of other disease states including endometriosis, vascular injury and kidney disease and AxI signaling is functionally implicated in the latter two indications.
  • AxI - Gas6 signaling amplifies platelet responses and is implicated in thrombus formation.
  • AxI may thus potentially represent a therapeutic target for a number of diverse pathological conditions including solid tumors, including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma and uveal melanoma; liquid tumors, including but not limited to, leukemias (particularly myeloid leukemias) and lymphomas; endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), rheumatoid arthritis; osteoporosis, osteoarthritis and cataracts.
  • solid tumors including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma and uveal mel
  • This invention is directed to certain ⁇ -heteroaryl substituted triazoles and ⁇ -heteroaryl substituted triazoles which are useful as AxI inhibitors, methods of using such compounds in treating diseases and conditions associated with AxI activity and pharmaceutical compositions comprising such compounds.
  • this invention is directed to a compound of formula (I):
  • R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -O-R 10 -OR 8 , -R 9 -O-R 10 -O-R 10 -OR 8 , -R 9 -O-R 10 -CN, -R 9 -O-R 10 -C(O)OR 8 , -R 9 -O-R 10 -C(O)OR 8 , -R
  • R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alky
  • each R 13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
  • this invention is directed to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
  • this invention is directed to methods of treating a disease or condition associated with AxI activity in a mammal, wherein the methods comprise administering to the mammal a therapeutically effective amount of a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
  • this invention provides assays to determine a compound of the invention effectiveness in inhibiting AxI activity in a cell-based assay.
  • Carboxy refers to the -C(O)OH radical.
  • Cyano refers to the -CN radical.
  • Niro refers to the -NO 2 radical.
  • Oxa refers to the -O- radical.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and which is attached to the rest of the molecule by a single bond, for example, methyl, ethyl, /7-propyl, 1-methylethyl (/so-propyl), n-butyl, n-pentyl, 1 ,1-dimethylethyl (f-butyl), 3-methylhexyl, 2-methylhexyl, and the like.
  • an alkyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 J 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 J 2 , -N(R 20 )C(O)OR 20 ,
  • each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
  • Alkenyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like.
  • an alkenyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 ) 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 J 2 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)R 20 , -N(R 20 )S(O) t R 20 (where t is 1 or 2), -S(O) 1 OR 20 (where t is 1 or 2),
  • each R 20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
  • Alkynyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one triple bond, optionally containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 ) 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)R 20 , -N(R 20 )S(O),R 20 (where t is 1 or 2), -S(O) 1 OR 20 (where t is 1 or 2), -S(O) p R 20 (where p is O, 1 or 2), and -S(O) t N(R 20 ) 2 (where t is 1 or 2) where each R 20 is independently hydrogen, alkyl,
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain.
  • an alkylene chain may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 ) 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)R 20 , -N(R 20 )S(O) t R 20 (where t is 1 or 2), -S(O) 1 OR 20 (where t is 1 or 2), -S(O) P R 20 (where p is O, 1 or 2), and -S(O) t N(R 20 ) 2 (
  • alkenylene or “alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, for example, ethenylene, propenylene, ⁇ -butenylene, and the like.
  • the alkenylene chain is attached to the rest of the molecule through a double bond or a single bond and to the radical group through a double bond or a single bond.
  • the points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkenylene chain may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 ) 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)R 20 , -N(R 20 )S(O) t R 20 (where t is 1 or 2), -S(O) 1 OR 20 (where t is 1 or 2), -S(O) P R 20 (where p is O, 1 or 2), and -S(O) t N(R 20 ) 2
  • Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one triple bond and having from two to twelve carbon atoms, for example, propynylene, n-butynylene, and the like.
  • the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond.
  • the points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain.
  • an alkynylene chain may be optionally substituted by one or more of the following substituents: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR 20 , -OC(O)-R 20 , -N(R 20 ) 2 , -C(O)R 20 , -C(O)OR 20 , -C(O)N(R 20 ) 2 , -N(R 20 )C(O)OR 20 , -N(R 20 )C(O)R 20 , -N(R 20 )S(O) t R 20 (where t is 1 or 2), -S(O) 1 OR 20 (where t is 1 or 2), -S(O) P R 20 (where p is O, 1 or
  • Alkoxy refers to a radical of the formula -OR 3 where R a is an alkyl radical as defined above containing one to twelve carbon atoms. The alkyl part of the alkoxy radical may be optionally substituted as defined above for an alkyl radical.
  • Alkoxyalkyl refers to a radical of the formula -R b -O-R a where R a is an alkyl radical as defined above and R b is an alkylene chain as defined above. The oxygen atom may be bonded to any carbon in the alkyl radical or the alkylene chain.
  • the alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkyl radical and the alkylene chain part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkylene chain.
  • Aryl refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 14 carbon atoms and at least one aromatic ring.
  • the aryl radical may be a monocyclic, bicyclic, or tricyclic ring system, which may included spiro ring systems.
  • An aryl radical is commonly, but not necessarily, attached to the parent molecule via an aromatic ring of the aryl radical.
  • an "aryl" radical as defined herein can not contain rings having more than 7 members and cannot contain rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms ⁇ i.e., a bridged ring system).
  • Aryl radicals include, but are not limited to, aryl radicals derived from acenaphthylene, anthracene, azulene, benzene, 6,7,8,9-tetrahydro-5H-benzo[7]annulene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, and phenanthrene.
  • optionally substituted aryl is meant to include aryl radicals optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted
  • Alkyl refers to a radical of the formula -R b -R 0 where R b is an alkylene chain as defined above and R c is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like.
  • the alkylene chain part of the aralkyl radical may be optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical may be optionally substituted as described above for an aryl.
  • “Aralkenyl” refers to a radical of the formula -R d -R c where R d is an alkenylene chain as defined above and R 0 is one or more aryl radicals as defined above.
  • the aryl part of the aralkenyl radical may be optionally substituted as described above for an aryl.
  • the alkenylene chain part of the aralkenyl radical may be optionally substituted as defined above for an alkenylene group.
  • “Aralkynyl” refers to a radical of the formula -R e R c where R e is an alkynylene chain as defined above and R c is one or more aryl radicals as defined above.
  • the aryl part of the aralkynyl radical may be optionally substituted as described above for an aryl.
  • the alkynylene chain part of the aralkynyl radical may be optionally substituted as defined above for an alkynylene chain.
  • “Aryloxy” refers to a radical of the formula -OR C where R 0 is an aryl as defined above. The aryl part of the aryloxy radical may be optionally substituted as defined above.
  • Alkyloxy refers to a radical of the formula -OR f where R f is an aralkyl radical as defined above.
  • R f is an aralkyl radical as defined above.
  • the aralkyl part of the aralkyloxy radical may be optionally substituted as defined above.
  • Cycloalkyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, more preferably from five to seven carbons and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
  • Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • Polycyclic radicals include, for example, C 10 radicals such as adamantanyl and decalinyl, and C 7 radicals such as norbornanyl, norbornenyl, as well as substituted polycyclic radicals for example substituted C 7 radicals such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • optionally substituted cycloalkyl is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocycly
  • Cycloalkylalkyl refers to a radical of the formula -R b R g where R b is an alkylene chain as defined above and R 9 is a cycloalkyl radical as defined above. The alkylene chain and the cycloalkyl radical may be optionally substituted as defined above.
  • Cycloalkylalkenyl refers to a radical of the formula -R d R g where R d is an alkenylene chain as defined above and R 9 is a cycloalkyl radical as defined above. The alkenylene chain and the cycloalkyl radical may be optionally substituted as defined above.
  • Cycloalkylalkynyl refers to a radical of the formula -R e R g where R e is an alkynylene radical as defined above and R 9 is a cycloalkyl radical as defined above.
  • the alkynylene chain and the cycloalkyl radical may be optionally substituted as defined above.
  • Halo refers to bromo, chloro, fluoro or iodo.
  • Haloalkyl refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, i-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like.
  • the alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl radical.
  • Haloalkoxy refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, for example, trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, and the like.
  • the alkoxy part of the haloalkoxy radical may be optionally substituted as defined above for an alkoxy radical.
  • Haloalkenyl refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.
  • the alkenyl part of the haloalkyl radical may be optionally substituted as defined above for an alkenyl radical.
  • Haloalkynyl refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above.
  • the alkynyl part of the haloalkyl radical may be optionally substituted as defined above for an alkynyl radical.
  • Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical which comprises one to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur.
  • the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include spiro, fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated.
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, 1 ,4-diazepanyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, octahydro-1 H-pyrrolo[3,2-c]pyridinyl, octahydro-1 /-/-pyrrolo[2,3- ⁇ yridinyl, octahydro-1 H-pyrrolo[2,3-ib]pyridinyl, octahydro-1 H-pyrrolo[3,4-ib]pyridinyl, octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1 H-pyrido
  • optionally substituted heterocyclyl is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalky
  • ⁇ /-heterocyclyl refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical.
  • An /V-heterocyclyl radical may be optionally substituted as described above for heterocyclyl radicals.
  • Heterocyclylalkyl refers to a radical of the formula -R b R h where R b is an alkylene chain as defined above and R h is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heterocyclylalkyl radical may be optionally substituted as defined above for an alkyene chain.
  • the heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for a heterocyclyl radical.
  • Heterocyclylalkenyl refers to a radical of the formula -R d R h where R d is an alkenylene chain as defined above and R h is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkenylene chain at the nitrogen atom.
  • the alkenylene chain of the heterocyclylalkenyl radical may be optionally substituted as defined above for an alkenylene chain.
  • the heterocyclyl part of the heterocyclylalkenyl radical may be optionally substituted as defined above for a heterocyclyl radical.
  • Heterocyclylalkynyl refers to a radical of the formula -R e R h where R e is an alkynylene chain as defined above and R h is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkynyl radical at the nitrogen atom.
  • the alkynylene chain part of the heterocyclylalkynyl radical may be optionally substituted as defined above for an alkynylene chain.
  • the heterocyclyl part of the heterocyclylalkynyl radical may be optionally substituted as defined above for a heterocyclyl radical.
  • Heteroaryl refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring.
  • a heteroaryl radical is commonly, but not necessarily, attached to the parent molecule via an aromatic ring of the heteroaryl radical.
  • the heteroaryl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.
  • the aromatic ring of the heteroaryl radical need not contain a heteroatom, as long as one ring of the heteroaryl radical contains a heteroatom.
  • 1 ,2,3,4-tetrahydroisoquinolin-7-yl is considered a "heteroaryl" for the purposes of this invention.
  • a "heteroaryl" radical as defined herein can not contain rings having more than 7 members or rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms ⁇ i.e., a bridged ring system).
  • heteroaryl radicals include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1 ,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[ ⁇ ][1 ,4]dioxepinyl, benzo[b][1 ,4]oxazinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[
  • optionally substituted heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkyl,
  • ⁇ /-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
  • An ⁇ /-heteroaryl radical may be optionally substituted as described above for heteroaryl radicals.
  • Heteroarylalkyl refers to a radical of the formula -R b R, where R b is an alkylene chain as defined above and R 1 is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for a heteroaryl.
  • heteroarylalkenyl refers to a radical of the formula -R d R, where R d is an alkenylene chain as defined above and R, is a heteroaryl radical as defined above.
  • the heteroaryl part of the heteroarylalkenyl radical may be optionally substituted as defined above for a heteroaryl.
  • the alkenylene chain part of the heteroarylalkenyl radical may be optionally substituted as defined above for an alkenylene chain.
  • Heteroarylalkynyl refers to a radical of the formula -R e R ⁇ where R e is an alkynylene chain as defined above and R, is a heteroaryl radical as defined above.
  • the heteroaryl part of the heteroarylalkynyl radical may be optionally substituted as defined above for a heteroaryl.
  • the alkynylene chain part of the heteroarylalkynyl radical may be optionally substituted as defined above for an alkynylene chain.
  • “Hydroxyalkyl” refers to an alkyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
  • Hydroalkenyl refers to an alkenyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
  • Hydroalkenyl refers to an alkynyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
  • C 7 -C 12 alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms
  • C 4 -Ci 2 Cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms.
  • the total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described.
  • Solid compound and “stable structure” are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
  • “Mammal” includes humans and domestic animals, such as cats, dogs, swine, cattle, sheep, goats, horses, rabbits, and the like. Preferably, for purposes of this invention, the mammal is a human.
  • Optional or “optionally” means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not.
  • optionally substituted aryl means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution.
  • substitutents on the functional group are also “optionally substituted” and so on, for the purposes of this invention, such iterations are limited to five, preferably such iterations are limited to two.
  • “Pharmaceutically acceptable excipient” includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
  • “Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, ethane-1 ,2-disulfonic acid
  • “Pharmaceutically acceptable base addition salt” refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, ⁇ /-ethylpiperidine, polyamine resins and the like.
  • Particularly preferred organic bases are isopropylamine
  • a “pharmaceutical composition” refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, for example, humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor.
  • “Therapeutically effective amount” refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a disease or condition of interest in the mammal, preferably a human.
  • a compound of the invention which constitutes a "therapeutically effective amount” will vary depending on the compound, the disease or condition and its severity, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
  • Treating covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
  • the terms “disease” and “condition” may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
  • the compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids.
  • the present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms.
  • Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as HPLC using a chiral column.
  • the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
  • stereoisomer refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable.
  • the present invention contemplates various stereoisomers and mixtures thereof and includes “enantiomers”, which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
  • a “tautomer” refers to a proton shift from one atom of a molecule to another atom of the same molecule.
  • the present invention includes tautomers of any said compounds.
  • “Atropisomers” are stereoisomers resulting from hindered rotation about single bonds where the barrier to rotation is high enough to allow for the isolation of the conformers (Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; Wiley & Sons: New York, 1994; Chapter 14). Atropisomerism is significant because it introduces an element of chirality in the absence of stereogenic atoms.
  • the invention is meant to encompass atropisomers, for example in cases of limited rotation around the single bonds emanating from the core triazole structure, atropisomers are also possible and are also specifically included in the compounds and/or prodrugs of the invention.
  • one embodiment is wherein the compound of formula (I) is a compound of formula (Ia):
  • R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -O-R 10 -
  • R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optional
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl
  • R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen,
  • R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -O-R 10 -OR 8 , -R 9 -O-R 10 -O-R 10 -OR 8 , -R 9 -O-R 10 -CN, -R 9 -O-R 10 -C(O)OR 8 , -R 9 -O-R 10 -C(O)OR 8 , -R
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN,
  • R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[£>][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
  • each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain
  • R 1 , R 4 and R 5 are each hydrogen;
  • R 2 is 2,3-dihydrobenzo[ ⁇ b][1 ,4]dioxinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -N(R 6 )R 7 , -R 9 -N(R 6 )C(O)OR 8 , -R 9 -N(R 6 )C(O)R 8 , -R 9 -N(R 6 )S(O)
  • R 3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -C(O)OR 12 , -R 13 -C(O)N(R 12 ) 2 , -R 13 -N(R 12 )C(O)OR 12 , -R
  • each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is ⁇ / 3 -(2,3-dihydrobenzo[jb][1 ,4]dioxin-6-yl)-1-phenyl-1H- 1 ,2,4-triazole-3,5-diamine.
  • R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen,
  • R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[jb][1 ,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl,
  • R 3 is heteroaryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclyl, optionally substituted heterocycl
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -
  • R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[ ⁇ ][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
  • R 1 , R 4 and R 5 are each hydrogen
  • R 2 is selected from the group consisting of benzo[t»]thiophenyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, 2,3-dihydrobenzo[ ⁇ ][1 ,4]dioxinyl and benzoxazolyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9
  • each R 8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R 9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain
  • R 1 , R 4 and R 5 are each hydrogen
  • R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R 7 , -R 9 -N(R 6 )R 7 , -
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) selected from the group consisting of: 1 -(5-trifluoromethylpyridin-2-yl)- ⁇ / 3 -(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and i ⁇ -phenylpyrimidine - ⁇ yO- ⁇ S-methyl ⁇ pyrrolidin-i-ylpiperidin-i-ylJpyridin- ⁇ -yl)- 1 /7-1 ,2,4-triazole-3,5-diamine.
  • R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R 7 , -R 9 -N(R 6 )R 7 ,
  • R 3 is quinazolinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -C(O)OR 12 , -R 13 -C(O)N(R 12 ) 2 , -R 13 -N(R 12 )C(O)OR 12 , -
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: I ⁇ J-dimethoxyquinazoline- ⁇ yO- ⁇ bicyclop ⁇ .ilheptan ⁇ -yOpiperazin-i- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
  • R 1 , R 4 and R 5 are each hydrogen
  • R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R 7 , -R 9 -N(R 6 )R 7 , -
  • R 3 is selected from the group consisting of isoquinolinyl and phenanthridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 ,
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted
  • R 1 , R 4 and R 5 are each hydrogen;
  • R 2 is selected from the group consisting of pyridinyl and 1H-pyrrolo[2,3-6]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -
  • R 3 is selected from the group consisting of thieno[3,2-o(]pyrimidinyl and thieno[3,2-c(]pyridazinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -C(O)OR 12 , -R 13 -
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C(O)N(R 8 ) 2 , or any R 6 and R 7 , together with the common nitrogen to which they are both attached, form an optionally substituted ⁇ /-heteroaryl or
  • Another embodiment of a compound of formula (Ia) 1 as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)- ⁇ / 3 -(6-(4-cyclopentyl-1 ,4-diazepan-1- yl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine;
  • R 2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R 7 , -R 9 -N(R 6 )R 7 ,
  • R 3 is selected from the group consisting of furo[3,2-c]pyridinyl and 6,7-dihydro-5H- cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C(O)N(R 8 ) 2 , or any R 6 and R 7 , together with
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: i ⁇ furotS ⁇ -cJpyridine- ⁇ yO- ⁇ pyrrolidin-i-yOpiperidin-i-yO- ⁇ -methylpyridin-S-yl)- 1H-1 ,2,4-triazole-3,5-diamine; and
  • R 2 is 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C(O)N(R 8 ) 2 , or any R 6 and R 7 , together
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)- ⁇ / 3 -(7-cyclopentyl-6,7,8,9-tetrahydro- 5H-pyrido[3,2-d]azepin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and
  • R 2 is 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 , -R 9 -C(O)R 8 , -R 9 -C(O)OR 8 , -R 9 -C(O)N(R 6 )R 7 , -R 9 -C(O)-R 10 -N(R 6 )R
  • R 3 is selected from the group consisting of isoquinolinyl and thieno[3,2-c/]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C(O)N(R 8 ) 2l or any R 6 and R 7 , together with the common
  • R 2 is selected from the group consisting of 6,7,8,9-tetrahydro-5H-cyclohepta[ ⁇ ]pyridinyl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, and 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substitute
  • R 3 is thieno[3,2-c(]pyrimidinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -C(O)OR 12 , -R 13 -C(O)N(R 12 ) 2>
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroaryl
  • R 1 , R 4 and R 5 are each hydrogen;
  • R 2 is pyrimidinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -OC(O)-R 8 ,
  • Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1 -(6,7-dimethoxyquinazoline-4-yl)- ⁇ / 3 -(2-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyrimidin-5-yl)-1 H-
  • R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -O-R 10 -
  • R 3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl
  • each R 13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R 14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain.
  • R 2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R 9 -OR 8 , -R 9 -O-R 10 -OR 8 , -R 9 -O-R 10 -O-R 10 -OR 8 , -R 9 -O-R 10 -CN, -R 9 -O-R 10 -C(O)OR 8 , -R 9 -O-R 10 -C(O)OR 8 , -R
  • each R 6 and R 7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 10 -OR 8 , -R 10 -CN, -R 10 -NO 2 , -R 10 -N(R 8 ) 2 , -R 10 -C(O)OR 8 and -R 10 -C(O)N(R 8 ) 2 , or any R 6
  • R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen,
  • R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[it»][1 ,4]dioxinyl,
  • R 3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R 13 -OR 12 , -R 13 -OC(O)-R 12 , -R 13 -N(R 12 ) 2 , -R 13 -C(O)R 12 , -R 13 -C(O)OR 12 , -R
  • R 1 , R 4 and R 5 are each independently selected from the group consisting of hydrogen,
  • R 2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[ib][1 ,4]dioxinyl, 4,5-dihydro-1/-/-benzo[b]azepin-2(3/-/)-onyl,
  • R 3 is a heteroaryl selected from the group consisting of pyridinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-c/]pyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl
  • Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)- ⁇ / 5 -(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
  • R 1 , R 2 , R 3 , R 4 and R 5 of the compounds of formula (Ib) are the same as set forth above for R 1 , R 2 , R 3 , R 4 and R 5 of the compounds of formula (Ia).
  • a particular embodiment is directed to compounds of the invention wherein the optionally substituted heteroaryls for R 2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted pyrimidinyl, optionally substituted 2,3-dihydrobenzo[b][1 ,4]dioxinyl, optionally substituted 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, optionally substituted 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, optionally substituted 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, optionally substituted 5,6,7,8-tetrahydroquinolinyl, optionally substituted 1H-pyrrolo[2,3-£>]pyridiny
  • a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl.
  • the optional substituents on the optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl are optionally substituted heterocyclyl, C 3 -C 6 monocyclic cycloalkyl radicals, C 3 -C 6 monocyclic cycloalkylalky radicals, C 7 -Ci 5 polycyclic cycloalkyl radicals, such as norbomanyl, norbomenyl, as well as substituted C 7 -Ci 5 polycyclic cycloalkyl radicals, such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl.
  • a particular embodiment is directed to compounds of the invention wherein the optionally substituted aryls and heteroaryls for R 3 are selected from the group consisting of optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted thieno[3,2-c/]pyrimidinyl, optionally substituted thieno[3,2- d]pyridazinyl, optionally substituted 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3- cf]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl.
  • a particular embodiment is directed to compounds of the invention wherein the optionally substituted heteroaryls for R 3 are selected from the group consisting of optionally substituted isoquinolinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted thieno[3,2-c/]pyrimidinyl, optionally substituted thieno[3,2-d]pyridazinyl, optionally substituted 6,7-dihydro-5H- cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl and wherein the optionally substituted heteroaryls for R 2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted
  • a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl, particularly optionally substituted piperidinylalkenyl, optionally substituted pyrrolidinylalkenyl, optionally substituted piperazinylalkenyl and optionally substituted morpholinoalkenyl.
  • a particular embodiment is where the optional substituents on the optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl are optionally substituted heterocyclyl, C 3 -C 6 monocyclic cycloalkyl radicals, C 3 -C 6 monocyclic cycloalkylalkyl radicals, C 7 -Ci 5 polycyclic cycloalkyl radicals, such as norbomanyl, norbomenyl, as well as substituted C 7 -Ci 5 polycyclic cycloalkyl radicals, such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl.
  • compositions of the invention comprising a pharmaceutically acceptable excipient and a compound of formula (I), as set forth above in the Summary of the Invention, certain embodiments are preferred.
  • One embodiment of these pharmaceutical compositions is wherein the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ia), as set forth above, or from any combination of embodiments of the compound of formula (Ia), as set forth above, or the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any combination of embodiments of the compound of formula (Ib), as set forth above.
  • certain embodiments are preferred.
  • the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease, osteoporosis, osteoarthritis and cataracts.
  • a manifestation of the disease or condition is solid tumor formation in said mammal.
  • One embodiment of these methods is the method wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, and uveal melanoma.
  • One embodiment of these methods is the method wherein a manifestation of the disease or condition is liquid tumor formation in said mammal.
  • One embodiment of these methods is the method wherein the disease or condition is myeloid leukemia or lymphoma.
  • One embodiment of these methods is the method wherein the disease or condition is endometriosis.
  • One embodiment of these methods is the method wherein the compounds of formula (I) utilized therein is selected from any one embodiment of the compound of formula (Ia), as set forth above, or from any combination of embodiments of the compound of formula (Ia), as set forth above, or the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any combination of embodiments of the compound of formula (Ib), as set forth above.
  • Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis, visual impairment due to macular degeneration, diabetic retinopathy or retinopathy of prematurity, kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), osteoporosis, osteoarthritis and cataracts.
  • vascular disease / injury including but not limited to restenosis, atherosclerosis and thrombosis
  • psoriasis visual impairment due to macular degeneration
  • diabetic retinopathy or retinopathy of prematurity kidney disease (including but not limited to
  • Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer, uveal melanoma, myeloid leukemia and lymphoma.
  • Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal of therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is endometriosis.
  • the oncogenic RTK, AxI was recently identified, using a retroviral-based functional genetic screening protocol, as a regulator of haptotactic migration, which is a key event in angiogenesis.
  • AxI inhibition by RNAi-mediated silencing blocked endothelial cell migration, proliferation and in vitro tube formation.
  • AxI signaling therefore, impacts multiple functions required for neovascularization in vitro, and regulates angiogenesis in vivo. Regulation of these pro-angiogenic processes required the catalytic activity of AxI. Thus, Axl-mediated angiogenic stimulation would be amenable to modulation by a small molecule inhibitor of AxI catalytic activity.
  • the compounds of the invention are small molecule inhibtiors of AxI catalytic activity, and are therefore useful in treating diseases and conditions which are associated with AxI catalytic activity including those diseases and conditions which are characterized by angiogenesis and/or cell proliferation.
  • the compounds of the invention and pharmaceutical compositions of the invention are useful in treating diseases and conditions which are alleviated by the modulation of AxI activity.
  • diseases and condtions which are alleviated by the "modulation of AxI activity” includes diseases and conditions which are alleviated by a decrease in AxI activity and diseases and conditions which are alleviated by an increase in AxI activity.
  • diseases and conditions are alleviated by a decrease in AxI activity.
  • Diseases and conditions which are alleviated by the modulation of AxI activity include, but are not limited to, solid tumors, including, but not limited to, breast, renal, endometrial, ovarian, thyroid, and non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer and uveal melanoma; liquid tumors, including but not limited to, leukemias (particularly myeloid leukemias) and lymphomas; endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease
  • the compounds of the invention are useful in treating diseases and conditions which are affected by the following biological processes: Invasion, migration, metastasis, or drug resistance as manifested in cancer; stem cell biology as manifested in cancer; invasion, migration, adhesion, or angiogenesis as manifested in endometriosis; vascular remodeling as manifested in cardiovascular disease, hypertension or vascular injury; bone homeostatasis as manifested in osteoporosis or osteoarthritis; viral infection as manifested, for example, in ebola virus infection; or differentiation as manifested in obesity.
  • the compounds of the invention may also be used to modulate inflammatory processes by treating sepsis, acting as vaccine adjuvants, and/or potentiating the immune response in immuno-compromised patients.
  • the compounds of the invention may be tested for their use in treating leukemias and lymphomas by testing the compounds in the xenograft in SCID mouse model using human Axl-expresing cancer cell lines including, but not limited to, HeLa, MDA-MB-231 , SK-OV-3, OVCAR-8, DU145, H1299, ACHN, A498 and Caki-1.
  • the compounds of the invention may be tested for their use in treating leukemias in the xenograft in SCID or nu/nu mouse model using human Axl-expressing AML and CML leukemia cell lines.
  • the compounds of the invention may be tested for their use in treating endometriosis by using the syngenic mouse model of endometriosis (see Somigliana, E. et al., "Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis", Hum. Reprod. (1999), Vol. 14, NO. 12, pp. 2944-50).
  • the compounds may also be tested for their use in treating endometriosis by using the rat model of endometriosis (see Lebovic, D.I.
  • the compounds of the invention may be tested for their use in treating restenosis by using the balloon-injured rate carotid artery model (see Kim, D.W. et al., "Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model", Circulation (2004), Vol. 109, No. 12, pp. 1558-63, Epub 2004 Mar 8).
  • the compounds of the invention may also be tested for their use in treating restenosis by using the percutaneous transluminal coronary angioplasty in apoE deficient mouse model (see von der Thusen, J. H. et al., "Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis", Arterioscler. Thromb. Vase. Biol. (2004), Vol. 24, No. 2, pp. 357-62).
  • the compounds of the invention may be tested for their use in treating atherosclerosis/thrombosis in the ApoE deficient mouse model (see Nakashima, Y. et al., "ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree", Arterioscler. Thromb. (1994), Vol. 14, No. 1 , pp. 133-40).
  • the compounds of the invention may also be tested for their use in treating thrombosis using the collagen-epinephrin-induced pulmonary thromboembolism model and the stasis induced venous thrombosis model (see Angelillo-Scherrer A. et al., "Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy", J Clin Invest. (2005) Vo1 115 pp237-46).
  • the compounds of the invention may be tested for their use in treating psoriasis by using the SCID mouse model or the human skin model of psoriasis (see Nickoloff, B.J. et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model", Am. J. Pathol. (1995), Vol. 146, No. 3, pp. 580-8).
  • the compounds of the invention may be tested for their use in treating age- related macular degeneration or diabetic retinopathy by using the rat corneal angiogenesis model (see Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res. 2005 Mar;80(3):435-42) or the laser-induced mouse choroidal neovasculation model (see Bora, P.
  • the compounds of the invention may be tested for their use in treating retinopathy of prematurity in the mouse retinopathy of prematurity model (see Smith, L.E. et al., "Oxygen-induced retinopathy in the mouse", Invest. Ophthalmol. Vis. Sci. (1994), Vol. 35, No. 1 , pp. 101-11 ).
  • the compounds of the invention may be tested for their use in treating glomerulonephritis or diabetic nephropathy in the rat anti-Thy1.1 -induced experimental mesengial proliferative glomerulonephritis model (see Smith, L.E. et al. cited above).
  • the compounds of the invention may be tested for their use in treating renal tranplant rejection by using a rat model of chronic renal transplant rejection (see Yin, J. L. et al., "Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection", Transplantation (2002), Vol. 73, No. 4, pp. 657-60).
  • the compounds of the invention may be tested for their use in treating rheumatoid arthritis by using the CAIA mouse model (see Phadke, K. et al., "Evaluation of the effects of various anti-arthritic drugs on type Il collagen-induced mouse arthritis model", lmmunopharmacology (1985),Vol. 10, No. 1 , pp. 51-60).
  • the compounds of the invention may be tested for their use in treating osteoarthritis by using the STR/ORT mouse model (see Brewster, M. et al., "Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis", Arthritis. Rheum. (1998), Vol. 41 , No. 9, pp. 1639-44).
  • the compounds of the invention may be tested for their use in treating osteoporosis by using the ovariectomized rat model (see Wronski, T.J. et al., "Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats", Endocrinology (1989), Vol. 125, no. 2, pp 810-6) or the ovariectomized mouse model (see Alexander, J. M. et al., "Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice", J Bone Miner Res. (2001), Vol. 16, no. 9, pp 1665-73; Fujioka, M. et al., "Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice", J Nutr. (2004), Vol. 134, no. 10, pp 2623-7).
  • the compounds of the invention may be tested for their use in treating cataracts by using the H 2 O 2 -induced model (see Kadoya, K. et al., "Role of calpain in hydrogen peroxide induced cataract", Curr. Eye Res. (1993), Vol. 12, No. 4, pp. 341-6) or the Emory mouse model (see Sheets, N.L et al., "Cataract- and lens-specific upregulation of ARK receptor tyrosine kinase in Emory mouse cataract", Invest. Ophthalmol. Vis. Sci. (2002), Vol. 43, No. 6, pp. 1870-5).
  • compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols.
  • compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient.
  • Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units.
  • compositions to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention.
  • a pharmaceutical composition of the invention may be in the form of a solid or liquid.
  • the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form.
  • the carriers) may be liquid, with the compositions being, for example, an oral oil, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
  • the pharmaceutical composition When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
  • the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form.
  • a solid composition will typically contain one or more inert diluents or edible carriers.
  • binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, com starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
  • excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, com starch and the like
  • lubricants such as magnesium stearate or Sterotex
  • glidants such as colloidal silicon dioxide
  • sweetening agents such as sucrose or saccharin
  • a flavoring agent such as peppermint,
  • the pharmaceutical composition when in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
  • a liquid carrier such as polyethylene glycol or oil.
  • the pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension.
  • the liquid may be for oral administration or for delivery by injection, as two examples.
  • preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer.
  • a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included.
  • the liquid pharmaceutical compositions of the invention may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose.
  • the parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic.
  • Physiological saline is a preferred adjuvant.
  • a liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition.
  • Preferred oral pharmaceutical compositions contain between about 4% and about 75% of the compound of the invention.
  • Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention.
  • the pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base.
  • the base for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers.
  • Thickening agents may be present in a pharmaceutical composition for topical administration.
  • the composition may include a transdermal patch or iontophoresis device.
  • Topical formulations may contain a concentration of the compound of the invention from about 0.1 to about 10% w/v (weight per unit volume).
  • the pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug.
  • the composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient.
  • bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
  • the pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit.
  • the composition may include materials that form a coating shell around the active ingredients.
  • the materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents.
  • the active ingredients may be encased in a gelatin capsule.
  • the pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound.
  • Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.
  • the pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol.
  • aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One of ordinary skill in the art, without undue experimentation may determine preferred aerosols.
  • compositions of the invention may be prepared by methodology well known in the pharmaceutical art.
  • a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution.
  • a surfactant may be added to facilitate the formation of a homogeneous solution or suspension.
  • Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
  • the compounds of the invention are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy.
  • a therapeutically effective daily dose is (for a 70 kg mammal) from about 0.001 mg/kg ⁇ i.e., 0.07 mg) to about 100 mg/kg ⁇ i.e., 7.0 gm); preferaby a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg ⁇ i.e., 0.7 mg) to about 50 mg/kg ⁇ i.e., 3.5 gm); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg ⁇ i.e., 70 mg) to about 25 mg/kg ⁇ i.e., 1.75 gm).
  • Compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents.
  • Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of the compound of the invention and each active agent in its own separate pharmaceutical dosage formulation.
  • a compound of the invention and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations.
  • the compounds of the invention and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.
  • R 1 , R 2 , R 3 , R 4 and R 5 are as described above in the Summary of the Invention for compounds of formula (Ia), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or ⁇ /-oxides, and methods to make compounds of formula (Ib); where R 1 , R 2 , R 3 , R 4 and R 5 are as described above in the Summary of the Invention for compounds of formula (Ib), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or ⁇ /-oxides. It is understood that in the following Reaction Schemes, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
  • Suitable protecting groups include hydroxy, amino, mercapto and carboxylic acid.
  • Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, f-butyldimethylsilyl, /-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like.
  • Suitable protecting groups for amino, amidino and guanidino include benzyl, f-butoxycarbonyl, benzyloxycarbonyl, and the like.
  • Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl and the like.
  • Suitable protecting groups for carboxylic acids include alkyl, aryl or arylalkyl esters.
  • Protecting groups may be added or removed in accordance with standard techniques, which are known to one of ordinary skill in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P. G. M.
  • the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
  • starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention.
  • Scheme 1 by first treating a compound of formula (A) (1.1 equiv) with an equivalent amount of an aniline of formula (B) in an polar solvent, including, but not limited to, isopropyl alcohol, at ambient temperatures overnight.
  • the diarylisourea product of formula (C) generally precipitates and isolation can be accomplished via filtration, washing with an appropriate solvent, and drying.
  • Hydrazine hydrate of formula (D) (2 equivalents) is added to a slurry of the compound of formula (C) in an alcohol or other appropriate solvent.
  • the ring formation reaction occurs at ambient temperature and the product triazole of formula (Ia) can be isolated by standard isolation techniques.
  • Reaction Scheme 1 in varying amounts depending on the steric and electronic nature of R 1 , R 2 and R 3 as well as the particular reaction conditions employed.
  • compounds of formula (Ib) are isolated as minor isomers along with compounds of formula (Ia) as major isomers, e.g., during column chromatography as described herein.
  • All compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one of ordinary skill in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques known to one skilled in the art.
  • the following specific Synthetic Examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention.
  • the number following each compound below refers to its number in Table 1 and Table 2, as discussed in more detail below.
  • the compounds of the invention were tested in the following assay for their ability to inhibit AxI activity.
  • REAGENTS AND BUFFERS Cell culture plate: 96 well assay plate (Corning 3610), white, clear bottom, tissue- culture treated. Cells: HeIa cells. Starvation medium: For AxI stimulation: 0.5% FCS (fetal calf serum) in DMEM, plus
  • Axl/Fc extracellular domain of AXL fused to imunoglobulin Fc region
  • R&D 154-AL
  • EGF epidermal growth factor
  • FCS fetal bovine serum
  • DMEM Dulbecco's modified Eagles medium
  • Poly-L-Lysine 0.01% solution 10 ⁇ g/ml, dilute In PBS (phosphate buffered saline).
  • AxI antibody cross-linking 10 ⁇ g/ml, dilute In PBS (phosphate buffered saline).
  • Quenching buffer 3% H 2 O 2 , 0.1% Azide in wash buffer, Azide and hydrogen peroxide (H 2 O 2 ) are added fresh.
  • Blocking buffer 5% BSA in TBST (tris buffered saline plus 0.1% Tween 20).
  • HRP horseradish peroxidase
  • a 96 well TC (tissue culture treated) plate was coated with 10 ⁇ g/ml_ poly-L- Lysine at 37°C for 30 min, washed twice with PBS, and air-dried for 5 minutes before cells were added. HeIa cells were seeded at 10,000 cells/well and the cells were starved in 100 ⁇ l_ starvation medium containing Axl/Fc for 24 hrs. Day 2:
  • the cells were pre-treated with test compounds by adding 100 ⁇ l_ of 2X test compound to the starvation medium on the cells.
  • the cells were incubated at 37 0 C for 1 hr before stimulation.
  • the cells were stimulated by Axl-antibody cross-linking as follows: A 5X i st /2 nd AxI antibody mixture was made (37.5 ⁇ g/mL 1 st / 100 ⁇ g/ml_ 2 nd ) in starvation medium and nutated at 4°C with thorough mixing for 1-2 hours for clustering. The resulting mix was warmed to 37 0 C. 50 ⁇ l_ of 5X AxI 1 st /2 nd of antibody cluster was added to the cells and the cells were incubated at 37°C for 5 min. After 5 minutes stimulation, the plate was flicked to remove medium and the plate was tapped onto paper towels.
  • Formaldehyde (4.0% in PBS, 100 ⁇ l_) was added to fix the cells and the cells were incubated at ambient temperature for 20 min without shaking. The cells were washed with a plate washer buffer to remove the formaldehyde solution. The plate was flicked to removed excess wash buffer and tapped onto paper towels. Quenching buffer (100 ⁇ l_) was added to each well and the cells were incubated at ambient temperature for 20 minutes without shaking.
  • the cells were washed with a plate washer buffer to remove the quenching buffer.
  • Blocking buffer 100 ⁇ L was added and the cells were incubated at ambient temperature for at least an hour with gentle shaking.
  • the wash buffer was removed, diluted secondary antibody (100 ⁇ L) was added, and the cells were incubated at ambient temperature for 1 hour with gentle shaking. During the incubation, the chemiluminescent reagent was brought to ambient temperature. The secondary antibody was removed by washing the cells 1X with wash buffer,
  • the resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity.
  • the cells were washed 1X with wash buffer and 1X with PBS by plate washer. The plate was tapped onto paper towels to remove excess liquid from wells and air-dried at ambient temperature for 5 minutes.
  • Crystal Violet working solution (60 ⁇ L) was added to each well and the cells were incubated at ambient temperature for 30 min. The crystal violet solution was removed, and the wells were rinsed with PBS, then washed 3X with PBS (200 ⁇ L) for 5 minutes each.

Abstract

N3-Heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl activity are also disclosed.

Description

Λ^-HETEROARYL SUBSTITUTED TRIAZOLES AND Λ/5-H ETEROARYL SUBSTITUTED
TRIAZOLES USEFUL AS AXL INHIBITORS
CROSS REFERENCE TO RELATED APPLICATIONS
This application claims the benefit under 35 U. S. C. § 119(e) of U.S. Provisional Patent Application No. 60/975,443, filed September 26, 2007; and U.S. Provisional Patent Application No. 60/882,875, filed December 29, 2006, where these two provisional applications are incorporated herein by reference in their entireties.
FIELD OF THE INVENTION
This invention is directed to Λ^-heteroaryl substituted triazoles and Λ^-heteroaryl substituted triazoles and pharmaceutical compositions thereof which are useful as inhibitors of the receptor protein tyrosine kinase known as AxI. This invention is also directed to methods of using the compounds and compositions in treating diseases and conditions associated with AxI activity, particularly in treating diseases and conditions associated with angiogenesis and/or cell proliferation.
BACKGROUND OF THE INVENTION
All of the protein kinases that have been identified to date in the human genome share a highly conserved catalytic domain of around 300 aa. This domain folds into a bi- lobed structure in which reside ATP-binding and catalytic sites. The complexity of protein kinase regulation allows many potential mechanisms of inhibition including competition with activating ligands, modulation of positive and negative regulators, interference with protein dimerization, and allosteric or competitive inhibition at the substrate or ATP binding sites.
AxI (also known as UFO, ARK, and Tyro7; nucleotide accession numbers NM_021913 and NM_001699; protein accession numbers NP_068713 and NP_001690) is a receptor protein tyrosine kinase (RTK) that comprises a C-terminal extracellular ligand-binding domain and N-terminal cytoplasmic region containing the catalytic domain. The extracellular domain of AxI has a unique structure that juxtaposes immunoglobulin and fibronectin Type III repeats and is reminiscent of the structure of neural cell adhesion molecules. AxI and its two close relatives, Mer /Nyk and Sky (Tyro3 / Rse / Dtk), collectively known as the Tyro3 family of RTK's, all bind and are stimulated to varying degrees by the same ligand, Gas6 (growth arrest specific-6), a ~76kDa secreted protein with significant homology to the coagulation cascade regulator, Protein S. In addition to binding to ligands, the AxI extracellular domain has been shown to undergo homophilic interactions that mediate cell aggregation, suggesting that one important function of AxI may be to mediate cell-cell adhesion. AxI is predominantly expressed in the vasculature in both endothelial cells (EC's) and vascular smooth muscle cells (VSMCs) and in cells of the myeloid lineage and is also detected in breast epithelial cells, chondrocytes, Sertoli cells and neurons. Several functions including protection from apoptosis induced by serum starvation, TNF-α or the viral protein E1A, as well as migration and cell differentiation have been ascribed to AxI signaling in cell culture. However, AxI-/- mice exhibit no overt developmental phenotype and the physiological function of AxI in vivo is not clearly established in the literature.
Angiogenesis (the formation of new blood vessels) is limited to functions such as wound healing and the female reproductive cycle in healthy adults. This physiological process has been co-opted by tumors, thus securing an adequate blood supply that feeds tumor growth and facilitates metastasis. Deregulated angiogenesis also a feature of many other diseases (for example, psoriasis, rheumatoid arthritis, endometriosis and blindness due to age-related macular degeneration (AMD), retinopathy of prematurity and diabetes) and often contributes to the progression or pathology of the condition. The overexpression of AxI and/or its ligand has also been reported in a wide variety of solid tumor types including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma, and uveal melanoma as well as in myeloid leukemia's. Furthermore, it possesses transforming activity in NIH3T3 and 32D cells. It has been demonstrated that loss of AxI expression in tumor cells blocks the growth of solid human neoplasms in an in vivo MDA-MB-231 breast carcinoma xenograft model. Taken together, these data suggest AxI signaling can independently regulate EC angiogenesis and tumor growth and thus represents a novel target class for tumor therapeutic development.
The expression of AxI and Gas6 proteins is upregulated in a variety of other disease states including endometriosis, vascular injury and kidney disease and AxI signaling is functionally implicated in the latter two indications. AxI - Gas6 signaling amplifies platelet responses and is implicated in thrombus formation. AxI may thus potentially represent a therapeutic target for a number of diverse pathological conditions including solid tumors, including, but not limited to, breast, renal, endometrial, ovarian, thyroid, non-small cell lung carcinoma and uveal melanoma; liquid tumors, including but not limited to, leukemias (particularly myeloid leukemias) and lymphomas; endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), rheumatoid arthritis; osteoporosis, osteoarthritis and cataracts.
SUMMARY OF THE INVENTION
This invention is directed to certain Λ^-heteroaryl substituted triazoles and Λ^-heteroaryl substituted triazoles which are useful as AxI inhibitors, methods of using such compounds in treating diseases and conditions associated with AxI activity and pharmaceutical compositions comprising such compounds.
Accordingly, in one aspect this invention is directed to a compound of formula (I):
Figure imgf000004_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alky!, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7,
-R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2,
-R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyi, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, form an optionally substituted
Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
In another aspect, this invention is directed to pharmaceutical compositions comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
In another aspect, this invention is directed to methods of treating a disease or condition associated with AxI activity in a mammal, wherein the methods comprise administering to the mammal a therapeutically effective amount of a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof, or a therapeutically effective amount of a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I), as described above, as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
In another aspect, this invention provides assays to determine a compound of the invention effectiveness in inhibiting AxI activity in a cell-based assay.
DETAILED DESCRIPTION OF THE INVENTION
DEFINITIONS
As used in the specification and appended claims, unless specified to the contrary, the following terms have the meaning indicated: "Amino" refers to the -NH2 radical.
"Carboxy" refers to the -C(O)OH radical. "Cyano" refers to the -CN radical. "Nitro" refers to the -NO2 radical. "Oxa" refers to the -O- radical. "Oxo" refers to the =0 radical.
"Thioxo" refers to the =S radical.
"Alkyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to twelve carbon atoms, preferably one to eight carbon atoms or one to six carbon atoms, and which is attached to the rest of the molecule by a single bond, for example, methyl, ethyl, /7-propyl, 1-methylethyl (/so-propyl), n-butyl, n-pentyl, 1 ,1-dimethylethyl (f-butyl), 3-methylhexyl, 2-methylhexyl, and the like. Unless stated otherwise specifically in the specification, an alkyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20J2, -C(O)R20, -C(O)OR20, -C(O)N(R20J2, -N(R20)C(O)OR20,
-N(R20)C(O)R20, -N(R20)S(O),R20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2), -S(O)pR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. "Alkenyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethenyl, prop-1-enyl, but-1-enyl, pent-1-enyl, penta-1 ,4-dienyl, and the like. Unless stated otherwise specifically in the specification, an alkenyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20J2, -N(R20)C(O)OR20, -N(R20)C(O)R20, -N(R20)S(O)tR20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2),
-S(O)pR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
"Alkynyl" refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing at least one triple bond, optionally containing at least one double bond, having from two to twelve carbon atoms, preferably one to eight carbon atoms and which is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like. Unless stated otherwise specifically in the specification, an alkynyl radical may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)C(O)R20, -N(R20)S(O),R20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2), -S(O)pR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
"Alkylene" or "alkylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like. The alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond. The points of attachment of the alkylene chain to the rest of the molecule and to the radical group can be through one carbon in the alkylene chain or through any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkylene chain may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)C(O)R20, -N(R20)S(O)tR20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2), -S(O)PR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl. "Alkenylene" or "alkenylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one double bond and having from two to twelve carbon atoms, for example, ethenylene, propenylene, π-butenylene, and the like. The alkenylene chain is attached to the rest of the molecule through a double bond or a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkenylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkenylene chain may be optionally substituted by one or more of the following substituents: halo, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)C(O)R20, -N(R20)S(O)tR20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2), -S(O)PR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
"Alkynylene" or "alkynylene chain" refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one triple bond and having from two to twelve carbon atoms, for example, propynylene, n-butynylene, and the like. The alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a double bond or a single bond. The points of attachment of the alkynylene chain to the rest of the molecule and to the radical group can be through one carbon or any two carbons within the chain. Unless stated otherwise specifically in the specification, an alkynylene chain may be optionally substituted by one or more of the following substituents: alkyl, alkenyl, halo, haloalkenyl, cyano, nitro, aryl, cycloalkyl, heterocyclyl, heteroaryl, oxo, thioxo, trimethylsilanyl, -OR20, -OC(O)-R20, -N(R20)2, -C(O)R20, -C(O)OR20, -C(O)N(R20)2, -N(R20)C(O)OR20, -N(R20)C(O)R20, -N(R20)S(O)tR20 (where t is 1 or 2), -S(O)1OR20 (where t is 1 or 2), -S(O)PR20 (where p is O, 1 or 2), and -S(O)tN(R20)2 (where t is 1 or 2) where each R20 is independently hydrogen, alkyl, haloalkyl, cycloalkyl, cycloalkylalkyl, aryl, aralkyl, heterocyclyl, heterocylylalkyl, heteroaryl or heteroarylalkyl.
"Alkoxy" refers to a radical of the formula -OR3 where Ra is an alkyl radical as defined above containing one to twelve carbon atoms. The alkyl part of the alkoxy radical may be optionally substituted as defined above for an alkyl radical. "Alkoxyalkyl" refers to a radical of the formula -Rb-O-Ra where Ra is an alkyl radical as defined above and Rb is an alkylene chain as defined above. The oxygen atom may be bonded to any carbon in the alkyl radical or the alkylene chain. The alkyl part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkyl radical and the alkylene chain part of the alkoxyalkyl radical may be optionally substituted as defined above for an alkylene chain.
"Aryl" refers to a hydrocarbon ring system radical comprising hydrogen, 6 to 14 carbon atoms and at least one aromatic ring. For purposes of this invention, the aryl radical may be a monocyclic, bicyclic, or tricyclic ring system, which may included spiro ring systems. An aryl radical is commonly, but not necessarily, attached to the parent molecule via an aromatic ring of the aryl radical. For purposes of this invention, an "aryl" radical as defined herein can not contain rings having more than 7 members and cannot contain rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms {i.e., a bridged ring system). Aryl radicals include, but are not limited to, aryl radicals derived from acenaphthylene, anthracene, azulene, benzene, 6,7,8,9-tetrahydro-5H-benzo[7]annulene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, and phenanthrene. Unless stated otherwise specifically in the specification, the term "optionally substituted aryl" is meant to include aryl radicals optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R21-OR20, -R21-OC(O)-R20, -R21-N(R20)2, -R21-C(O)R20, -R21-C(O)OR20, -R21-C(O)N(R20)2, -R21-O-R22-C(O)N(R20)2, -R21-N(R20)C(O)OR20, -R21-N(R20)C(O)R20, -R21-N(R20)S(O)tR20 (where t is 1 or 2), -R21-S(O)tOR20 (where t is 1 or 2), -R21-S(O)PR20 (where p is 0, 1 or 2), and -R21-S(O),N(R20)2 (where t is 1 or 2), where each R20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R20's, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl, each R21 is independently a direct bond or a straight or branched alkylene or alkenylene chain, and R22 is a straight or branched alkylene or alkenylene chain. "Aralkyl" refers to a radical of the formula -Rb-R0 where Rb is an alkylene chain as defined above and Rc is one or more aryl radicals as defined above, for example, benzyl, diphenylmethyl and the like. The alkylene chain part of the aralkyl radical may be optionally substituted as described above for an alkylene chain. The aryl part of the aralkyl radical may be optionally substituted as described above for an aryl. "Aralkenyl" refers to a radical of the formula -Rd-Rc where Rd is an alkenylene chain as defined above and R0 is one or more aryl radicals as defined above. The aryl part of the aralkenyl radical may be optionally substituted as described above for an aryl. The alkenylene chain part of the aralkenyl radical may be optionally substituted as defined above for an alkenylene group. "Aralkynyl" refers to a radical of the formula -ReRc where Re is an alkynylene chain as defined above and Rc is one or more aryl radicals as defined above. The aryl part of the aralkynyl radical may be optionally substituted as described above for an aryl. The alkynylene chain part of the aralkynyl radical may be optionally substituted as defined above for an alkynylene chain. "Aryloxy" refers to a radical of the formula -ORC where R0 is an aryl as defined above. The aryl part of the aryloxy radical may be optionally substituted as defined above.
"Aralkyloxy" refers to a radical of the formula -ORf where Rf is an aralkyl radical as defined above. The aralkyl part of the aralkyloxy radical may be optionally substituted as defined above.
"Cycloalkyl" refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which may include fused or bridged ring systems, having from three to fifteen carbon atoms, preferably having from three to ten carbon atoms, more preferably from five to seven carbons and which is saturated or unsaturated and attached to the rest of the molecule by a single bond.
Monocyclic radicals include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic radicals include, for example, C10 radicals such as adamantanyl and decalinyl, and C7 radicals such as norbornanyl, norbornenyl, as well as substituted polycyclic radicals for example substituted C7 radicals such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like. Unless otherwise stated specifically in the specification, the term "optionally substituted cycloalkyl" is meant to include cycloalkyl radicals which are optionally substituted by one or more substituents independently selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R21-OR20, -R21-OC(O)-R20, -R21-N(R20)2, -R21-C(O)R20, -R21-C(O)OR20, -R21-C(O)N(R20)2, -R21-N(R20)C(O)OR20, -R21-N(R20)C(O)R20, -R21-N(R20)S(O)tR20 (where t is 1 or 2), -R21-S(O)tOR20 (where t is 1 or 2), -R21-S(O)pR20 (where p is 0, 1 or 2), and -R21-S(O)tN(R20)2 (where t is 1 or 2), where each R20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R20's, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N- heterocyclyl or an optionally substituted Λ/-heteroaryl, and each R21 is independently a direct bond or a straight or branched alkylene or alkenylene chain.
"Cycloalkylalkyl" refers to a radical of the formula -RbRg where Rb is an alkylene chain as defined above and R9 is a cycloalkyl radical as defined above. The alkylene chain and the cycloalkyl radical may be optionally substituted as defined above. "Cycloalkylalkenyl" refers to a radical of the formula -RdRg where Rd is an alkenylene chain as defined above and R9 is a cycloalkyl radical as defined above. The alkenylene chain and the cycloalkyl radical may be optionally substituted as defined above. "Cycloalkylalkynyl" refers to a radical of the formula -ReRg where Re is an alkynylene radical as defined above and R9 is a cycloalkyl radical as defined above. The alkynylene chain and the cycloalkyl radical may be optionally substituted as defined above.
"Halo" refers to bromo, chloro, fluoro or iodo. "Haloalkyl" refers to an alkyl radical, as defined above, that is substituted by one or more halo radicals, as defined above, for example, trifluoromethyl, difluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, i-fluoromethyl-2-fluoroethyl, 3-bromo-2-fluoropropyl, 1-bromomethyl-2-bromoethyl, and the like. The alkyl part of the haloalkyl radical may be optionally substituted as defined above for an alkyl radical. "Haloalkoxy" refers to an alkoxy radical, as defined above, that is substituted by one or more halo radicals, as defined above, for example, trifluoromethoxy, difluoromethoxy, trichloromethoxy, 2,2,2-trifluoroethoxy, and the like. The alkoxy part of the haloalkoxy radical may be optionally substituted as defined above for an alkoxy radical. "Haloalkenyl" refers to an alkenyl radical, as defined above, that is substituted by one or more halo radicals, as defined above. The alkenyl part of the haloalkyl radical may be optionally substituted as defined above for an alkenyl radical.
"Haloalkynyl" refers to an alkynyl radical, as defined above, that is substituted by one or more halo radicals, as defined above. The alkynyl part of the haloalkyl radical may be optionally substituted as defined above for an alkynyl radical.
"Heterocyclyl" refers to a stable 3- to 18-membered non-aromatic ring radical which comprises one to twelve carbon atoms and from one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur. Unless stated otherwise specifically in the specification, the heterocyclyl radical may be a monocyclic, bicyclic, tricyclic or tetracyclic ring system, which may include spiro, fused or bridged ring systems; and the nitrogen, carbon or sulfur atoms in the heterocyclyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized; and the heterocyclyl radical may be partially or fully saturated. Examples of such heterocyclyl radicals include, but are not limited to, dioxolanyl, 1 ,4-diazepanyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, octahydro-1 H-pyrrolo[3,2-c]pyridinyl, octahydro-1 /-/-pyrrolo[2,3- φyridinyl, octahydro-1 H-pyrrolo[2,3-ib]pyridinyl, octahydro-1 H-pyrrolo[3,4-ib]pyridinyl, octahydropyrrolo[3,4-c]pyrrolyl, octahydro-1 H-pyrido[1 ,2-a]pyrazinyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, thienyl[1 ,3]dithianyl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1 ,1-dioxo-thiomorpholinyl, azetidinyl, octahydropyrrolo[3,4-c]pyrrolyl, octahydropyrrolo[3,4-b]pyrrolyl, decahydroprazino[1 ,2-a]azepinyl, azepanyl, azabicyclo[3.2.1]octyl, and 2,7-diazaspiro[4.4]nonanyl. Unless stated otherwise specifically in the specification, the term " optionally substituted heterocyclyl" is meant to include heterocyclyl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R21 -OR20, -R21-OC(O)-R20, -R21-N(R20)2, -R21-C(O)R20, -R21-C(O)OR20, -R21-C(O)N(R20)2, -R21-N(R20)C(O)OR20, -R21-N(R20)C(O)R20, -R21-N(R20)S(O)tR20 (where t is 1 or 2), -R21 -S(O)1OR20 (where t is 1 or 2), -R21-S(O)pR20 (where p is O, 1 or 2), and -R21-S(O)tN(R20)2 (where t is 1 or 2), where each R20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R20ls, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted N- heterocyclyl or an optionally substituted Λ/-heteroaryl, and each R21 is independently a direct bond or a straight or branched alkylene or alkenylene chain.
"Λ/-heterocyclyl" refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical. An /V-heterocyclyl radical may be optionally substituted as described above for heterocyclyl radicals.
"Heterocyclylalkyl" refers to a radical of the formula -RbRh where Rb is an alkylene chain as defined above and Rh is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkyl radical may be optionally substituted as defined above for an alkyene chain. The heterocyclyl part of the heterocyclylalkyl radical may be optionally substituted as defined above for a heterocyclyl radical.
"Heterocyclylalkenyl" refers to a radical of the formula -RdRh where Rd is an alkenylene chain as defined above and Rh is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkenylene chain at the nitrogen atom. The alkenylene chain of the heterocyclylalkenyl radical may be optionally substituted as defined above for an alkenylene chain. The heterocyclyl part of the heterocyclylalkenyl radical may be optionally substituted as defined above for a heterocyclyl radical.
"Heterocyclylalkynyl" refers to a radical of the formula -ReRh where Re is an alkynylene chain as defined above and Rh is a heterocyclyl radical as defined above, and if the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl may be attached to the alkynyl radical at the nitrogen atom. The alkynylene chain part of the heterocyclylalkynyl radical may be optionally substituted as defined above for an alkynylene chain. The heterocyclyl part of the heterocyclylalkynyl radical may be optionally substituted as defined above for a heterocyclyl radical.
"Heteroaryl" refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen and sulfur, and at least one aromatic ring. A heteroaryl radical is commonly, but not necessarily, attached to the parent molecule via an aromatic ring of the heteroaryl radical. For purposes of this invention, the heteroaryl radical may be a monocyclic, bicyclic or tricyclic ring system, which may include spiro ring systems; and the nitrogen, carbon or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized. For purposes of this invention, the aromatic ring of the heteroaryl radical need not contain a heteroatom, as long as one ring of the heteroaryl radical contains a heteroatom. For example, 1 ,2,3,4-tetrahydroisoquinolin-7-yl is considered a "heteroaryl" for the purposes of this invention. For purposes of this invention, a "heteroaryl" radical as defined herein can not contain rings having more than 7 members or rings wherein two non-adjacent members thereof are connected by a direct bond or through an atom or a group of atoms {i.e., a bridged ring system). Examples of heteroaryl radicals include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1 ,3-benzodioxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[ό][1 ,4]dioxepinyl, benzo[b][1 ,4]oxazinyl, 1 ,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzothieno[3,2-d]pyrimidinyl, benzotriazolyl, benzo[4,6]imidazo[1 ,2-a]pyridinyl, carbazolyl, cinnolinyl, cyclopenta[d]pyrimidinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, 5,6-dihydrobenzo[h]quinazolinyl, 5,6-dihydrobenzo[h]cinnolinyl, 7\8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, 6,7-dihydro-5H-benzo[6,7]cyclohepta[1 ,2-c]pyridazinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, furo[3,2-c]pyridinyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, 1 ,6-naphthyridinonyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 5,6,68,7,8,9, 10, 10a-octahydrobenzo[h]quinazolinyl, 1 -phenyl- 1 H-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, phenanthridinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyrazolo[3,4-d]pyrimidinyl, pyridinyl, pyrido[3,2-d]pyrimidinyl, pyrido[3,4-d]pyrimidinyl, pyrazinyl, pyrimidinyl, pyridazinyl, pyrrolyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, 5,6,7,8-tetrahydroquinazolinyl, 2,3,4,5-tetrahydrobenzo[6]oxepinyl, 3,4-dihydro-2H-benzo[b][1 ,4]dioxepinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, ejAΘ-tetrahydro-δH-pyridoβ^-φzepinyl, 5,6,7,8-tetrahydrobenzo[4,5]thieno[2,3-αf]pyrimidinyl, 6,7,8,9-tetrahydro-5H-cyclohepta[4,5]thieno[2,3-φyrimidinyl,
5,6,7,8-tetrahydropyrido[4,5-c]pyridazinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, 1 ,2,3,4-tetrahydroisoquinolin-7-yl, triazinyl, thieno[2,3-c/]pyrimidinyl, thieno[3,2-c/]pyrimidinyl, thieno[2,3-c]pyridinyl, thieno[3,2-c/]pyridazinyl and thiophenyl {i.e., thienyl). Unless stated otherwise specifically in the specification, the term " optionally substituted heteroaryl" is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R21-OR20, -R21-OC(O)-R20, -R21-N(R20)2, -R21-C(O)R20, -R21-C(O)OR20, -R21-C(O)N(R20)2, -R21-N(R20)C(O)OR20, -R21-N(R20)C(O)R20, -R21-N(R20)S(O),R20 (where t is 1 or 2), -R21-S(O),OR20 (where t is 1 or 2), -R21-S(O)PR20 (where p is 0, 1 or 2), and -R21-S(O)tN(R20)2 (where t is 1 or 2), where each R20 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R20ls, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl, and each R21 is independently a direct bond or a straight or branched alkylene or alkenylene chain.
"Λ/-heteroaryl" refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical. An Λ/-heteroaryl radical may be optionally substituted as described above for heteroaryl radicals. "Heteroarylalkyl" refers to a radical of the formula -RbR, where Rb is an alkylene chain as defined above and R1 is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkyl radical may be optionally substituted as defined above for a heteroaryl. The alkylene chain part of the heteroarylalkyl radical may be optionally substituted as defined above for an alkylene chain. "Heteroarylalkenyl" refers to a radical of the formula -RdR, where Rd is an alkenylene chain as defined above and R, is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkenyl radical may be optionally substituted as defined above for a heteroaryl. The alkenylene chain part of the heteroarylalkenyl radical may be optionally substituted as defined above for an alkenylene chain. "Heteroarylalkynyl" refers to a radical of the formula -ReRι where Re is an alkynylene chain as defined above and R, is a heteroaryl radical as defined above. The heteroaryl part of the heteroarylalkynyl radical may be optionally substituted as defined above for a heteroaryl. The alkynylene chain part of the heteroarylalkynyl radical may be optionally substituted as defined above for an alkynylene chain. "Hydroxyalkyl" refers to an alkyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
"Hydroxyalkenyl" refers to an alkenyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
"Hydroxyalkenyl" refers to an alkynyl radical as defined above which is substituted by one or more hydroxy radicals (-OH).
Certain chemical groups named herein may be preceded by a shorthand notation indicating the total number of carbon atoms that are to be found in the indicated chemical group. For example; C7-C12alkyl describes an alkyl group, as defined below, having a total of 7 to 12 carbon atoms, and C4-Ci2Cycloalkylalkyl describes a cycloalkylalkyl group, as defined below, having a total of 4 to 12 carbon atoms. The total number of carbons in the shorthand notation does not include carbons that may exist in substituents of the group described.
"Stable compound" and "stable structure" are meant to indicate a compound that is sufficiently robust to survive isolation to a useful degree of purity from a reaction mixture, and formulation into an efficacious therapeutic agent.
"Mammal" includes humans and domestic animals, such as cats, dogs, swine, cattle, sheep, goats, horses, rabbits, and the like. Preferably, for purposes of this invention, the mammal is a human.
"Optional" or "optionally" means that the subsequently described event or circumstances may or may not occur, and that the description includes instances where said event or circumstance occurs and instances in which it does not. For example, "optionally substituted aryl" means that the aryl radical may or may not be substituted and that the description includes both substituted aryl radicals and aryl radicals having no substitution. When a functional group is described as "optionally substituted," and in turn, substitutents on the functional group are also "optionally substituted" and so on, for the purposes of this invention, such iterations are limited to five, preferably such iterations are limited to two.
"Pharmaceutically acceptable excipient" includes without limitation any adjuvant, carrier, excipient, glidant, sweetening agent, diluent, preservative, dye/colorant, flavor enhancer, surfactant, wetting agent, dispersing agent, suspending agent, stabilizer, isotonic agent, solvent, or emulsifier which has been approved by the United States Food and Drug Administration as being acceptable for use in humans or domestic animals.
"Pharmaceutically acceptable salt" includes both acid and base addition salts. "Pharmaceutically acceptable acid addition salt" refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid and the like, and organic acids such as, but not limited to, acetic acid, 2,2-dichloroacetic acid, adipic acid, alginic acid, ascorbic acid, aspartic acid, benzenesulfonic acid, benzoic acid, 4-acetamidobenzoic acid, camphoric acid, camphor-10-sulfonic acid, capric acid, caproic acid, caprylic acid, carbonic acid, cinnamic acid, citric acid, cyclamic acid, dodecylsulfonic acid, ethane-1 ,2-disulfonic acid, ethanesulfonic acid, 2- hydroxyethanesulfonic acid, formic acid, fumaric acid, galactaric acid, gentisic acid, glucoheptonic acid, gluconic acid, glucuronic acid, glutamic acid, glutaric acid, 2-oxo- glutaric acid, glycerophosphoric acid, glycolic acid, hippuric acid, isobutyric acid, lactic acid, lactobionic acid, lauric acid, maleic acid, malic acid, malonic acid, mandelic acid, methanesulfonic acid, mucic acid, naphthalene-1 ,5-disulfonic acid, naphthalene-2- sulfonic acid, 1-hydroxy-2-naphthoic acid, nicotinic acid, oleic acid, orotic acid, oxalic acid, palmitic acid, pamoic acid, propionic acid, pyroglutamic acid, pyruvic acid, salicylic acid, 4-aminosalicylic acid, sebacic acid, stearic acid, succinic acid, tartaric acid, thiocyanic acid, p-toluenesulfonic acid, trifluoroacetic acid, undecylenic acid, and the like. "Pharmaceutically acceptable base addition salt" refers to those salts which retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid. Salts derived from inorganic bases include, but are not limited to, the sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like. Preferred inorganic salts are the ammonium, sodium, potassium, calcium, and magnesium salts. Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, such as ammonia, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, diethanolamine, ethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, hydrabamine, choline, betaine, benethamine, benzathine, ethylenediamine, glucosamine, methylglucamine, theobromine, triethanolamine, tromethamine, purines, piperazine, piperidine, Λ/-ethylpiperidine, polyamine resins and the like. Particularly preferred organic bases are isopropylamine, diethylamine, ethanolamine, trimethylamine, dicyclohexylamine, choline and caffeine.
A "pharmaceutical composition" refers to a formulation of a compound of the invention and a medium generally accepted in the art for the delivery of the biologically active compound to mammals, for example, humans. Such a medium includes all pharmaceutically acceptable carriers, diluents or excipients therefor. "Therapeutically effective amount" refers to that amount of a compound of the invention which, when administered to a mammal, preferably a human, is sufficient to effect treatment, as defined below, of a disease or condition of interest in the mammal, preferably a human. The amount of a compound of the invention which constitutes a "therapeutically effective amount" will vary depending on the compound, the disease or condition and its severity, and the age of the mammal to be treated, but can be determined routinely by one of ordinary skill in the art having regard to his own knowledge and to this disclosure.
"Treating" or "treatment" as used herein covers the treatment of the disease or condition of interest in a mammal, preferably a human, having the disease or condition of interest, and includes:
(i) preventing the disease or condition from occurring in a mammal, in particular, when such mammal is predisposed to the condition but has not yet been diagnosed as having it;
(ii) inhibiting the disease or condition, i.e., arresting its development; (iii) relieving the disease or condition, i.e., causing regression of the disease or condition; or
(iv) stabilizing the disease or condition.
As used herein, the terms "disease" and "condition" may be used interchangeably or may be different in that the particular malady or condition may not have a known causative agent (so that etiology has not yet been worked out) and it is therefore not yet recognized as a disease but only as an undesirable condition or syndrome, wherein a more or less specific set of symptoms have been identified by clinicians.
The compounds of the invention, or their pharmaceutically acceptable salts may contain one or more asymmetric centres and may thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that may be defined, in terms of absolute stereochemistry, as (R)- or (S)- or, as (D)- or (L)- for amino acids. The present invention is meant to include all such possible isomers, as well as their racemic and optically pure forms. Optically active (+) and (-), (R)- and (S)-, or (D)- and (L)- isomers may be prepared using chiral synthons or chiral reagents, or resolved using conventional techniques, such as HPLC using a chiral column. When the compounds described herein contain olefinic double bonds or other centres of geometric asymmetry, and unless specified otherwise, it is intended that the compounds include both E and Z geometric isomers. Likewise, all tautomeric forms are also intended to be included.
A "stereoisomer" refers to a compound made up of the same atoms bonded by the same bonds but having different three-dimensional structures, which are not interchangeable. The present invention contemplates various stereoisomers and mixtures thereof and includes "enantiomers", which refers to two stereoisomers whose molecules are nonsuperimposeable mirror images of one another.
A "tautomer" refers to a proton shift from one atom of a molecule to another atom of the same molecule. The present invention includes tautomers of any said compounds. "Atropisomers" are stereoisomers resulting from hindered rotation about single bonds where the barrier to rotation is high enough to allow for the isolation of the conformers (Eliel, E. L.; Wilen, S. H. Stereochemistry of Organic Compounds; Wiley & Sons: New York, 1994; Chapter 14). Atropisomerism is significant because it introduces an element of chirality in the absence of stereogenic atoms. The invention is meant to encompass atropisomers, for example in cases of limited rotation around the single bonds emanating from the core triazole structure, atropisomers are also possible and are also specifically included in the compounds and/or prodrugs of the invention.
The chemical naming protocol and structure diagrams used herein are a modified form of the I.U.P.A.C. nomenclature system wherein the compounds of the invention are named herein as derivatives of the central core structure, i.e., the triazole structure. For complex chemical names employed herein, a substituent group is named before the group to which it attaches. For example, cyclopropylethyl comprises an ethyl backbone with cyclopropyl substituent. In chemical structure diagrams, all bonds are identified, except for some carbon atoms, which are assumed to be bonded to sufficient hydrogen atoms to complete the valency.
For purposes of this invention, the depiction of the bond attaching the R3 substituent to the parent triazole moiety in formula (I), as shown below:
Figure imgf000021_0001
is intended to include only the two regioisomers shown below (compounds of formula (Ia) and (Ib)):
N — N N — N
R1 Ft* R1 R4
(Ia) (Ib)
The numbering system of the ring atoms in compounds of formula (Ia) is shown below:
Figure imgf000022_0001
For example, a compound of formula (Ia) wherein R1, R4 and R5 are each hydrogen, R2 is 2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl and R3 is isoquinolin-1-yl; i.e., a compound of formula (Ia) having the following formula:
Figure imgf000022_0002
is named herein as 1-(isoquinolin-1-yl)-Λ/3-(2-(pyrrolidin-1-ylmethyl)benzo[c(]oxazol-5-yl)- 1 H-1 ,2,4-triazole-3,5-diamine.
The numbering system of the ring atoms in compounds of formula (Ib) is shown below:
Figure imgf000022_0003
For example, a compound of formula (Ib) wherein R1, R4and R5 are each hydrogen, R2 is 2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl and R3 is isoquinolin-1-yl, i.e., a compound of formula (Ib) having the following formula:
Figure imgf000022_0004
is named herein as 1-(isoquinolin-1-yl)-Λ/5-(2-(pyrrolidin-1-ylmethyl)benzo[c/]oxazol-5-yl)- 1 H-1 ,2,4-triazole-3,5-diamine. EMBODIMENTS OF THE INVENTION
Of the various aspects of the invention, as set forth above in the Summary of the Invention, certain embodiments are preferred.
Accordingly, one embodiment is wherein the compound of formula (I) is a compound of formula (Ia):
Figure imgf000023_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8,
-R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7,
-R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13,
-R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2),
-R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12,
-R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[£>][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1H-pyrrolo[2,3-ib]pyridinyl, benzo[6]thiophenyl, 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl,
4b,5,6,7,7a,8-hexahydropentaleno[2,1-ύ]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[ib]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8,
-R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2); R3 is aryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2l -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN,
-R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen; R2 is 2,3-dihydrobenzo[ιb][1 ,4]dioxinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is O1 1 or 2), and
-R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN,
-R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is Λ/3-(2,3-dihydrobenzo[jb][1 ,4]dioxin-6-yl)-1-phenyl-1H- 1 ,2,4-triazole-3,5-diamine.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[jb][1 ,4]dioxinyl, 4,5-dihydro-1 H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-b]pyridinyl, benzo[/b]thiophenyl, 7',8l-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3l-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-fo]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7,
-R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)pR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is heteroaryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12,
-R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[ό][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5/-/-pyrido[3,2-of]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-ib]pyridinyl, benzo[fc>]thiophenyl, 7',8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl,
4b,5,6,7,7a,8-hexahydropentaleno[2,1-t)]pyridinyl, and 6,7,8,9-tetrahydrocyclohepta[ιb]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8,
-R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of pyridinyl, pyrimidinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-c/]pyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-c(]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each hydrogen;
R2 is selected from the group consisting of benzo[t»]thiophenyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, 2,3-dihydrobenzo[ύ][1 ,4]dioxinyl and benzoxazolyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of isoquinolinyl, quinazolinyl and thieno[3,2- cdpyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN,
-R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of:
1 -(isoquinolin-1 -yl)-Λ/3-(2-(pyrrolidin-1 -ylmethyl)benzo[d]oxazol-5-yl)-1 H-1 ,2,4-triazole-
3,5-diamine; 1-(6-chloroquinazolin-4-yl)-Λ/3-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1 /-/-1 ,2,4- triazole-3,5-diamine;
Λ/3-(2,3-dihydrobenzo[b][1 ,4]dioxin-6-yl)-1 -(isoquinolin-1 -yl)-1 H-1 ,2,4-triazole-3,5- diamine;
Λ/3-(2,3-dihydrobenzo[fe][1 ,4]dioxin-6-yl)-1-(6,7-dimethoxyquinazolin-4-yl)-1/-/-1 ,2,4- triazole-3,5-diamine;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(4,5-dihydro-1H-benzo[b]azepin-2(3H)-on-8-yl)-1H- 1 ,2,4-triazole-3,5-diamine;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(1-(4-(2-(dimethylamino)ethyl)piperazin-1- yl)oxomethyl)benzo[b]thiophen-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine; Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each hydrogen;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of pyridinyl and pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12,
-R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) selected from the group consisting of: 1 -(5-trifluoromethylpyridin-2-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and i^δ-phenylpyrimidine -^yO-Λ^^S-methyl^Φpyrrolidin-i-ylpiperidin-i-ylJpyridin-δ-yl)- 1 /7-1 ,2,4-triazole-3,5-diamine.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8,
-R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is quinazolinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2),
-R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: I^ΘJ-dimethoxyquinazoline-^yO-Λ^^θ^^bicyclop^.ilheptan^-yOpiperazin-i- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(ΘJ-dimethoxyquinazoline-^yO-Λ/^β-^-^-methylpiperazin-i -yl)piperidin-1 -yl)pyridin- 3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; i^δ.Z-dimethoxyquinazoline-^yO-Λ^^Θ^Φcyclopentyl-i ^-diazepan-i-ylJpyridin-S-yl)- 1 H-1 ,2,4-triazole-3,5-diamine;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-pyrrolidin-1-ylpiperidin-1-yl)pyridine-3-yl)-1H- 1 ,2,4-triazole-3,5-diamine;
1 -(6, 7-dimethoxyquinazoline-4-yl)- /^-(θ-^-piperidin-i -ylpiperidin-1 -yl)pyridine-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; 1 -(ΘJ-dimethoxyquinazoline-ΦyO-Λ^^β^^pyrrolidin-i -ylmethyl)piperidin-1 -yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; i-CβJ-dimethoxyquinazoline-ΦyO-ΛA'^θ^diethylaminoethylmethylaminoJpyridin-S-yO-IH-
1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1-yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; i-CΘ.Z-dimethoxyquinazoline^-yO-Λ^-CΘ^S-diethylaminopyrrolidin-i-yOpyridin-S-yO-I H- 1 ,2,4-triazole-3,5-diamine;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4-diazepan-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-methylquinazolin-4-yl)-/V3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1 -(6-fluoroquinazolin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; I^ΘJ-dimethoxyquinazoline^-yO-Λ^^Θ-bromopyridin-S-yO-δ^S^Θ-bromopyridin-S-yl)^- cyanoguanadino)-1 H-1 ,2,4-triazole-3-amine;
1 -(Θ.Z-dimethoxyquinazoline^-yO-Λ^^Θ-bromopyridin-S-yO-i H-1 ,2,4-triazole-3,5- diamine;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-(4-methylpiperazin-1-yl)piperidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-piperidin-1 -ylpiperidin-1 - yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-dimethylaminopiperidin-1 - yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(3-(diethylamino)pyrrolidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; i-Cθy-dimethoxyquinazoline^-ylJ-Λ^-CΘ^S^S-CdimethylaminoJpyrrolidin-i- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(ΘJ-dimethoxyquinazoline^-yO-Λ^^Θ^S-piperidin-i -ylpropenyl)pyridin-3-yl)-1 H-1 ,2,4- triazole-3,5-diamine; 1 -(6, 7-dimethoxyquinazoline-4-yl)- /^-(6-(3-(4-PyITOlJdIn-I -ylpiperidin-1 - yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-cyclopentylpiperazin-1-yl)propenyl)pyridin- 3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(3-(4-isopropylpiperazin-1 -yl)propen-1 - yl)pyridine-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin-1- yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each hydrogen;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7,
-R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of isoquinolinyl and phenanthridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12,
-R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of:
1 -(isoquinolin-1 -yl)-Λ/3-(6-(4-(bicyclo[2.2.1 ]heptan-2-yl)piperazin-1 -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine;
1 -(isoquinolin-1 -yO-Λ/^θ-^-methylpiperazin-i -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5- diamine; and i^phenanthridin-θ-yO-Λ^^θ^^pyrrolidin-i-yOpiperidin-i-yO-δ-methylpyridin-S-yO-i/-/- 1 ,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein:
R1, R4 and R5 are each hydrogen; R2 is selected from the group consisting of pyridinyl and 1H-pyrrolo[2,3-6]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of thieno[3,2-o(]pyrimidinyl and thieno[3,2-c(]pyridazinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and
-R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ia)1 as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-cyclopentyl-1 ,4-diazepan-1- yl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(4-methylpiperazin-1-yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 - yl )pyridi ne-3-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(4-methylpiperazin-1 - yl)piperidin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2- yl)piperazin-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-piperidin-1 -ylpiperidin-1 - yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1 H-
1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(pyrrolidin-1-ylmethyl)piperidin-
1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(azepan-1 -yl)piperidin-1 - yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-
(diethylaminoethylmethylamino)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1- y I ) py rid i n-3-y I )- 1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(3-diethylaminopyrrolidin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4- diazepan-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-tιϊazole-3,5-diamine; i^-chloro-Z-methylthienotS^-dlpyrimidine^-yO-Λ^^Θ-CS-bicyclop^.iJheptan^- yloctahydropyrrol[3,4-c]pyrrolyl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diannine; 1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylpiperazin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrirnidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1]heptari- 2-ylpiperazin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1 ]heptan-2- ylpiperazin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2- yl)piperazin-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-bicyclo[2.2.1]heptan-2- ylpiperidin-4-yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(1-bicyclo[2.2.1]heptan-2-ylpiperidin-4- yl )py rid i ne-3-yl )- 1 H-1 ,2,4-triazole-3,5-diamine;
1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-(bicyclo[2.2.1]heptan-2-yl)-5- methylpiperidin-4-yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1- yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1-yl)-5- methylpyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1 - yl)-5-methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-W3-(2-(3-(S)-methyl-4-(1 S,2SI4f?)- bicyclo^^.ilheptan^-ylpiperazin-i-ylVS-methylpyridin-δ-yO-I H-i ^^-triazole- 3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(S)-methyl-4-(2S)- bicycloP^.^heptan^-ylpiperazin-i-yO-S-methylpyridin-S-yO-IH-i ^^-triazole- 3,5-diamine; 1-(thieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-chloropyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin-
1 -yl)-3-chloropyridin-5-yl)-1 H-1 ,2,4-tιϊazole-3,5-diamine;
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin- 1 -yl)-3-methylpyridin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine;
1-(4-methylthieno[3,2-d]pyridazine -7-yl)-/V3-(2-(4-(1 S,2S,4R)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1 -yl)pyridin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin-
1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-bromopyridin-5-yl)-1 H-1 ,2,4-triazole-3,5- diamine;
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(pyrrolidin-1 -yl)propen-1 -yl)pyridin-5-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(3-dimethylaminopyrrolidin-1-yl)propen-
1 -yl )pyrid i n-5-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(3-diethylaminopyrrolidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-pyrrolidin-1 -yl-piperidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-methylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-isopropylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-cyclopentylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(morpholin-4-yl)propen-1-yl)pyridin-5-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(piperidin-1 -yl)propen-1 -yl)pyridin-5-yl)-
1 H-1 ,2,4-triazole-3,5-diamine;
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 - yl)propen-1 -yl)pyhdin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-piperidin-1 -ylpiperidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of furo[3,2-c]pyridinyl and 6,7-dihydro-5H- cyclopenta[4,5]thieno[2,3-d]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2),
-R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: i^furotS^-cJpyridine-ΦyO-Λ^^β^^pyrrolidin-i-yOpiperidin-i-yO-δ-methylpyridin-S-yl)- 1H-1 ,2,4-triazole-3,5-diamine; and
1-(6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-c(]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1- yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen;
R2 is 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of thieno[3,2-c(]pyrimidinyl and quinazolinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2),
-R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(7-cyclopentyl-6,7,8,9-tetrahydro- 5H-pyrido[3,2-d]azepin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(7-cyclopentyl-6,7,8,9-tetrahydro-5/-/-pyrido[3,2- d]azepin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen;
R2 is 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and
-R9-S(O),N(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of isoquinolinyl and thieno[3,2-c/]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2),
-R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2l or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of:
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-methyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(isoquinolin-1 -yO-Λ^-Ce-methyl-S.βJ.δ-tetrahydro-i ,6-naphthyridin-3-yl)-1 H-1 ,2,4- triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-benzyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(ethylcarboxy)-5,6,7,8-tetrahydro- 1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)- 5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5,6,7,8-tetrahydro-1 ,6-naphthyridin- 3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)- 5,6,7,8-tetrahydro-i ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(2-dimethylaminoethyl)- 5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-cyclopentyl-5,6,7,8-tetrahydro- 1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-c(]pyriπnidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylcarbonyl)- 5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(1-methylpiperidin-4-yl)-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(piperidin-4-ylcarbonyl)-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(7-rnethylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclopentyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclopropylmethyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bicyclo[2.2.1]heptan-2-yl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(dimethylaminomethyl)carbonyl- 5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen;
R2 is selected from the group consisting of 6,7,8,9-tetrahydro-5H-cyclohepta[ό]pyridinyl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-b]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, and 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is thieno[3,2-c(]pyrimidinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2>
-R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of:
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(pyrrolidin-1ylcarbonyl)-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(2-(dimethylamino)-1- oxyethylamino)-5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-amino-5,6,7,8-tetrahydroquinolin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(1-methylpiperidin-4-ylamino)- δ.θy.δ-tetrahydroquinolin-S-ylJ-IH-i ^^-triazole-S^-diamine; 1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-yV3-(7',8'-dihydro-5'H- spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl)-1H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-c(]pyrimidin-4-yl)-/V3-(6-(pyrrolidin-1-yl)-4b,5,6,7,7a,8- hexahydropentaleno[2,1-/b]pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-/V3-(6-(4-methylpiperazin-1-yl)-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-cyclopentylamino-5, 6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(7-(pyrrolidin-1-yl)-6,7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylamino)-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonylamino-
5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-cyclopentylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclohexylamino-5, 6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bicyclo[2.2.1]heptan-2-yl-amino-
5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bis-(cyclopropylmethyl)amino-
5,6,7,8-tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) wherein: R1, R4 and R5 are each hydrogen; R2 is pyrimidinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8,
-R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of quinazolinyl and thieno[3,2-c(]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ia), as set forth above, is the compound of formula (Ia) which is selected from the group consisting of: 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyrimidin-5-yl)-1 H-
1 ,2,4-triazole-3,5-diamine;
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-piperidin-1 -ylmethylpiperidin-1 -yl)pyrimidin-5- yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1 -(2-chloro-7-methylthieno[3,2-αf]pyrimidin-4-yl)-/V3-(2-(4-pyrrolidin-1 ylpiperidin-1 - yl)pyrimidin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(piperidin-1-ylmethyl)piperidin-1- yl)pyrimidin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine. Another embodiment of the invention, as set forth above in the Summary of the
Invention, is where the compound of formula (I) is a compound of formula (Ib):
Figure imgf000056_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8,
-R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7,
-R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13,
-R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, form an optionally substituted
Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain.
Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) wherein: R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8,
-R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2); R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12
(where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[it»][1 ,4]dioxinyl,
4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-cf]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-ib]pyridinyl, benzo[6]thiophenyl, 7\8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-t>]pyridinyl, and
6,7,8,9-tetrahydro-5H-cyclohepta[ib]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8
(where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2l or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[ib][1 ,4]dioxinyl, 4,5-dihydro-1/-/-benzo[b]azepin-2(3/-/)-onyl,
6,7,8,9-tetrahydro-5/-/-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-ύ]pyridinyl, benzo[6]thiophenyl, 7',8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl,
4b,5,6,7,7a,8-hexahydropentaleno[2,1-ib]pyridinyl, and
6,7,8,9-tetrahydro-5H-cyclohepta[jb]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8,
-R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2); R3 is a heteroaryl selected from the group consisting of pyridinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-c/]pyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain. Another embodiment of a compound of formula (Ib), as set forth above, is the compound of formula (Ib) selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine;
1-(4-methylthieno[2,3-d]pyridazin-7-yl)-Λ/5-(2-(4-(1 S,2S,4R)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl )-3-methyl pyrid i n-5-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; and
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 - yl)propen-1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine. Other preferred embodiments of R1, R2, R3, R4 and R5 of the compounds of formula (Ib) are the same as set forth above for R1, R2, R3, R4 and R5 of the compounds of formula (Ia).
In any of the embodiments disclosed above, a particular embodiment is directed to compounds of the invention wherein the optionally substituted heteroaryls for R2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted pyrimidinyl, optionally substituted 2,3-dihydrobenzo[b][1 ,4]dioxinyl, optionally substituted 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, optionally substituted 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, optionally substituted 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, optionally substituted 5,6,7,8-tetrahydroquinolinyl, optionally substituted 1H-pyrrolo[2,3-£>]pyridinyl, benzo[£>]thiophenyl, optionally substituted 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3l-yl, and optionally substituted 4b,5,6,7,7a,8-hexahydropentaleno[2,1-/?]pyridinyl. Of this embodiment, a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl. Of this embodiment, a particular embodiment is where the optional substituents on the optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl are optionally substituted heterocyclyl, C3-C6 monocyclic cycloalkyl radicals, C3-C6 monocyclic cycloalkylalky radicals, C7-Ci5 polycyclic cycloalkyl radicals, such as norbomanyl, norbomenyl, as well as substituted C7-Ci5 polycyclic cycloalkyl radicals, such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl.
In any of the embodiments disclosed above, a particular embodiment is directed to compounds of the invention wherein the optionally substituted aryls and heteroaryls for R3 are selected from the group consisting of optionally substituted phenyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted isoquinolinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted thieno[3,2-c/]pyrimidinyl, optionally substituted thieno[3,2- d]pyridazinyl, optionally substituted 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3- cf]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl.
In any of the embodiments disclosed above, a particular embodiment is directed to compounds of the invention wherein the optionally substituted heteroaryls for R3 are selected from the group consisting of optionally substituted isoquinolinyl, optionally substituted pyridinyl, optionally substituted pyrimidinyl, optionally substituted quinazolinyl, optionally substituted phenanthridinyl, optionally substituted thieno[3,2-c/]pyrimidinyl, optionally substituted thieno[3,2-d]pyridazinyl, optionally substituted 6,7-dihydro-5H- cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and optionally substituted furo[3,2-c]pyridinyl and wherein the optionally substituted heteroaryls for R2 are selected from the group consisting of optionally substituted benzoxazolyl, optionally substituted pyridinyl, optionally substituted isoquinolinyl, optionally substituted pyrimidinyl, optionally substituted 2,3-dihydrobenzo[t»][1 ,4]dioxinyl, optionally substituted 4,5-dihydro-1/-/-benzo[b]azepin-2(3H)-onyl, optionally substituted 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, optionally substituted 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, optionally substituted 5,6,7,8-tetrahydroquinolinyl, optionally substituted 1H-pyrrolo[2,3-£>]pyridinyl, benzo[ό]thiophenyl, optionally substituted 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, and optionally substituted 4b,5,6,7,7a,8-hexahydropentaleno[2,1-6]pyridinyl. Of this embodiment, a particular embodiment is where the optional substituents for these heteroaryls are optionally substituted heterocycyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl, particularly optionally substituted piperidinylalkenyl, optionally substituted pyrrolidinylalkenyl, optionally substituted piperazinylalkenyl and optionally substituted morpholinoalkenyl. Of this embodiment, a particular embodiment is where the optional substituents on the optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl and optionally substituted heterocyclylalkenyl are optionally substituted heterocyclyl, C3-C6 monocyclic cycloalkyl radicals, C3-C6 monocyclic cycloalkylalkyl radicals, C7-Ci5 polycyclic cycloalkyl radicals, such as norbomanyl, norbomenyl, as well as substituted C7-Ci5 polycyclic cycloalkyl radicals, such as 7,7-dimethyl-bicyclo[2.2.1]heptanyl.
Of the various aspects of the pharmaceutical compositions of the invention comprising a pharmaceutically acceptable excipient and a compound of formula (I), as set forth above in the Summary of the Invention, certain embodiments are preferred. One embodiment of these pharmaceutical compositions is wherein the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ia), as set forth above, or from any combination of embodiments of the compound of formula (Ia), as set forth above, or the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any combination of embodiments of the compound of formula (Ib), as set forth above.
Of the various aspects of methods of treating a disease or condition associated with AxI activity in a mammal, wherein the method comprises administering to a mammal in need thereof a therapeutically effective amount of a compound of formula (I), certain embodiments are preferred. One embodiment of these methods is the method wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease, osteoporosis, osteoarthritis and cataracts. One embodiment of these methods is the method wherein a manifestation of the disease or condition is solid tumor formation in said mammal.
One embodiment of these methods is the method wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, and uveal melanoma.
One embodiment of these methods is the method wherein a manifestation of the disease or condition is liquid tumor formation in said mammal.
One embodiment of these methods is the method wherein the disease or condition is myeloid leukemia or lymphoma. One embodiment of these methods is the method wherein the disease or condition is endometriosis.
One embodiment of these methods is the method wherein the compounds of formula (I) utilized therein is selected from any one embodiment of the compound of formula (Ia), as set forth above, or from any combination of embodiments of the compound of formula (Ia), as set forth above, or the compound of formula (I) therein is selected from any one embodiment of the compound of formula (Ib), as set forth above, or from any combination of embodiments of the compound of formula (Ib), as set forth above.
Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis, visual impairment due to macular degeneration, diabetic retinopathy or retinopathy of prematurity, kidney disease (including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), osteoporosis, osteoarthritis and cataracts.
Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal a therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer, uveal melanoma, myeloid leukemia and lymphoma. Another embodiment of the invention are those methods of treating a disease or condition associated with AxI activity by administering to the mammal of therapeutically effective amount of a pharmaceutical composition of the invention, as set forth above in the Summary of the Invention, wherein the disease or condition is endometriosis. It is understood that any embodiment of the compounds of formula (Ia) and compounds of formula (Ib), as set forth above, and any specific substituent set forth herein for a R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R14 and R15 group in the compounds of formula (Ia) and the compounds of formula (Ib), as set forth above, may be independently combined with other embodiments and/or substituents of compounds of formula (Ia) and compounds of formula (Ib) to form embodiments of the inventions not specifically set forth above. In addition, in the event that a list of substitutents is listed for any particular R group in a particular embodiment and/or claim, it is understood that each individual substituent may be deleted from the particular embodment and/or claim and that the remaining list of substituents will be considered to be within the scope of the invention. Specific embodiments of the invention are described in more detail in the following sections.
UTILITY AND TESTING OF THE COMPOUNDS OF THE INVENTION
The oncogenic RTK, AxI, was recently identified, using a retroviral-based functional genetic screening protocol, as a regulator of haptotactic migration, which is a key event in angiogenesis. AxI inhibition by RNAi-mediated silencing blocked endothelial cell migration, proliferation and in vitro tube formation. These observations, which were disclosed at the American Association Cancer Research General Meeting, April 16-20, 2005, Anaheim, California, and The 7th Annual Symposium on Anti-Angiogenic Agents, February 10-13, 2005, San Diego, California; (Requirement for The Receptor Tyrosine Kinase AxI in Angiogenesis and Tumor Growth, Holland, SJ. Powell, M.J., Franci, C1 Chan, E., Friera, A.M., Atchison, R., Xu, W., McLaughlin, J., Swift.S.E., Pali, E., Yam, G., Wong, S., Xu, X., Hu, Y., Lasaga, J., Shen, M., Yu, S., Daniel, R., Hitoshi, Y., Bogenberger, J., Nor, J. E., Payan, D. G and Lorens, J. B), were substantiated by an in vivo study which demonstrated that stable, shRNAi-mediated AxI knockdown impaired formation of functional human blood vessels in a mouse model of human angiogenesis. These observations were published in a peer reviewed journal (Holland SJ, Powell MJ, Franci C, Chan EW, Friera AM, Atchison RE, McLaughlin J, Swift SE, Pali ES, Yam G, Wong S, Lasaga J, Shen MR, Yu S, Xu W, Hitoshi Y, Bogenberger J, Nor JE, Payan DG, Lorens JB. "Multiple roles for the receptor tyrosine kinase axl in tumor formation." Cancer Res. (2005) VoI 65 pp 9294-303. These observations are also disclosed in U.S.
Published Patent Application 2005/0118604 and European Patent Application 1 563 094, the disclosures of which are incorporated in full by reference. AxI signaling, therefore, impacts multiple functions required for neovascularization in vitro, and regulates angiogenesis in vivo. Regulation of these pro-angiogenic processes required the catalytic activity of AxI. Thus, Axl-mediated angiogenic stimulation would be amenable to modulation by a small molecule inhibitor of AxI catalytic activity.
Accordingly, the compounds of the invention are small molecule inhibtiors of AxI catalytic activity, and are therefore useful in treating diseases and conditions which are associated with AxI catalytic activity including those diseases and conditions which are characterized by angiogenesis and/or cell proliferation. In particular, the compounds of the invention and pharmaceutical compositions of the invention are useful in treating diseases and conditions which are alleviated by the modulation of AxI activity. For purposes of this invention, diseases and condtions which are alleviated by the "modulation of AxI activity" includes diseases and conditions which are alleviated by a decrease in AxI activity and diseases and conditions which are alleviated by an increase in AxI activity. Preferably such diseases and conditions are alleviated by a decrease in AxI activity. Diseases and conditions which are alleviated by the modulation of AxI activity include, but are not limited to, solid tumors, including, but not limited to, breast, renal, endometrial, ovarian, thyroid, and non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer and uveal melanoma; liquid tumors, including but not limited to, leukemias (particularly myeloid leukemias) and lymphomas; endometriosis, vascular disease / injury (including but not limited to restenosis, atherosclerosis and thrombosis), psoriasis; visual impairment due to macular degeneration; diabetic retinopathy and retinopathy of prematurity; kidney disease
(including but not limited to glomerulonephritis, diabetic nephropathy and renal transplant rejection), rheumatoid arthritis; osteoarthritis, osteoporosis and cataracts.
In addition to the foregoing, the compounds of the invention are useful in treating diseases and conditions which are affected by the following biological processes: Invasion, migration, metastasis, or drug resistance as manifested in cancer; stem cell biology as manifested in cancer; invasion, migration, adhesion, or angiogenesis as manifested in endometriosis; vascular remodeling as manifested in cardiovascular disease, hypertension or vascular injury; bone homeostatasis as manifested in osteoporosis or osteoarthritis; viral infection as manifested, for example, in ebola virus infection; or differentiation as manifested in obesity. The compounds of the invention may also be used to modulate inflammatory processes by treating sepsis, acting as vaccine adjuvants, and/or potentiating the immune response in immuno-compromised patients.
The following animal models provide guidance to one of ordinary skill in the art in testing the compounds of the invention for their use in treating the disease or condition indicated.
The compounds of the invention may be tested for their use in treating leukemias and lymphomas by testing the compounds in the xenograft in SCID mouse model using human Axl-expresing cancer cell lines including, but not limited to, HeLa, MDA-MB-231 , SK-OV-3, OVCAR-8, DU145, H1299, ACHN, A498 and Caki-1. The compounds of the invention may be tested for their use in treating leukemias in the xenograft in SCID or nu/nu mouse model using human Axl-expressing AML and CML leukemia cell lines.
The compounds of the invention may be tested for their use in treating endometriosis by using the syngenic mouse model of endometriosis (see Somigliana, E. et al., "Endometrial ability to implant in ectopic sites can be prevented by interleukin-12 in a murine model of endometriosis", Hum. Reprod. (1999), Vol. 14, NO. 12, pp. 2944-50). The compounds may also be tested for their use in treating endometriosis by using the rat model of endometriosis (see Lebovic, D.I. et al., "Peroxisome proliferator-activated receptor-gamma induces regression of endometrial explants in a rat model of endometriosis", FeAt//. Steril. (2004), 82 Suppl 3, pp. 1008-13).
The compounds of the invention may be tested for their use in treating restenosis by using the balloon-injured rate carotid artery model (see Kim, D.W. et al., "Novel oral formulation of paclitaxel inhibits neointimal hyperplasia in a rat carotid artery injury model", Circulation (2004), Vol. 109, No. 12, pp. 1558-63, Epub 2004 Mar 8).
The compounds of the invention may also be tested for their use in treating restenosis by using the percutaneous transluminal coronary angioplasty in apoE deficient mouse model (see von der Thusen, J. H. et al., "Adenoviral transfer of endothelial nitric oxide synthase attenuates lesion formation in a novel murine model of postangioplasty restenosis", Arterioscler. Thromb. Vase. Biol. (2004), Vol. 24, No. 2, pp. 357-62).
The compounds of the invention may be tested for their use in treating atherosclerosis/thrombosis in the ApoE deficient mouse model (see Nakashima, Y. et al., "ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree", Arterioscler. Thromb. (1994), Vol. 14, No. 1 , pp. 133-40).
The compounds of the invention may also be tested for their use in treating thrombosis using the collagen-epinephrin-induced pulmonary thromboembolism model and the stasis induced venous thrombosis model (see Angelillo-Scherrer A. et al., "Role of Gas6 receptors in platelet signaling during thrombus stabilization and implications for antithrombotic therapy", J Clin Invest. (2005) Vo1 115 pp237-46).
The compounds of the invention may be tested for their use in treating psoriasis by using the SCID mouse model or the human skin model of psoriasis (see Nickoloff, B.J. et al., "Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model", Am. J. Pathol. (1995), Vol. 146, No. 3, pp. 580-8). The compounds of the invention may be tested for their use in treating age- related macular degeneration or diabetic retinopathy by using the rat corneal angiogenesis model (see Sarayba MA, Li L, Tungsiripat T, Liu NH, Sweet PM, Patel AJ, Osann KE, Chittiboyina A, Benson SC, Pershadsingh HA, Chuck RS. Inhibition of corneal neovascularization by a peroxisome proliferator-activated receptor-gamma ligand. Exp Eye Res. 2005 Mar;80(3):435-42) or the laser-induced mouse choroidal neovasculation model (see Bora, P. S., et al., "Immunotherapy for choroidal neovascularization in a laser-induced mouse model simulating exudative (wet) macular degeneration", Proc. Natl. Acad. ScL U. S. A. (2003), Vol. 100, No. 5, pp. 2679-84, Epub 2003 Feb 14).
The compounds of the invention may be tested for their use in treating retinopathy of prematurity in the mouse retinopathy of prematurity model (see Smith, L.E. et al., "Oxygen-induced retinopathy in the mouse", Invest. Ophthalmol. Vis. Sci. (1994), Vol. 35, No. 1 , pp. 101-11 ). The compounds of the invention may be tested for their use in treating glomerulonephritis or diabetic nephropathy in the rat anti-Thy1.1 -induced experimental mesengial proliferative glomerulonephritis model (see Smith, L.E. et al. cited above). The compounds of the invention may be tested for their use in treating renal tranplant rejection by using a rat model of chronic renal transplant rejection (see Yin, J. L. et al., "Expression of growth arrest-specific gene 6 and its receptors in a rat model of chronic renal transplant rejection", Transplantation (2002), Vol. 73, No. 4, pp. 657-60).
The compounds of the invention may be tested for their use in treating rheumatoid arthritis by using the CAIA mouse model (see Phadke, K. et al., "Evaluation of the effects of various anti-arthritic drugs on type Il collagen-induced mouse arthritis model", lmmunopharmacology (1985),Vol. 10, No. 1 , pp. 51-60).
The compounds of the invention may be tested for their use in treating osteoarthritis by using the STR/ORT mouse model (see Brewster, M. et al., "Ro 32-3555, an orally active collagenase selective inhibitor, prevents structural damage in the STR/ORT mouse model of osteoarthritis", Arthritis. Rheum. (1998), Vol. 41 , No. 9, pp. 1639-44).
The compounds of the invention may be tested for their use in treating osteoporosis by using the ovariectomized rat model (see Wronski, T.J. et al., "Endocrine and pharmacological suppressors of bone turnover protect against osteopenia in ovariectomized rats", Endocrinology (1989), Vol. 125, no. 2, pp 810-6) or the ovariectomized mouse model (see Alexander, J. M. et al., "Human parathyroid hormone 1-34 reverses bone loss in ovariectomized mice", J Bone Miner Res. (2001), Vol. 16, no. 9, pp 1665-73; Fujioka, M. et al., "Equol, a metabolite of daidzein, inhibits bone loss in ovariectomized mice", J Nutr. (2004), Vol. 134, no. 10, pp 2623-7).
The compounds of the invention may be tested for their use in treating cataracts by using the H2O2-induced model (see Kadoya, K. et al., "Role of calpain in hydrogen peroxide induced cataract", Curr. Eye Res. (1993), Vol. 12, No. 4, pp. 341-6) or the Emory mouse model (see Sheets, N.L et al., "Cataract- and lens-specific upregulation of ARK receptor tyrosine kinase in Emory mouse cataract", Invest. Ophthalmol. Vis. Sci. (2002), Vol. 43, No. 6, pp. 1870-5).
PHARMACEUTICAL COMPOSITIONS OF THE INVENTION AND ADMINISTRATION
Administration of the compounds of the invention, or their pharmaceutically acceptable salts, in pure form or in an appropriate pharmaceutical composition, can be carried out via any of the accepted modes of administration of agents for serving similar utilities. The pharmaceutical compositions of the invention can be prepared by combining a compound of the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient, and may be formulated into preparations in solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, solutions, suppositories, injections, inhalants, gels, microspheres, and aerosols. Typical routes of administering such pharmaceutical compositions include, without limitation, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal. The term parenteral as used herein includes subcutaneous injections, intravenous, intramuscular, intrasternal injection or infusion techniques. Pharmaceutical compositions of the invention are formulated so as to allow the active ingredients contained therein to be bioavailable upon administration of the composition to a patient. Compositions that will be administered to a subject or patient take the form of one or more dosage units, where for example, a tablet may be a single dosage unit, and a container of a compound of the invention in aerosol form may hold a plurality of dosage units. Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see Remington: The Science and Practice of Pharmacy, 20th Edition (Philadelphia College of Pharmacy and Science, 2000). The composition to be administered will, in any event, contain a therapeutically effective amount of a compound of the invention, or a pharmaceutically acceptable salt thereof, for treatment of a disease or condition of interest in accordance with the teachings of this invention. A pharmaceutical composition of the invention may be in the form of a solid or liquid. In one aspect, the carrier(s) are particulate, so that the compositions are, for example, in tablet or powder form. The carriers) may be liquid, with the compositions being, for example, an oral oil, injectable liquid or an aerosol, which is useful in, for example, inhalatory administration.
When intended for oral administration, the pharmaceutical composition is preferably in either solid or liquid form, where semi-solid, semi-liquid, suspension and gel forms are included within the forms considered herein as either solid or liquid.
As a solid composition for oral administration, the pharmaceutical composition may be formulated into a powder, granule, compressed tablet, pill, capsule, chewing gum, wafer or the like form. Such a solid composition will typically contain one or more inert diluents or edible carriers. In addition, one or more of the following may be present: binders such as carboxymethylcellulose, ethyl cellulose, microcrystalline cellulose, gum tragacanth or gelatin; excipients such as starch, lactose or dextrins, disintegrating agents such as alginic acid, sodium alginate, Primogel, com starch and the like; lubricants such as magnesium stearate or Sterotex; glidants such as colloidal silicon dioxide; sweetening agents such as sucrose or saccharin; a flavoring agent such as peppermint, methyl salicylate or orange flavoring; and a coloring agent.
When the pharmaceutical composition is in the form of a capsule, for example, a gelatin capsule, it may contain, in addition to materials of the above type, a liquid carrier such as polyethylene glycol or oil.
The pharmaceutical composition may be in the form of a liquid, for example, an elixir, syrup, solution, emulsion or suspension. The liquid may be for oral administration or for delivery by injection, as two examples. When intended for oral administration, preferred composition contain, in addition to the present compounds, one or more of a sweetening agent, preservatives, dye/colorant and flavor enhancer. In a composition intended to be administered by injection, one or more of a surfactant, preservative, wetting agent, dispersing agent, suspending agent, buffer, stabilizer and isotonic agent may be included. The liquid pharmaceutical compositions of the invention, whether they be solutions, suspensions or other like form, may include one or more of the following adjuvants: sterile diluents such as water for injection, saline solution, preferably physiological saline, Ringer's solution, isotonic sodium chloride, fixed oils such as synthetic mono or diglycerides which may serve as the solvent or suspending medium, polyethylene glycols, glycerin, propylene glycol or other solvents; antibacterial agents such as benzyl alcohol or methyl paraben; antioxidants such as ascorbic acid or sodium bisulfite; chelating agents such as ethylenediaminetetraacetic acid; buffers such as acetates, citrates or phosphates and agents for the adjustment of tonicity such as sodium chloride or dextrose. The parenteral preparation can be enclosed in ampoules, disposable syringes or multiple dose vials made of glass or plastic. Physiological saline is a preferred adjuvant. An injectable pharmaceutical composition is preferably sterile.
A liquid pharmaceutical composition of the invention intended for either parenteral or oral administration should contain an amount of a compound of the invention such that a suitable dosage will be obtained. Typically, this amount is at least 0.01% of a compound of the invention in the composition. When intended for oral administration, this amount may be varied to be between 0.1 and about 70% of the weight of the composition. Preferred oral pharmaceutical compositions contain between about 4% and about 75% of the compound of the invention. Preferred pharmaceutical compositions and preparations according to the present invention are prepared so that a parenteral dosage unit contains between 0.01 to 10% by weight of the compound prior to dilution of the invention.
The pharmaceutical composition of the invention may be intended for topical administration, in which case the carrier may suitably comprise a solution, emulsion, ointment or gel base. The base, for example, may comprise one or more of the following: petrolatum, lanolin, polyethylene glycols, bee wax, mineral oil, diluents such as water and alcohol, and emulsifiers and stabilizers. Thickening agents may be present in a pharmaceutical composition for topical administration. If intended for transdermal administration, the composition may include a transdermal patch or iontophoresis device. Topical formulations may contain a concentration of the compound of the invention from about 0.1 to about 10% w/v (weight per unit volume).
The pharmaceutical composition of the invention may be intended for rectal administration, in the form, for example, of a suppository, which will melt in the rectum and release the drug. The composition for rectal administration may contain an oleaginous base as a suitable nonirritating excipient. Such bases include, without limitation, lanolin, cocoa butter and polyethylene glycol.
The pharmaceutical composition of the invention may include various materials, which modify the physical form of a solid or liquid dosage unit. For example, the composition may include materials that form a coating shell around the active ingredients. The materials that form the coating shell are typically inert, and may be selected from, for example, sugar, shellac, and other enteric coating agents. Alternatively, the active ingredients may be encased in a gelatin capsule.
The pharmaceutical composition of the invention in solid or liquid form may include an agent that binds to the compound of the invention and thereby assists in the delivery of the compound. Suitable agents that may act in this capacity include a monoclonal or polyclonal antibody, a protein or a liposome.
The pharmaceutical composition of the invention may consist of dosage units that can be administered as an aerosol. The term aerosol is used to denote a variety of systems ranging from those of colloidal nature to systems consisting of pressurized packages. Delivery may be by a liquefied or compressed gas or by a suitable pump system that dispenses the active ingredients. Aerosols of compounds of the invention may be delivered in single phase, bi-phasic, or tri-phasic systems in order to deliver the active ingredient(s). Delivery of the aerosol includes the necessary container, activators, valves, subcontainers, and the like, which together may form a kit. One of ordinary skill in the art, without undue experimentation may determine preferred aerosols. The pharmaceutical compositions of the invention may be prepared by methodology well known in the pharmaceutical art. For example, a pharmaceutical composition intended to be administered by injection can be prepared by combining a compound of the invention with sterile, distilled water so as to form a solution. A surfactant may be added to facilitate the formation of a homogeneous solution or suspension. Surfactants are compounds that non-covalently interact with the compound of the invention so as to facilitate dissolution or homogeneous suspension of the compound in the aqueous delivery system.
The compounds of the invention, or their pharmaceutically acceptable salts, are administered in a therapeutically effective amount, which will vary depending upon a variety of factors including the activity of the specific compound employed; the metabolic stability and length of action of the compound; the age, body weight, general health, sex, and diet of the patient; the mode and time of administration; the rate of excretion; the drug combination; the severity of the particular disorder or condition; and the subject undergoing therapy. Generally, a therapeutically effective daily dose is (for a 70 kg mammal) from about 0.001 mg/kg {i.e., 0.07 mg) to about 100 mg/kg {i.e., 7.0 gm); preferaby a therapeutically effective dose is (for a 70 kg mammal) from about 0.01 mg/kg {i.e., 0.7 mg) to about 50 mg/kg {i.e., 3.5 gm); more preferably a therapeutically effective dose is (for a 70 kg mammal) from about 1 mg/kg {i.e., 70 mg) to about 25 mg/kg {i.e., 1.75 gm). Compounds of the invention, or pharmaceutically acceptable salts thereof, may also be administered simultaneously with, prior to, or after administration of one or more other therapeutic agents. Such combination therapy includes administration of a single pharmaceutical dosage formulation which contains a compound of the invention and one or more additional active agents, as well as administration of the compound of the invention and each active agent in its own separate pharmaceutical dosage formulation. For example, a compound of the invention and the other active agent can be administered to the patient together in a single oral dosage composition such as a tablet or capsule, or each agent administered in separate oral dosage formulations. Where separate dosage formulations are used, the compounds of the invention and one or more additional active agents can be administered at essentially the same time, i.e., concurrently, or at separately staggered times, i.e., sequentially; combination therapy is understood to include all these regimens.
PREPARATION OF THE COMPOUNDS OF THE INVENTION
The following Reaction Scheme illustrates methods to make compounds of this invention, i.e., compounds of formula (I):
Figure imgf000075_0001
where R1, R2, R3, R4 and R5 are described above in the Summary of the Invention for compounds of formula (I), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or /V-oxides. In particular, the following Reaction Scheme illustrates methods to make compounds of formula (Ia):
Figure imgf000075_0002
where R1, R2, R3, R4 and R5 are as described above in the Summary of the Invention for compounds of formula (Ia), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or Λ/-oxides, and methods to make compounds of formula (Ib);
Figure imgf000076_0001
where R1, R2, R3, R4 and R5 are as described above in the Summary of the Invention for compounds of formula (Ib), as isolated stereoisomers or mixtures thereof, as tautomers or mixtures thereof, or as pharmaceutically acceptable salts or Λ/-oxides. It is understood that in the following Reaction Schemes, combinations of substituents and/or variables of the depicted formulae are permissible only if such contributions result in stable compounds.
It will also be appreciated by those skilled in the art that in the processes described below the functional groups of intermediate compounds may need to be protected by suitable protecting groups. Such functional groups include hydroxy, amino, mercapto and carboxylic acid. Suitable protecting groups for hydroxy include trialkylsilyl or diarylalkylsilyl (for example, f-butyldimethylsilyl, /-butyldiphenylsilyl or trimethylsilyl), tetrahydropyranyl, benzyl, and the like. Suitable protecting groups for amino, amidino and guanidino include benzyl, f-butoxycarbonyl, benzyloxycarbonyl, and the like. Suitable protecting groups for mercapto include -C(O)-R" (where R" is alkyl, aryl or arylalkyl), p-methoxybenzyl, trityl and the like. Suitable protecting groups for carboxylic acids include alkyl, aryl or arylalkyl esters.
Protecting groups may be added or removed in accordance with standard techniques, which are known to one of ordinary skill in the art and as described herein. The use of protecting groups is described in detail in Green, T.W. and P. G. M.
Wuts, Protective Groups in Organic Synthesis (1999), 3rd Ed., Wiley. As one of skill in the art would appreciate, the protecting group may also be a polymer resin such as a Wang resin, Rink resin or a 2-chlorotrityl-chloride resin.
It will also be appreciated by those skilled in the art, although such protected derivatives of compounds of this invention may not possess pharmacological activity as such, they may be administered to a mammal and thereafter metabolized in the body to form compounds of the invention which are pharmacologically active. Such derivatives may therefore be described as "prodrugs". All prodrugs of compounds of this invention are included within the scope of the invention. It is understood that one of ordinary skill in the art would be able to make the compounds of the invention by methods simliar to the methods described herein or by methods known to one of ordinary skill in the art. It is also understood that one of ordinary skill in the art would be able to make in a similar manner as described below other compounds of formula (I) not specifically illustrated below by using the appropriate starting components and modifying the parameters of the synthesis as needed. In general, starting components may be obtained from sources such as Sigma Aldrich, Lancaster Synthesis, Inc., Maybridge, Matrix Scientific, TCI, and Fluorochem USA, etc. or synthesized according to sources known to those skilled in the art (see, for example, Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, 5th edition (Wiley, December 2000)) or prepared as described in this invention. 1H NMR spectra were recorded in CDCI3, DMSO-Cf6, CD3OD, Acetone-αfe with trimethylsilane (TMS) as internal reference using Gemini 300 MHz instrument. Reagents and solvents were purchased from commercial sources and used without further purification. Flash column chromatography was conducted using silica gel (230-400 mesh) under a positive pressure of nitrogen. LCMS spectra for purity and mass were recorded using Waters LCMS instruments. Deionized water was used to dilute the reactions and wash the products. Brine used was prepared by dissolving sodium chloride into deionized water to saturation point.
Compounds of formula (Ia), as set forth below in Reaction Scheme 1 below, where R1, R2 and R3 are as defined above in the Summary of the Invention for compounds of formula (I) and R4 and R5 are hydrogen, are generally prepared as illustrated below in Reaction Scheme 1 where R1, R2 and R3 are as defined above in the Summary of the Invention for compounds of formula (I):
REACTION SCHEME 1
PhO
Figure imgf000077_0001
Compounds of formula (A), formula (B) and formula (D) are commercially available or can be prepared by methods known to one skilled in the art or by methods disclosed herein.
In general, compounds of formula (Ia) are prepared, as set forth by Reaction
Scheme 1 , by first treating a compound of formula (A) (1.1 equiv) with an equivalent amount of an aniline of formula (B) in an polar solvent, including, but not limited to, isopropyl alcohol, at ambient temperatures overnight. The diarylisourea product of formula (C) generally precipitates and isolation can be accomplished via filtration, washing with an appropriate solvent, and drying. Hydrazine hydrate of formula (D) (2 equivalents) is added to a slurry of the compound of formula (C) in an alcohol or other appropriate solvent. Generally, the ring formation reaction occurs at ambient temperature and the product triazole of formula (Ia) can be isolated by standard isolation techniques. Compounds of formula (Ia) can be subsequently treated with an appropriately substituted alkylating or acylating agent under standard conditions to form compounds of formula (Ia) where R4 and R5 are as described above in the Summary of the Invention for compounds of formula (I). Compounds of formula (Ib) can be prepared using the synthetic route outlined in
Reaction Scheme 1 in varying amounts depending on the steric and electronic nature of R1, R2 and R3 as well as the particular reaction conditions employed. In some instances, compounds of formula (Ib) are isolated as minor isomers along with compounds of formula (Ia) as major isomers, e.g., during column chromatography as described herein. All compounds of the invention which exist in free base or acid form can be converted to their pharmaceutically acceptable salts by treatment with the appropriate inorganic or organic base or acid by methods known to one of ordinary skill in the art. Salts of the compounds of the invention can be converted to their free base or acid form by standard techniques known to one skilled in the art. The following specific Synthetic Examples are provided as a guide to assist in the practice of the invention, and are not intended as a limitation on the scope of the invention. The number following each compound below refers to its number in Table 1 and Table 2, as discussed in more detail below.
SYNTHETIC EXAMPLE 1
Synthesis of 1-(isoquinolin-1-yl)-Λ/3-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1H-
1 ,2,4-triazole-3,5-diamine
Figure imgf000079_0001
A. Synthesis of 5-amino-2-r(pyrrolidin-1-yQmethyllbenzoxazole
Figure imgf000079_0002
To a solution of 5-nitro-2-[(pyrrolidin-1-yl)methyl]benzoxazole (300 mg, 1.21 mmol) in a mixed solvent of EtOAc-MeOH (1 :1 , 70 mL) was added 10% Pd-C (40 mg), the flask was purged with argon, then the argon was replaced with H2, the reaction mixture was stirred under H2 atmosphere for 30 min. After filtration through Celite, washed with ethyl acetate. The solvents were evaporated to provide 263 mg (100%) of 5-amino-2-[(pyrrolidin-1-yl)methyl]benzoxazole as a yellow solid.
B. Synthesis of (Z)-phenyl /V-cvano-Λ/-(2-(pyrrolidin-1-ylmethyl)benzordloxazol-5- vOcarbamimidate A solution of 5-amino-2-[(pyrrolidin-1-yl)methyl]benzoxazole (200 mg, 0.92 mmol) and diphenylcyanocarbonimidate (263 mg, 1.10 mmol) in isopropyl alcohol (3.5 mL) was stirred overnight at ambient temperature, the resulting white solid product, (Z)-phenyl /V- cyano-/V-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)carbamimidate, was filtered and used directly for the next step (290 mg, 87%). C. Synthesis of 1-(isoquinolin-1-yl)-Λ/3-(2-(pyrrolidin-1-ylmethvπbenzordloxazol-5-yl)- 1 H-1.2.4-triazole-3.5-diamine
A solution of (Z)-phenyl /V-cyano-/V-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5- yl)carbamimidate (36 mg, 0.1 mmol) and 1-hydrazinoisoquinoline in /V-methyl-2- pyrrolidone (0.5 mL) was shaken at 100 0C for 3 hours. After cooling to ambient temperature, the volatiles were evaporated under reduced pressure. The residue was purified by HPLC eluting with acetonitrile - water to provide 1 -(isoquinolin-1 -yl)-/V3-(2- (pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #1 ; 1H NMR (CD3OD, 300 MHz) 8.98 (d, J = 8.4 Hz, 1 H), 8.36 (d, J = 5.7 Hz, 1 H), 7.99 (d, J = 8.1 Hz, 1 H), 7.84-7.58 (m, 4H), 7.26 (dd, .7 = 2.4, 8.7 Hz, 1 H), 6.99 (d, J = 9.0 Hz, 1 H), 5.05 (s, 2H), 3.76 (m, 2H), 3.65 (m, 2H), 3.30 (m, 3H), 2.11 (m, 4H) ppm; MS (ES) 427.16 (M+H).
SYNTHETIC EXAMPLE 2
In a similar manner as described above utilizing the appropriately substituted starting materials and reagents, the following compounds of formula (Ia) were prepared: 1 -(6-chloroquinazolin-4-yl)-/V3-(2-(pyrrolidin-1 -ylmethyl)benzo[d]oxazol-5-yl)-1 H-1 ,2,4- triazole-3,5-diamine, compound #2, MS (ES) 462.08 (M+H); Λ/^.S-dihydrobenzoβHI ,4]dioxin-6-yl)-1 -phenyl-1 H-1 ,2,4-triazole-3,5-diamine, compound #3, tan solid; 1H NMR (DMSO-c/6, 300 MHz) 8.65 (s, 1 H), 7.57 (d, 2H), 7.55 (t, 2H), 7.30-7.22 (m, 2H), 6.93 (d, 1 H), 6.68 (s, 2H), 4.19-4.14 (m, 4H) ppm;
MS (ES) 310.2 (M+H); Λ/3-(2,3-dihydrobenzo[ό][1 ,4]dioxin-6-yl)-1 -(isoquinolin-1 -yl)-1 H-1 , 2,4-triazole-3,5- diamine, compound #4, yellow solid; MS (ES) 361.64 (M+H); Λ/3-(2,3-dihydrobenzo[ιb][1 ,4]dioxin-6-yl)-1 -(6,7-dimethoxyquinazolin-4-yl)-1 H-1 ,2,4- triazole-3,5-diamine, compound #5, yellow solid; MS (ES) 422.05 (M+H).
1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)piperazin-1- yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #6, 1H NMR (DMSO-d6, 300 MHz) 9.13 (d, 2H), 9.10-9.00 (m, 1 H), 8.80 (s, 1 H), 8.71 (s, 1 H), 8.20 (s, 1 H), 7.79 (d, 1 H), 7.39 (s, 1 H), 6.98 (d, 1 H), 4.21-4.18 (m, 2H), 4.01-3.95 (m, 4H), 3.59-3.42 (m, 3H), 3.20-3.03 (m, 4H), 2.62-2.37 (m, 4H), 2.30 (s, 1 H), 2.04-1.98
(m, 1 H), 1.63-1.57 (m, 3H), 1.40 (s, 2H), 1.21 (d, 1 H) ppm; MS (ES) 543.44 (M+H); i^isoquinolin-i-yO-Λ^^θ^^bicyclop^.iJheptan^-yOpiperazin-i-yOpyridin-S-yO-i/-/-
1 ,2,4-triazole-3,5-diamine, compound #7, 1H NMR (DMSO-d6, 300 MHz) 9.23 (d, 1 H), 8.80 (s, 1 H), 8.39 (s, 1 H), 8.31 (d, 1 H), 8.10 (s, 1 H), 8.00 (d, 1 H), 7.83-7.66 (m, 4H), 7.40 (s, 1 H), 6.79 (d, 2H), 2.53-2.41 (m, 8H), 2.31 (s, 2H), 2.16 (s, 1 H), 1.80-1.63 (m, 2H), 1.50-1.17 (m, 5H), 0.89 (d, 1 H) ppm; MS (ES) 482.23 (M+H);
1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin- 3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #8, 1H NMR (DMSO-d6, 300 MHz)
9.21 (s, 1 H), 8.98 (s, 1 H), 8.78 (s, 1 H), 8.60 (d, 1H), 8.21 (s, 1 H), 8.14 (s, 1 H), 7.68 (d, 1H), 7.33 (s, 1H), 6.79 (d, 1H), 4.17 (d, 2H), 3.97 (d, 4H), 2.78-2.63 (m, 2H), 2.58-2.23 (m, 10H), 2.20 (s, 2H), 1.80 (d, 2H), 1.41-1.37 (m, 2H) ppm; MS
(ES) 546.26 (M+H);
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(4,5-dihydro-1 H-benzo[b]azepin-2(3H)-on-8-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #9, 1H NMR (DMSOd6, 300 MHz) 9.47 (s, 1 H), 9.34 (s, 1 H), 9.04 (s, 1 H), 8.80 (s, 1 H), 8.14 (br s, 2H), 7.43 (m, 1 H), 7.36 (s, 1 H), 7.20 (s, 1 H), 7.08 (m, 1 H), 3.98 (s, 3H), 3.90 (s, 3H), 2.59 (m, 2H), 2.13 (m,
2H), 2.05 (m, 2H) ppm; MS (ES) 447.1 (M+H); 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-cyclopentyl-1 ,4-diazepan-1 - yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #10, 1H NMR (DMSOd6, 300 MHz) 9.48 (s, 1 H), 8.45 (m, 1 H), 8.21 (m, 1 H), 8.04 (m, 1 H), 7.98 (br s, 2H), 7.05 (m, 1 H), 4.21 (m, 1 H), 3.65 (m, 6H), 3.20 (m, 2H), 2.37 (s, 3H), 2.18 (m, 2H),
1.98 (m, 2H), 1.60 (m, 6H) ppm; MS (ES) 525.1 (M+H);
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-cyclopentyl-1 ,4-diazepan-1 -yl)pyridin-3-yl)- 1H-1 ,2,4-triazole-3,5-diamine; compound #11 , 1H NMR (DMSOd6, 300 MHz)
9.22 (S, 1 H), 9.00 (m, 1 H), 8.81 (s, 1 H), 8.59 (m, 1 H), 8.17 (br s, 2H), 7.82 (m, 1 H), 7.37 (s, 1 H), 6.90 (m, 1 H), 4.12 (m, 1 H), 3.99 (s, 3H), 3.96 (s, 3H), 3.58 (m,
6H), 3.17 (m, 2H), 2.17 (m, 2H), 1.99 (m, 2H),1.60 (m, 6H) ppm; MS (ES) 531.2
(M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(7-cyclopentyl-6,7,8,9-tetrahydro-
5H-pyrido[3,2-d]azepin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #12, 1H NMR (DMSOd6, 300 MHz) 9.58 (s, 1 H), 8.55 (s, 1 H), 8.26 (s, 1 H), 8.14 (m, 1 H),
7.97 (br s, 2H), 3.10 (m, 3H), 3.00 (m, 3H), 2.68 (m, 1 H), 2.36 (s, 3H), 1.85 (m,
2H), 1.60 (m, 4H), 1.38 (m, 4H) ppm; MS (ES) 496.2 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(7-cyclopentyl-6,7,8,9-tetrahydro-5H-pyrido[3,2- d]azepin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #13, 1H NMR (DMSOd6, 300 MHz) 9.73 (s, 1 H), 9.13 (s, 1 H), 8.97 (s, 1 H), 8.84 (m, 1 H), 8.20 (br s, 2H), 7.77 (s, 1 H), 7.38 (s, 1 H), 4.52 (m, 2H), 3.99 (s, 3H), 3.95 (s, 3H), 3.52 (m, 3H),
3.16 (m, 2H), 1.97 (m, 4H), 1.60 (m, 6H) ppm; MS (ES) 502.2 (M+H); i^-chloro^-methylthienotS^-dlpyrimidine^-yO-Λ^^e-methyl-S.Θ/.δ-tetrahydro-i .e- naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #14, 1H NMR (DMSOd6, 300 MHz) 9.57 (s, 1 H), 8.62 (s, 1 H), 8.29 (s, 1 H), 7.95 (br s, 2H),
7.80 (s, 1 H), 3.55 (s, 2H), 2.82 (s, 2H), 2.69 (d, 2H), 2.37 (d, 6H) ppm; MS (ES)
428.05 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-methylpiperazin-1-yl)pyridin-3- yl)-1tf-1 ,2,4-triazole-3,5-diamine, compound #15, 1H NMR (DMSOd6, 300 MHz) 9.24 (d, 1 H), 8.47 (m, 1 H), 8.23 (d, 1 H), 7.92 (m, 3H), 6.88 (m, 1 H), 3.39 (m, 4H),
2.43-2.36 (m, 7H), 2.23 (m, 3H) ppm; MS (ES) 457.04 (M+); i^isoquinolin-i-yO-Λ^^e-methyl-δ.θJ.δ-tetrahydro-i .e-naphthyridin-S-yO-IH-i ^^- triazole-3,5-diamine, compound #16, 1H NMR (DMSOd6, 300 MHz) 9.26 (m,
2H), 8.48 (s, 1 H), 8.31 (d, 1 H), 8.01 (d, 1 H), 7.82 (t, 1 H), 7.70 (m, 3H), 7.48 (s, 2H), 3.47 (s, 2H), 2.79 (d, 2H), 2.67 (d, 2H), 2.34 (s, 3H) ppm; MS (ES) 373.45
(M+H); 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 - yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #17, 1H NMR (DMSO- dβ, 300 MHz) 9.20 (s, 1H), 8.44 (s, 1 H), 8.23 (s, 1 H), 7.92 (m, 3H), 6.87 (d, 1 H), 4.05 (s, 2H), 2.92-2.78 (m, 4H), 2.42 (s, 3H), 2.15 (m, 1 H),1.88 (s, 4H), 1.66 (s,
4H), 1.40 (m, 2H) ppm; MS (ES) 511.01 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-benzyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #18, 1H NMR
(DMSO-de, 300 MHz) 9.59 (s, 1 H), 8.60 (s, 1 H), 8.08 (s, 1 H), 7.95 (br s, 2H), 7.81 (s, 1 H), 7.35 (m, 5H), 3.70 (s, 2H), 2.60 (s, 2H), 2.79 (m, 4H), 2.37 (s, 3H) ppm; MS (ES) 503.90 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(ethylcarboxy)-5,6,7,8-tetrahydro-
1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #19, 1H NMR
(DMSOd6, 300 MHz) 9.58 (s, 1 H), 8.65 (d, 1 H), 8.26 (s, 1 H), 7.97 (s, 2H), 7.82 (d, 1 H), 4.11 (m, 2H), 2.98 (d, 2H), 2.81 (m, 3H), 2.37 (m, 3H), 2.13 (m, 1 H), 1.89
(m, 1 H), 1.21 (m, 3H) ppm; MS (ES) 485.36 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(pyrrolidin-1ylcarbonyl)-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #20, 1H NMR
(DMSOd6, 300 MHz) 9.52 (s, 1H), 8.66 (d, 1H), 8.26 (s, 1H), 7.96 (s, 2H), 7.77 (d, 1 H), 3.52 (m, 2H), 2.84 (m, 4H), 2.36 (m, 3H), 1.91 (m, 1 H), 1.88 (m, 2H), 1.78 (m, 4H), 1.22 (s, 2H) ppm; MS (ES) 510.39 (M+); -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)-
5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound # 21 , 1H NMR (DMSO-d6, 300 MHz) 9.68 (d, 1 H), 8.70 (d, 1 H), 8.26
(s, 1 H), 7.98 (br s, 2H), 7.90 (d,1 H), 4.83 (s, 1 H), 4.69 (s, 1 H), 3.80 (m, 2H), 2.90 (t, 2H), 2.79 (t, 2H), 2.37 (s, 3H), 2.26 (d, 6H) ppm; MS (ES) 499.13 (M+H);-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)-
5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine formic acid salt (formic acid salt of compound #21 ); -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(4-methylpiperazin-1- yl)piperidin-1-yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #22, 1H NMR (DMSO-de, 300 MHz) 9.20 (s, 1 H), 8.44 (d, 1 H), 8.23 (s, 1 H), 8.17 (s, 1 H), 7.92 (s,2H), 7.88 (d, 1 H), 6.86 (d, 1 H), 4.18 (d, 2H), 2.70 (t, 2H), 2.37 (s, 3H), 2.30 (m, 9H), 2.12 (s, 3H), 1.82 (d, 2H), 1.38 (m, 2H) ppm; MS (ES) 540.15 (M+); -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyridine-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #23, 1H NMR (DMSOd6, 300 MHz) 9.11 (s, 1 H), 8.96 (s, 1 H), 8.74 (s,1 H), 8.59 (d, 1H), 8.18 (s, 2H), 7.65 (d, 1 H), 7.31 (s, 1 H)7 6.78 (d, 1 H), 4.02(d, 2H), 3.95 (d, 6H), 2.77 (m, 2H), 2.13 (m, 2H), 1.86 (m, 3H), 1.64 (s, 5H), 1.37 (m, 3H) ppm; MS (ES) 516.75 (M+); -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1 ]heptan-2- yl)piperazin-1-yl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #24, 1H NMR (DMSO-de, 300 MHz) 9.23 (s, 1 H), 8.44 (d, 1 H), 8.22 (s, 1 H), 7.92 (m, 3H), 6.64 (d,1 H), 4.23 (m, 2H), 3.15 (m, 4H), 2.59 (m, 1 H), 2.37 (s, 3H), 2.29 (s, 1 H), 1.98 (m, 1 H), 1.58 (m, 4H), 1.39 (s, 4H), 1.22 (d, 2H) ppm; MS (ES) 537.13 (M+);-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl yN3-^, 6, 7,8-tetrahydro-1 ,6-naphthyridin- 3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #25, 1H NMR (DMSOd6, 300 MHz) 9.84 (s, 1 H), 9.06 (s, 2H), 8.82 (s, 1 H), 8.23 (s, 1 H), 8.00 (s, 2H), 7.89 (s, 1 H), 4.40 (s, 2H), 3.49 (s, 2H), 3.04 (t, 2H), 2.38 (s, 3H), ppm; MS (ES) 413.77 (M+); -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-piperidin-1 -ylpiperidin-1 -yl)pyridine-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #27, 1H NMR (DMSOd6, 300 MHz) 9.12 (S1 1 H), 8.97 (s, 1 H), 8.75 (s, 1 H), 8.60 (s, 1 H), 8.19 (s,2H), 7.65 (d,1 H), 7.32 (s, 1H), 6.78 (d, 1H), 4.17 (d, 2H), 3.97 (d, 6H), 2.66 (t, 3H), 2.42 (d, 4H), 2.75 (d, 2H), 1.46 (s, 6H), 1.38 (d, 2H) ppm; MS (ES) 531.50 (M+H); 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-piperidin-1 -ylpiperidin-1 - yl)pyridine-3-yl)-1/-/-1 ,2I4-triazole-3,5-diamine, compound # 28, 1H NMR (DMSO- Cl6, 300 MHz) 9.20 (s, 1 H), 8.43 (s, 1 H), 8.23 (s,1 H), 7.91 (s, 2H), 7.88 (d, 1 H), 6.85 (d, 1 H), 4.20 (d, 2H), 2.67 (t, 3H), 2.43 (s, 4H), 2.37 (s, 3H), 1.76 (d, 2H), 1.45-1.37 (m, 8H) ppm; MS (ES) 525.11 (M+);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(2-(dimethylamino)-1- oxyethylamino)-5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #29, 1H NMR (DMSO-d6, 300 MHz) 10.33 (s, 1 H), 9.63 (s, 1 H), 8.84 (s, 1H), 8.65 (d, 1H), 8.25 (s, 1 H), 8.10 (d,2H), 4.20 (s, 2H), 3.87 (m, 2H), 3.22 (d, 1 H), 3.07 (t, 2H), 2.80 (s, 6H), 2.40 (s, 3H), 2.04 (m, 1 H), 1.92 (m, 1 H) ppm; MS
(ES) 513.17 (M+);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-amino-5,6,7,8-tetrahydroquinolin- 3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #30, 1H NMR (DMSO-d6, 300 MHz) 9.98 (s, 1 H), 8.82 (s, 1 H), 8.23 (s, 1 H), 8.06 (d, 5H), 3.60 (s, 2H), 3.25 (d, 1 H), 2.99 (d, 2H), 2.38 (s, 3H),2.10 (m, 1 H), 1.95 (m, 1 H) ppm; MS (ES) 428.09
(M+);
1 -(isoquinolin-1 -yl)-Λ/3-(6-(4-methylpiperazin-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5- diamine, compound #31 , 1H NMR (DMSOd6, 300 MHz) 9.24 (d, 1 H), 8.86 (br s, 1 H)1 8.37 (d, 1 H), 8.29 (d, 1 H), 8.01 (d, 1 H), 7.83-7.79 (m, 2H), 7.74-7.67 (m, 2H), 7.40 (br s, 2H), 6.80 (d, 1 H), 3.30 (m, 4H), 2.45 (m, 4H), 2.25 (s, 3H) ppm;
MS (ES) 402.28 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H- 1 ,2,4-triazole-3,5-diamine, compound #32, 1H NMR (CD3OD-CDCI3, 300 MHz) 8.50 (m, 1 H), 8.29 (m, 1 H), 7.91 (m, 1 H), 7.68 (s, 1 H), 7.31 (m, 1 H), 6.44 (m, 1 H), 2.65 (m, 2H), 2.43 (s, 3H); MS (ES) 397.95 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(pyrrolidin-1-ylmethyl)piperidin- 1-yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #33, 1H NMR (CD3OD, 300 MHz) 8.67 (s, 1 H), 7.98 (m, 2H), 7.42 (m, 1 H), 4.23 (d, 2H), 3.73 (br s, 2H), 3.18 (m, 4H), 2.43 (s, 3H), 2.19 (m, 6H), 1.50 (m, 2H); MS (ES) 525.09 (M+H); 1 -(θ^-dimethoxyquinazoline^-yO-Λ^^θ^^pyrrolidin-i -ylmethyl)piperidin-1 -yl)pyridin-3- yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #34, 1H NMR (CD3OD, 300 MHz) 8.98 (s, 1 H), 8.84 (s, 1 H), 8.50 (m, 1H), 8.12 (m, 1 H), 7.38 (m, 2H), 4.16 (m, 2H), 4.07 (s, 3H), 3.97 (s, 3H), 3.73 (m, 2H), 3.17 (m, 4H), 2.65 (m, 1 H), 2.19 (m, 4H), 2.04 (m, 4H), 1.46 (m, 2H); MS (ES) 531.19 (M+H); 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(azepan-1 -yl)piperidin-1 - yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #35, 1H NMR (CD3OD, 300 MHz) 8.57 (s, 1 H), 8.39 (s, 1 H), 7.98 (m, 1 H), 6.94 (m, 1 H), 4.38 (m, 1 H),
3.53 (m, 2H), 2.93 (t, 2H), 2.43 (s, 3H), 2.20-1.60 (m, 16H); MS (ES) 539.07 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-
(diethylaminoethylmethylamino)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #36, 1H NMR (CD3OD, 300 MHz) 8.75 (s, 1 H), 8.47 (s, 1 H), 8.00 (m, 1 H), 6.92 (m, 1 H), 3.93 (m, 4H), 3.42 (m, 4H), 3.08 (s, 3H), 2.41 (s, 3H), 1.36 (m, 6H); MS (ES) 487.07 (M+H);
1-(6J-dimethoxyquinazoline-4-yl)-Λ^-(6-(diethylaminoethylmethylamino)pyridin-3-yl)-1H- 1 ,2,4-triazole-3,5-diamine, compound #37, 1H NMR (CD3OD, 300 MHz) 9.10 (s, 1 H), 8.75 (s, 1 H), 8.46 (s, 1 H), 8.40 (s, 1 H), 7.28 (m, 1 H), 6.79 (m, 1 H), 4.04 (s, 3H), 3.97 (s, 3H), 3.85 (m, 4H), 3.40 (m, 4H), 3.08 (s, 3H), 1.31 (m, 6H); MS (ES) 493.37 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1- yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #38; 1H NMR (CD3OD- CDCI3, 300 MHz) 8.42 (m, 3H), 7.96 (m, 2H), 7.82 (m, 2H), 7.17 (m, 1 H)1 6.78 (m, 2H), 4.38 (m, 2H), 3.62 (m, 2H), 2.68-1.21 (m, 13H); MS (ES) 515.08 (M+H); 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1 -yl)pyridin-3- yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #39; 1H NMR (CD3OD, 300 MHz) 9.03 (s, 1 H), 8.74 (s, 1 H), 8.35 (s, 2H), 8.06 (m, 2H), 7.27 (s, 1 H), 6.82 (m, 2H), 4.38 (m, 2H), 4.03 (s, 3H), 3.90 (s, 3H), 3.60 (m, 2H), 2.40-1.80 (m, 4H), 1.30 (m, 6H); MS (ES) 519.18 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(1-(4-(2-(dimethylamino)ethyl)piperazin-1- yl)oxomethyl)benzo[b]thiophen-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #40; 1H NMR (CD3OD, 300 MHz) 9.09 (m, 1 H), 8.72 (m, 1 H), 8.39 (s, 2H), 8.11 (s, 1 H), 7.73 (m, 1 H), 7.61 (m, 1 H), 7.47 (m, 1 H), 7.21 (s, 1 H), 4.00-3.84 (m, 6H),
3.54 (m, 1 H), 3.30 (s, 3H), 2.91 (s, 3H), 2.77 (m, 1 H), 2.65 (m, 4H), 1.33 (m, 1 H); MS (ES) 603.14 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #41 ; 1H-NMR (DMSO-d6, 300 MHz) 9.50 (s, 1 H), 8.40 (s, 1 H), 8.27 (s, 1 H), 7.97 (br. s, 3H),
3.55 (m, 2H), 3.41-3.37 (m, 2H), 3.26 (m, 1H), 3.13-3.09 (m, 2H), 2.75 (t, 2H), 2.38 (s, 3H), 2.30 (s, 3H), 2.15-2.11 (m, 2H), 2.02 (m, 2H), 1.86-1.73 (m, 4H) ppm; MS (ES) 525.20 (M); 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-
3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #42; 1H-NMR (DMSO-d6, 300 MHz) 9.29 (br. s, 1 H)1 9.07 (s, 1H), 8.79 (s, 1 H), 8.73 (s, 1 H), 8.19 (br. s, 2H),
7.52 (s, 1 H), 7.36 (s, 1 H), 3.99 (s, 3H), 3.96 (s, 3H), 3.55 (m, 2H), 3.39-3.35 (m, 2H), 3.26 (m, 1 H), 3.13-3.09 (m, 2H), 2.72 (t, 2H), 2.22 (s, 3H), 2.14-2.11 (m, 2H), 2.02 (m, 2H), 1.86-1.72 (m, 4H) ppm; MS (ES) 531.20 (M+H); 1 -(phenanthridin-6-yl)-/V3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; compound #43; 1H-NMR (DMSOd6, 300 MHz) 9.26 (s,
1 H), 9.23 (br. s, 1 H), 8.92 (d, J = 8.1 Hz, 1 H), 8.79 (d, J = 7.2 Hz, 1 H), 8.35 (s, 1 H), 8.09 (d, J = 7.2 Hz, 1 H), 8.00 (t, J = 7.2 Hz 1 H), 7.87 (s, 1 H), 7.83-7.71 (m, 3H), 7.46 (br. s, 2H), 3.55 (m, 2H), 3.39-3.35 (m, 2H), 3.25 (m, 1 H), 3.11-3.08 (m, 2H), 2.78-2.70 (m, 2H), 2.24 (s, 3H), 2.12-2.10 (m, 2H), 2.01 (m, 2H), 1.85-1.71 (m, 4H) ppm; MS (ES) 520.27 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(3-diethylaminopyrrolidin-1- yl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #44;
1 -(δJ-dimethoxyquinazoline^-yO-Λ^^Θ^S-diethylaminopyrrolidin-i -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #45; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4- diazepan-1-yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #46; 1H NMR (DMSO-d6, 300 MHz) 9.54 (s, 1 H), 8.45 (m, 1 H), 8.18 (m, 1 H), 8.02 (m, 3H), 7.08 (m, 1 H), 3.55 (m, 6H), 3.14 (m, 2H), 2.55 (m, 2H), 2.35 (s, 3H), 2.24 (m, 3H), 1.98 (m, 1 H), 1.54 (m, 3H), 1.37 (m, 3H), 1.22 (m, 1 H) ppm; MS (ES) 551.1 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4-diazepan-1- yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #47; 1H NMR (DMSOd6, 300 MHz) 9.08 (s, 1 H), 8.79 (m, 1 H), 8.64 (m, 2H), 8.20 (m, 2H), 8.02 (m, 1 H), 7.76 (m, 1 H), 7.37 (m, 1 H), 3.97 (s, 3H), 3.86 (s, 3H), 3.53 (m, 1 H), 3.09 (m, 2H), 2.24 (m, 4H), 1.94 (m, 4H), 1.58-1.28 (m, 12H) ppm; MS (ES) 557.2 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1- yl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #48; 1H NMR (DMSOd6, 300 MHz) 9.40 (s, 1 H), 8.52 (m, 1 H), 8.22 (m, 1 H), 7.99 (m, 3H), 7.04 (m, 1 H), 4.29 (m, 2H), 3.63 (m, 2H), 3.09 (m, 6H), 2.35 (s, 3H), 1.08 (m, 1 H), 0.65 (m, 2H), 0.37 (m, 2H) ppm; MS (ES) 497.1 (M+H); 1 -(5-trifluoromethylpyridin-2-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #49; 1H NMR (DMSO-d6> 300 MHz) 9.32 (s, 1 H), 8.74 (s, 1 H), 8.59 (m, 1 H), 8.27 (m, 1 H), 7.87 (m, 4H), 7.12 (m, 1 H)1 4.24 (m, 2H), 3.62 (m, 2H), 3.16 (m, 6H), 1.06 (m, 1 H), 0.64 (m, 2H), 0.36 (m, 2H) ppm; MS (ES) 460.6 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(2-dimethylaminoethyl)- 5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #50; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylamino)- 5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound # 51 ; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-cyclopentyl-5,6,7,8-tetrahydro-
1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #52; 1-(furo[3,2-c]pyridine-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-3-yl)- 1H-1 ,2,4-triazole-3,5-diamine, compound #53; 1H-NMR (DMSO-d6, 300 MHz) 9.04 (br. s, 1 H), 8.36 (d, J = 2.1 Hz, 1 H), 8.25 (d, J = 5.7 Hz, 1 H), 8.19 (d, J = 1.8 Hz, 1 H), 7.89 (br. s, 2H), 7.78-7.76 (m, 1 H), 7.53-7.50 (m, 2H), 3.26 (m, 4H), 3.22
(m, 4H), 2.67 (m, 4H), 2.42 (m, 1 H), 2.25 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 460.20 (M+H); 1-(6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-d]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1- yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #54; 1 H-NMR (DMSO-d6, 300 MHz) 8.85 (br. s, 1 H), 8.69 (s, 1 H), 8.18 (s, 1 H),
7.79 (br. s, 2H), 7.73 (s, 1 H), 3.05-3.01 (m, 4H), 2.71 (m, 1 H), 2.65 (m, 4H), 2.42 (m, 4H), 2.28-2.25 (m, 2H), 2.20 (s, 3H), 1.96-1.92 (m, 2H), 1.72 (m, 4H), 1.58- 1.54 (m, 4H) ppm; MS (ES) 517.15 (M+H); 1 -(2-methylquinazolin-4-yl)-/V3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl)- 1 H-1 ,2,4-triazole-3,5-diamine, compound #55; 1 H-NMR (DMSOd6, 300 MHz)
9.63 (d, J = 8.4 Hz, 1 H), 9.25 (br. s, 1 H), 8.26 (s, 1 H), 8.20 (s, 1 H), 7.94-7.84 (m, 2H), 7.66-7.61 (m, 1 H), 3.28 (m, 4H), 3.24 (m, 4H), 2.72 (s, 3H), 2.70 (m, 4H), 2.43 (m, 1 H), 2.27 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 485.18 (M+H), 483.30 (M- H); 1 -(6-fluoroquinazolin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl)-5-methylpyridin-3-yl)- 1H-1 ,2,4-triazole-3,5-diamine, compound #56; 1H-NMR (DMSOd6, 300 MHz) 9.52 (d, J = 9.9 Hz, 1 H), 9.33 (br. s, 1 H), 8.93 (s, 1 H), 8.37 (br. s, 2H), 8.21 (s, 1 H), 8.04-8.01 (m, 1 H), 7.94 (s, 1 H), 3.28 (m, 4H), 3.24 (m, 4H), 2.68 (m, 4H), 2.56 (m, 1H), 2.28 (m, 4H), 2.28 (s, 3H), 1.73 (m, 4H) ppm; MS (ES) 489.15 (M+H), 487.14 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(5-bicyclo[2.2.1]heptan-2- yloctahydropyrrol[3,4-c]pyrrolyl)pyridine-3-yl)-1/-/-1 )2,4-triazole-3,5-diamine, compound #57;
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-bromopyridin-3-yl)-5-(3-(6-bromopyridin-3-yl)-2- cyanoguanadino)-1H-1 ,2,4-triazole-3-amine, compound #58; MS (ES) 666.96
(M+H), 664.99 (M-H);
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-bromopyridin-3-yl)-1 H-1 ,2,4-triazole-3,5- diamine, compound #59; 1H NMR (CDCI3, 300 MHz) 9.58 (s, 1 H), 9.07 (s, 1 H), 8.81 (s, 1H), 8.78 (s, 1H), 8.32-8.11 (m, 2H), 7.91 (m, 1H), 7.32 (m, 2H), 3.91 (s, 6H) ppm; MS (ES) 444.96 (M+H);
1-(2-chloro-7-methylthieno[3,2-c(]pyrimidin-4-yl)-Λ/3-(7I,8'-dihydro-5'H- spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #60;
1-(2-chloro-7-methylthieno[3,2-cf]pyrimidin-4-yl )-AΛ-(6-(1 -methylpiperidin-4-ylcarbonyl)- 5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #61 ;
1 -(6,7-dimethoxyquinazoline-4-yl)-A/3-(2-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyrimidin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #62; 1H NMR (CD3OD, 300 MHz) 9.25 (m, 1 H), 8.42 (m, 1 H), 8.29 (m, 2H), 7.85 (m, 1 H), 7.66 (m, 2H), 7.49 (s, 1 H), 4.06 (s, 3H), 4.03 (S, 3H), 3.83 (m, 4H), 3.30-2.80 (m, 7H), 2.06 (m, 4H), 1.85 (m, 2H);
MS (ES) 518.20 (M+H);
1-(6,7-dimethoxyquinazoline-4-yl)-A/3-(2-(4-piperidin-1-ylmethylpiperidin-1-yl)pyrimidin-5- yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #63;1H NMR (CD3OD, 300 MHz) 8.73 (s, 1H), 8.65 (s, 1 H), 7.96 (s, 1 H), 7.65 (s, 1H), 7.67 (m, 2H), 7.52 (m, 2H), 4.76 (m, 2H), 3.94 (m, 2H), 3.85 (s, 3H), 3.82 (s, 3H), 3.20-2.58 (m, 8H), 2.43-
1.88 (m, 5H), 1.43-1.28 (m, 4H); MS (ES) 546.23 (M+H);
1-(2-chloro-7-methylthieno[3,2-cOpyrimidin-4-yl)-A/3-(6-(pyrrolidin-1-yl)-4b,5,6,7,7a,8- hexahydropentaleno[2, 1 -ύ]pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #64; 1-(6,7-dimethoxyquinazoline-4-yl)-A/3-(6-(3-(4-(4-methylpiperazin-1-yl)piperidin-1- yl)propenyl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #65; 1H NMR (DMSO-d6, 300 MHz) 9.65 (s, 1 H), 9.04 (s, 1 H), 8.88-8.75 (m, 2H), 8.31-8.14 (m, 3H), 7.94 (d, 1 H), 7.36 (m, 2H), 6.51 (m, 2H), 3.98 (s, 6H), 2.91 (s, 3H), 2.55-2.10 (m, 12H), 1.73 (m, 2H), 1.41 (m, 3H), 1.23-1.08 (m, 2H) ppm; MS (ES) 586.27 (M+H), 584.39 (M-H); 1-(2-chloro-7-methylthieno[3>2-QGpyrimidin-4-yl)-Λ/3-(6-(4-methylpiperazin-1-yl)-5,6,7,8- tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #66;
1 -(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(3-(4-piperidin-1 -ylpiperidin-1 - yl)propenyl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #67; 1H NMR (DMSO-d6, 300 MHz) 9.66 (s, 1 H), 9.04 (s, 1 H), 8.86 (s, 1 H), 8.80 (s, 1 H), 8.35-
8.13 (m, 2H), 7.94 (m, 1H), 7.36 (m, 2H), 6.50 (m, 2H), 3.98 (s, 6H), 3.13 (m, 2H), 2.98 (m, 2H), 2.78 (m, 4H), 2.44 (m, 3H), 1.99 (m, 2H), 1.82 (m, 2H), 1.66-1.21 (m, 6H) ppm; MS (ES) 571.25 (M+H), 569.43 (M-H);
1-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylpiperazin-1- yl)pyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #68; 1H NMR (DMSOd6,
300 MHz) 9.423 (s, 1 H), 8.79 (br s, 2H), 8.52 (m, 1 H), 8.23 (m, 1 H), 7.98 (m, 1 H), 7.04 (m, 1H), 3.62 (m, 4H), 3.02 (m, 4H), 2.36 (s, 3H), 2.04 (m, 1H), 0.99 (m, 2H), 0.84 (m, 2H) ppm; MS (ES) 483.1 (M+H);
1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-dimethylaminopiperidin-1- yl)(propenyl)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #69; 1H NMR
(DMSOd6, 300 MHz) 9.65 (s, 1 H), 9.04 (s, 1 H), 8.86 (s, 1 H), 8.81 (s, 1 H), 8.24 (s, 2H), 8.18 (s, 1 H), 7.96 (d, 1 H), 7.36 (m, 1 H), 6.50 (m, 2H), 3.98 (s, 6H), 3.11 (m, 2H), 2.92 (m, 2H), 2.51-2.25 (m, 3H), 1.96 (m, 2H), 1.77 (m, 2H), 1.47 (m, 2H), 1.21-1.05 (m, 2H) ppm; MS (ES) 531.26 (M+H), 529.44 (M-H); 1-(2-chloro-7-methylthieno[3,2-αf]pyrimidin-4-yl)-/V3-(6-cyclopentylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #70;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1]heptan- 2-ylpiperazin-1 -yl)pyridine-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine trifluoroacetic acid salt, compound #71 ; 1 -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1 ]heptan-2- ylpiperazin-1-yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #72;
1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-((1 S,2S,4f?)-bicyclo[2.2.1]heptan-2- yl)piperazin-1 -yl)pyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine trifluoroacetic acid salt, compound #73; 1H-NMR (DMSOd6, 300 MHz) 9.29 (br. s, 1 H), 8.87 (s, 1 H), 8.54 (s, 1 H), 8.14 (br. s, 2H), 8.03 (d, J = 9.3 Hz, 1 H), 7.03 (d, J = 8.7 Hz, 1 H),
3.58-3.48 (m, 4H), 3.20-3.08 (m, 4H), 2.43 (s, 3H), 2.29-2.27 (m, 2H), 2.02-1.98 (m, 1 H), 1.61-1.57 (m, 4H), 1.39 (m, 6H), 1.25-1.15 (m, 1 H) ppm; MS (ES) 503.32 (M+H);
1-(6,7-dimethoxyquinazoline-4-yl ^N3 -(5, 7,8,9-tetrahydrospiro[cyclohepta[b]pyridine-6, 2'- [1 ,3]dioxolane]-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #74; 1H-NMR (DMSO-Cl6, 300 MHz) 9.28 (br. s, 1 H), 9.06 (s, 1 H), 8.81 (d, J = 12.9 Hz, 1 H), 8.18 (br. s, 2H), 7.53 (d, J = 17.4 Hz, 1 H), 7.37 (d, J = 12.9 Hz, 1 H), 3.99 (s, 3H), 3.94 (s, 3H), 3.88-3.86 (m, 4H), 2.93 (m, 2H), 2.89 (m, 2H), 1.89 (m, 2H), 1.62 (m, 2H) ppm; MS (ES) 491.19 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(5,7,8,9- tetrahydrospiro[cyclohepta[b]pyridine-6,2'-[1 ,3]dioxolane]-3-yl)-1 H-1 ,2,4-triazole- 3,5-diamine, compound #75; 1H-NMR (DMSOd6, 300 MHz) 10.37 (br. s, 1 H), 8.77 (s, 1 H), 8.27 (s, 1 H), 8.24 (s, 1 H), 8.09 (br. s, 2H), 3.95-3.88 (m, 4H), 3.23 (s, 2H), 3.12-3.10 (m, 2H), 2.39 (s, 3H), 1.98-1.96 (m, 2H), 1.74 (m, 2H) ppm; MS (ES) 485.66 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5,6,8,9- tetrahydrospiro[cyclohepta[b]pyridine-7,2'-[1 ,3]dioxolane]-3-yl)-1 H-1 ,2,4-triazole- 3,5-diamine, compound #76; 1H-NMR (DMSO-d6, 300 MHz) 10.35 (br. s, 1H), 8.83 (s, 1 H), 8.27 (s, 1 H), 8.18 (s, 1 H), 8.08 (br. s, 2H), 3.95-3.94 (m, 4H), 3.04 (m, 2H), 3.90 (m, 2H), 2.39 (s, 3H), 1.84 (m, 4H) ppm; MS (ES) 485.05 (M+H),
483.15 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(7-(pyrrolidin-1-yl)-6, 7,8,9- tetrahydro-5H-cyclohepta[b]pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #77; 1H-NMR (DMSOd6, 300 MHz) 10.13 (br. s, 1 H), 8.82 (s, 1 H), 8.25 (s, 1 H), 8.06 (br. s, 2H), 3.49 (m, 4H), 3.26 (m, 1 H), 3.14-3.07 (m, 4H), 2.39 (s, 3H), 1.98
(m, 4H), 1.85 (m, 2H), 1.62-1.50 (m, 2H) ppm; MS (ES) 485.05 (M+H), 496.09 (M), 494.32 (M-H); I^ΘJ-dimethoxyquinazoline^-yO-Λ^^Θ^S^S^diethylaminoJpyrrolidin-i- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #78; 1H NMR (DMSO-d6, 300 MHz) 9.64 (s, 1 H), 9.05 (s, 1 H), 8.86 (s, 1 H), 8.77 (s, 1 H), 8.24
(m, 2H), 7.94 (d, 1 H), 7.35 (s, 2H), 6.52 (s, 2H), 3.98 (s, 6H), 3.32-3.01 (m, 7H), 2.53 (m, 8H), 1.87 (m, 2H), 1.61 (m, 2H) ppm; MS (ES) 545.25 (M+H), 543.26 (M-H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(3-(dimethylamino)pyrrolidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #79; 1H NMR
(DMSOd6, 300 MHz) 9.61 (s, 1 H), 9.01 (s, 1 H), 8.86 (s, 1 H), 8.79 (s, 1 H), 8.23 (s, 2H), 8.17 (s, 1 H), 7.92 (d, 1 H), 7.36 (m, 1 H), 6.51 (m, 2H), 3.98 (s, 6H), 3.12 (m, 2H), 2.92 (m, 2H), 2.51-2.25 (m, 3H), 1.75 (m, 2H), 1.42 (m, 2H), 1.21-1.01 (m, 2H) ppm; MS (ES) 517.19 (M+H), 515.02 (M-H); I^ΘJ-dimethoxyquinazoline^-yO-Λ^^e^S-piperidin-i-ylpropenyOpyridin-S-yO-i H-1 ,2,4- triazole-3,5-diamine, compound #80; 1H NMR (DMSOd6, 300 MHz) 9.65 (s, 1 H), 9.05 (s, 1 H), 8.84 (s, 1 H), 8.81 (s, 1 H), 8.24 (s, 2H), 8.19 (s, 1 H), 7.96 (d, 1 H), 7.32 (m, 1 H), 6.50 (m, 2H), 3.91 (s, 6H), 3.13 (m, 2H), 2.23 (m, 4H), 1.63-1.47 (m, 6H) ppm; MS (ES) 488.56 (M+H), 486.57 (M-H); 1 -(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(3-(4-pyrrolidin-1 -ylpiperidin-1 - yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #81 ; 1H NMR (DMSOd6, 300 MHz) 9.60 (s, 1 H), 9.06 (s, 1 H), 8.82 (s, 1 H), 8.81 (s, 1 H), 8.32- 8.13 (m, 4H), 7.91 (m, 1 H), 7.36 (m, 2H), 6.53 (m, 2H), 3.95 (s, 6H), 3.15 (m, 2H), 2.91 (m, 2H), 2.73 (m, 4H), 2.44 (m, 3H), 1.92 (m, 2H), 1.85 (m, 2H), 1.67-1.18 (m, 4H) ppm; MS (ES) 557.27 (M+H), 555.52 (M-H);
1-(2-chloro-7-methylthieno[3,2-c(|pyrimidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8- tetrahydroquinolin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #82; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(1-bicyclo[2.2.1]heptan-2- ylpiperidin-4-yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #83; 1H NMR (DMSOd6, 300 MHz) 9.81 (m, 1 H), 8.92 (m, 1 H), 8.26 (m, 1 H), 8.05 (m,
3H), 7.33 (m, 1 H), 3.53 (m, 1 H), 3.02 (m, 4H), 2.37 (s, 3H), 2.26 (m, 2H), 2.05 (m, 6H), 1.56 (m, 4H), 1.39 (m, 3H) ppm; MS (ES) 536.2 (M+H);
Figure imgf000091_0001
tetrahydroquinolin-3-yl)-1H-1 ,2,4-thazole-3,5-diamine, compound #84; 1-(7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3- yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #85;
1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #86; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(piperidin-4-ylcarbonyl)-5, 6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #87;
1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-bicyclo[2.2.1]heptan-2-ylpiperidin-4- yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #88; 1H NMR (DMSO- dβ, 300 MHz) 9.57 (m, 1H), 8.89 (m, 2H), 8.18 (m, 3H), 8.03 (m, 1 H), 7.25 (m, 1 H), 2.98 (m, 3H), 2.42 (s, 3H), 2.22-1.22 (m, 17H) ppm; MS (ES) 502.2 (M+H); 1 -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1 - yl)pyridine-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #89; 1H NMR (DMSO- d6, 300 MHz) 9.15 (m, 1 H), 8.86 (m, 1 H), 8.49 (m, 1 H), 8.12 (m, 3H), 7.95 (m, 1 H), 6.86 (m, 1 H), 3.38 (m, 4H), 2.52 (m, 4H), 2.41 (s, 3H), 2.19 (m, 2H), 0.84 (m,1H), 0.46 (m, 2H), 0.07 (m, 2H) ppm; MS (ES) 463.1 (M+H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-cyclopentylpiperazin-1-yl)propenyl)pyridin- 3-yl)-1 H-1 ,2,4-triazole-3,5-diamine, compound #90; 1H NMR (DMSO-d6, 300 MHz) 9.65 (s, 1 H), 8.94 (s, 1 H), 8.67 (s, 1 H), 8.65 (s, 1 H), 8.23-8.11 (m, 4H), 7.89 (m, 1 H), 7.31 (m, 2H), 6.59 (m, 2H), 3.88 (s, 6H), 3.18 (m, 2H), 2.91-2.73 (m, 6H), 2.39 (m, 3H), 1.88 (m, 2H), 1.89 (m, 2H), 1.69-1.09 (m, 4H) ppm; MS (ES) 557.21 (M+H), 555.47 (M-H);
1 -(2-chloro-7-methylthieno[3,2-cOpyrimidin-4-yl)-Λ/3-(2-(4-pyrrolidin-1 ylpiperidin-1 - yl)pyrimidin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #91 ; 1H-NMR (DMSO- dβ, 300 MHz) 9.35 (br. s, 1 H), 8.75 (s, 2H), 8.28 (s, 1 H), 7.99 (br. s, 2H), 4.69- 4.64 (m, 2H), 3.42-3.32 (m, 2H), 3.11-3.09 (m, 2H), 2.87 (t, J = 12.6 Hz, 2H), 2.42 (m, 1 H), 2.37 (s, 3H), 2.13-2.09 (m, 2H), 2.00 (m, 2H), 1.84-1.80 (m, 2H),
1.52-1.50 (m, 2H) ppm; MS (ES) 512.16 (M+H); 1 -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-( 1 -(bicyclo[2.2.1 ]heptan-2-yl)-5- methylpiperidin-4-yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #93, 1H NMR (DMSO-d6, 300 MHz): 9.42 (s, 1 H, exch. With D2O), 9.00 (broad s, 1 H, exch. with D2O), 8.88 (s, 1 H), 8.43 (s, 1 H), 8.18 (s, 1 H), 8.11 (broad s, exch. with
D2O), 8.05 (s, 1 H),3.30-3.60 (m, 4H), 3.10-3.30 (m, 3H), 2.59 (m, 1 H), 2.49 (s, 3H), 2.39 (s, 2H), 2.30 (m, 4H), 1.99 (m, 1 H), 1.54 (m, 3H), 1.38 (m, 3H), 1.20 (m, 1 H). MS(ES) 517.26 (M+H); 1-(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1-yl)-5- methylpyridine-3-yl)-1W-1 ,2,4-triazole-3,5-diamine, compound #94, 1H NMR
(DMSO-d6, 300 MHz) 9.44 (s, 1 H), 9.89 (s, 1 H), 8.44 (s, 1 H), 8.19 (s, 1 H), 8.14 (br s, 2H), 8.05 (s, 1 H), 3.60 (m, 2H), 3.42 (m, 2H), 3.16 (m, 4H), 2.42 (s, 3H), 2.32 (s, 3H), 1.08 (m, 1 H), 0.66 (m, 2H), 0.38 (m, 2H) ppm; MS (ES) 477.2 (M+H); 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1 - yl)-5-methylpyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #95; 1H NMR (DMSO-de, 300 MHz) 9.55 (s, 1 H), 8.42 (s, 1 H), 8.29 (s, 1 H), 7.99 (m, 3H), 3.60 (m, 2H), 3.42 (m, 2H), 3.19 (m, 6H), 2.37 (s, 3H), 2.32 (s, 3H), 1.09 (m, 1 H), 0.66 (m, 2H), 0.39 (m, 2H) ppm; MS (ES) 511.2 (M+H); 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #96; 1H NMR (DMSO-d6, 300 MHz) 9.56 (s, 1 H), 8.88 (s, 1 H), 8.67 (s, 1 H), 8.15 (m, 3H), 7.92 (d, 1 H), 4.72 (d, 2H), 3.82 (m, 2H), 2.89 (m, 1 H), 2.79 (m, 4H), 2.42 (s, 3H), 2.18 (s, 3H),1.97 (m, 2H), 1.62 (m, 4H) ppm; MS (ES) 505.15 (M+H); i-CZ-methylthienotS^-dlpyrimidin-^yO-Λ^-Ce-cyclopentyl-δ.e.Z.δ-tetrahydro-i .θ- naphthyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #97; 1H NMR (DMSO-d6, 300 MHz) 9.47 (s, 1 H), 8.87 (s, 1 H), 8.64 (s, 1 H), 8.22 (s, 1 H), 8.17 (s, 1 H), 8.12 (s, 2H), 7.85 (s, 2H), 3.66 (s, 2H), 2.79 (s, 4H), 2.71 (t, 1 H), 2.42 (s, 3H), 1.91 (s, 2H), 1.66 (s, 2H), 1.50 (m, 4H) ppm; MS (ES) 448.21
(M+H);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonylamino- 5,6,7,8-tetrahydroquinolin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #98; 1H NMR (DMSOd6, 300 MHz) 9.43 (s, 1 H), 8.87 (s, 1 H), 8.64 (s, 1 H), 8.14 (m, 3H), 7.85 (m, 2H), 2.82 (m, 6H), 2.42 (s, 3H), 2.27 (t, 3H), 2.08 (m,
4H), 1.93 (m, 1 H), 1.95 (m, 1 H), 1.66 (m, 4H) ppm; MS (ES) 519.35 (M+H);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-cyclopentylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #99; 1H NMR (DMSOd6, 300 MHz) 9.46 (s, 1 H), 8.88 (s, 1 H), 8.66 (d, 1 H), 8.14 (m, 4H), 7.84 (d,1 H), 3.12 (m, 2H), 2.85 (m, 4H), 2.43 (s, 3H), 2.15 (m,
1 H), 1.92 (m, 2H), 1.67 (m, 3H), 1.50 (m, 4H) ppm; MS (ES) 462.30 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclohexylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #100; 1H NMR (CDCI3, 300 MHz) 9.53 (s, 1 H), 8.63 (s, 1 H), 8.26 (s, 2H), 7.96 (s, 2H), 7.77 (s, 1 H), 6.60 (s, 1 H), 3.00 (m, 2H), 2.75 (m, 4H), 2.37 (s,
3H), 2.05 (m, 2H), 1.90 (m, 2H), 1.65 (m, 2H), 1.58 (m, 2H), 1.26 (m, 2H), !.O8 (m, 2H) ppm; MS (ES) 510.14 (M+);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclopropylmethyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #101 ; 1H NMR (DMSO-d6, 300 MHz) 9.61 (s, 1 H), 8.60 (s, 1 H), 8.24
(s, 1 H), 7.96 (s, 2H), 7.88 (s, 1 H), 3.76 (s, 2H), 2.85 (s, 4H), 2.37 (s, 3H), 0.96 (m, 1 H), 0.54 (d, 2H), 0.19 (d, 2H) ppm; MS (ES) 468.09 (M+);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bicyclo[2.2.1]heptan-2-yl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #102; 1H NMR (DMSOd6, 300 MHz) 9.58 (s, 1 H), 8.63 (s, 1 H), 8.22
(s, 1 H), 7.11 (s, 1 H), 7.96 (s, 2H), 7.80 (s, 1 H), 3.54 (s, 1 H), 2.81 (m, 3H), 2.41 (s, 1 H), 2.34 (s, 3H), 2.27 (t, 1 H), 2.16 (s, 1 H), 1.74 (m, 2H), 1.50-1.17 (m, 5H), 0.96 (d, 2H) ppm; MS (ES) 508.13 (M+); i^-chloro^-methylthienotS^-dJpyrimidin^-yl^Λ^^Θ-bicyclo^^.ijheptan^-yl-amino- 5,6,7,8-tetrahydroquinolin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #103; 1H NMR (DMSO-Cl6, 300 MHz) 9.53 (d, 1 H), 8.63 (m, 1 H), 8.24 (d, 1 H), 8.15 (s, 1 H), 7.97 (s, 2H), 7.79 (s, 1 H), 2.97 (m, 2H), 2.82 (m, 2H), 2.71 (m, 2H), 2.38 (s, 3H), 2.28 (s, 1 H), 2.10 (m, 2H), 1.87 (t, 1 H), 1.71 (m, 2H), 1.48 (m, 1 H), 1.33 (s, 1 H), 1.26 (m, 3H), 0.74 (t, 1 H) ppm; MS (ES) 522.17 (M+); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bis-(cyclopropylmethyl)amino- 5,6,7,8-tetrahydroquinolin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #104; 1H NMR (DMSOd6, 300 MHz) 9.59 (s, 1 H), 8.68 (s, 1 H), 8.22 (s, 1 H), 7.97 (s, 2H), 7.80 (s, 1 H), 6.51 (s, 1 H), 2.90(m, 8H), 2.38 (s, 3H), 2.14 (m, 1 H), 1.82 (s, 2H), 1.05 (s, 2H), 0.58 (s, 4H), 0.28 (s, 4H) ppm; MS (ES) 536.27 (M+);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(7-(pyrrolidin-1-yl)-6,7,8,9-tetrahydro-5H- cyclohepta[b]pyridine-3-yl)-1 /-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #105; 1H-NMR (CDCl3/MeOD-4, 300 MHz) 8.66 (s, 1 H), 8.50 (s, 1 H),
8.03 (S, 1 H), 7.78 (s, 1 H), 7.64 (s, 1 H), 3.24 (m, 1 H), 3.19 (m, 4H), 3.01 (m, 1 H), 2.72-2.87 (m, 3H), 2.34 (s, 3H), 2.50 (m, 1 H), 1.91 (m, 4H), 1.50 (m, 2H); MS
(ES) 462.14 (M+H); 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(S)-methyl-4-(1 S,2S,4R)- bicyclo[2.2.1]heptan-2-ylpiperazin-1-yl)-3-methylpyridin-5-yl)-1/-/-1 ,2,4-triazole- 3,5-diamine (trifluoroacetic acid salt), compound #106; 1H-NMR (DMSOd6, 300 MHz) 9.43 (s, 1 H), 8.88 (s, 1 H), 8.45 (m, 1 H), 8.18 (m, 1 H), 8.13 (broad s, 1 H),
8.04 (m, 1 H), 3.66 (m, 2H), 3.28 (m, 4H), 2.56 (m, 1 H), 2.49 (m, 4H), 2.42 (s, 3H), 2.34 (s, 3H), 2.30 (m, 1 H), 2.00 (m, 1 H), 1.52 (d, 3H), 1.35-1.60 (m, 4H), 1.26 (m, 1 H); MS (ES) 531.17 (M+H);
1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(S)-methyl-4-(2S)- bicyclo[2.2.1]heptan-2-ylpiperazin-1-yl)-3-methylpyridin-5-yl)-1/-/-1 ,2,4-triazole-
3,5-diamine (trifluoroacetic acid salt), compound #107; 1H-NMR (DMSOd6, 300 MHz) 9.34 (S1 1 H), 8.43 9s, 1 H), 8.23 (s, 1 H), 8.01 (s, 1 H), 7.86 (s, 1 H), 2.58 (m, 1H), 2.52 (s, 3H), 2.49 (m, 4H), 2.40 (s, 3H), 2.35 (m, 4H), 2.03 (m, 1H), 1.53 (d, 3H), 1.40-1.65 (m, 7H), 1.26 (m, 1 H); MS (ES) 565.12/566.55 (M+H); 1-(thieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1-yl)-3-methylpyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #108; 1H-NMR (DMSOd6, 300 MHz) 9.25 (s, 1 H), 8.86 (s, 1 H), 8.49 (d, 1 H), 8.44 (s, 1 H), 8.03 (m, 1 H), 7.59 (m, 1 H), 3.31 (m, 3H), 2.58 (m,1 H), 2.49 (m, 4H), 2.36 (s, 3H), 2.32 (m, 1 H), 2.00 (m, 1 H), 1.54 (d, 3H), 1.42-1.61 (m, 7H), 1.25 (m, 1 H); MS (ES) 517.17(M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-chloropyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid), compound #109; 1H-NMR (CDCIs/MeOD^, 300 MHz) 8.24 (m, 1H), 8.20 (m, 1 H), 7.68 9s, 1 H), 3.53 (m, 1 H), 3.13 (m, 1 H), 2.51 (m, 1 H), 2.34 (s, 3H), 2.27 (m, 1 H), 1.76-1.90 (m, 4H), 1.38-1.56 (m, 11 H); MS (ES) 571.09 (M+H);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin- 1-yl)-3-chloropyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #110; 1H-NMR (CDCl3/MeOD-4, 300 MHz) 8.73 (s, 1 H), 8.29 (s, 1 H), 8.21 (s, 1 H), 7.65 (s, 1 H), 3.23 (m, 1 H), 3.15 (m, 1 H), 2.50 (m, 1 H), 2.40 (s, 3H), 2.27 (m, 1 H), 1.75-1.91 (m, 4H), 1.38-1.53 (m, 11H); MS (ES) 537.15 (M+H);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin- 1-yl)-3-methylpyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine, compound #111 ; 1H- NMR (DMSOd6, 300 MHz) 9.27 (s, 1 H), 8.86 (s, 1 H), 8.38 (s, 1 H), 8.17 (s, 1 H), 8.10 (s, 2H), 7.97 (s, 1 H), 2.97 (m, 4H), 2.48 (m, 7H), 2.28 (s, 3H), 2.14 (m, 1 H), 1.71 (m, 2H), 1.15-1.36 (m, 6H), 0.87 (m, 2H); MS (ES) 517.21 (M+H);
1-(4-methylthieno[3,2-d]pyridazine -7-yl)-Λ/3-(2-(4-(1 S,2S,4f?)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ^^-triazole-S.S-diamine (trifluoroacetic acid salt), compound #112; 1H-NMR (DMSO-d6, 300 MHz) 10.91 (s, 1 H, exchanges with D2O) , 9.20 (broad s, 1 H, exchanges with D2O), 8.54 (s, 1 H), 8.41 (d, 1 H), 8.00 (s, 1 H), 7.79 (d, 1 H), 3.51 (m, 6H), 3.24 (m, 4H), 2.87 (s,
3H), 2.60 (m, 1 H), 2.49 (m, 2H), 2.29 (s, 3H), 1.98 (m, 1 H), 1.60 (m, 2H), 1.40 (m, 2H), 1.23 (m, 1 H); MS (ES) 517.13 (M+H);
1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(3-(4-isopropylpiperazin-1 -yl)propen-1 - yl)pyridine-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #113; 1H NMR (DMSOd6, 300 MHz) 9.55 (s, 1 H), 8.91 (s, 1 H), 8.61
(s, 1 H), 8.61 (s, 1 H), 8.21-8.01 (m, 4H), 7.78 (m, 1 H), 7.19 (m, 2H), 6.45 (m, 2H), 3.71 (s, 6H), 3.12 (m, 2H), 2.72-2.58 (m, 6H), 2.21 (m, 3H), 1.92 (m, 2H), 1.79 (m, 2H), 1.58-1.05 (m, 2H) ppm; MS (ES) 531.20 (M+H), 529.41 (M-H); 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin-1- yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine (bis trifluoroacetic acid salt), compound #114; 1H NMR (DMSOd6, 300 MHz) 9.22 (s, 1 H), 9.10 (s, 1 H), 8.80 (s, 1 H), 8.69 (s, 1 H), 8.26 (s, 2H), 7.76 (d, 1 H), 7.35 (s, 1 H), 7.00 (d, 1 H), 3.97 (s, 6H), 3.75 (m, 1 H), 3.46-2.82 (m, 5H), 2.48 (s, 3H), 1.39-1.18 (m, 3H)1 1.06 (m, 1 H), 0.65 (m, 2H), 0.40 (m, 2H) ppm; MS (ES) 517.23 (M+H), 515.49 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #115; 1H NMR (DMSOd6, 300 MHz) 9.26 (s, 1 H), 8.44 (s, 1 H), 8.24 (s, 1 H) 8.13 (s, 1 H), 7.94 (m, 2H), 6.88 (d, 1 H), 3.86 (m, 2H), 3.71 (m, 1 H), 3.52-2.86 (m, 4H), 2.48 (S1 3H), 2.36 (s, 3H), 2.11 (m, 1 H), 1.03 (d, 2H), 0.84 (m, 1 H), 0.45 (m, 2H) ppm; MS (ES) 511.16 (M+H);
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin- 1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #116; 1H NMR (DMSO-d6, 300 MHz) 9.63 (s br, 1 H), 9.36 (s, 1 H), 8.88 (s, 1 H), 8.54 (s, 1 H), 8.14 (s, 2H), 8.04 (d, 1 H), 7.10 (d, 1 H), 4.31 (m, 2H), 3.76 (m, 1 H), 3.52-2.86 (m, 4H), 2.48 (s, 3H), 2.41 (s, 3H), 1.33 (m, 2H), 1.07 (s, 1 H),
0.65 (m, 2H), 0.35 (d, 2H) ppm; MS (ES) 477.19 (M+H), 475.30 (M-H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine formic acid salt, compound #117 (formic acid salt of compound #115); 1H NMR (DMSO-d6, 300 MHz) 9.26 (s, 1 H), 8.44 (s, 1 H), 8.24 (s, 1 H) 8.13 (s, 1 H), 7.94 (m, 2H), 6.88 (d,
1 H), 3.86 (m, 2H), 3.71 (m, 1 H), 3.52-2.86 (m, 4H), 2.48 (s, 3H), 2.36 (s, 3H), 2.11 (m, 1 H), 1.03 (d, 2H), 0.84 (m, 1 H), 0.45 (m, 2H) ppm; MS (ES) 511.12 (M+H), 509.34 (M-H); 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-bromopyridin-5-yl)-1 HA ,2,4-triazole-3,5- diamine (trifluoroacetic acid salt), compound #118; 1H NMR (DMSOd6, 300 MHz)
9.84 (s, 1 H), 8.89 (s, 1 H), 8.80 (s, 1 H), 8.20 (s, 2H), 8.16 (s, 1 H), 8.00 (d, 1 H), 7.58 (d, 1 H), 2.48 (s, 3H) ppm; MS (ES) 404.86 (M+H);
1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(pyrrolidin-1 -yl)propen-1 -yl)pyridin-5-yl)- 1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #119; 1H NMR (DMSO-d6, 300 MHz) 9.87 (s, 1 H), 8.41 (s br, 1 H), 8.89 (s, 2H), 8.23-8.12 (m,
4H), 7.59 (d, 1 H), 6.81 (d, 1 H), 6.58 (m, 1 H), 3.92 (m, 2H), 3.43 (m, 2H), 2.89 (m, 2H), 2.54-2.41 (m, 6H), 1.85-1.23 (m, 5H) ppm; MS (ES) 434.15 (M+H), 432.22 (M-H); 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(3-dimethylaminopyrrolidin-1-yl)propen- 1-yl)pyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #120;
1H NMR (DMSO-d6, 300 MHz) 9.72 (s, 1 H), 8.98 (m, 2H), 8.17 (m, 2H), 8.17-8.05 (m, 4H), 7.45 (d, 1 H), 6.65 (d, 2H), 3.18 (m, 2H), 2.72 (m, 1 H), 2.44 (m, 2H), 2.30 (m, 2H), 2.25 (s, 6H), 2.19 (m, 5H), 1.77 (m, 1 H), 1.52 (m, 1 H) ppm; MS (ES) 477.19 (M+H), 475.25 (M-H); 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(3-diethylaminopyrrolidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (bis formic acid salt), compound #121 ; 1H NMR (DMSOd6, 300 MHz) 9.81 (s, 1 H), 8.98 (m, 2H), 8.22 (m, 2H), 8.15-8.02 (m, 4H), 7.39 (d, 1 H), 6.59 (d, 2H), 3.22 (m, 2H), 2.71 (m, 1 H), 2.46-
2.38 (m, 5H), 2.30 (m, 1H), 2.23-2.17 (m, 5H), 1.76 (m, 1 H), 1.52 (m, 1 H), 1.03 (t, 6H) ppm; MS (ES) 505.21 (M+H), 503.39 (M-H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-pyrrolidin-1-yl-piperidin-1-yl)propen-1- yl)pyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (bis formic acid salt), compound #122; 1H NMR (DMSOd6, 300 MHz) 9.68 (s, 1 H), 8.87 (s, 2H), 8.45 (m, 1H), 8.31-8.08 (m, 3H), 7.58 (d, 1 H), 6.79 (d, 1 H), 6.59 (m, 1 H), 3.74 (m, 2H), 3.50 (m, 2H), 3.04 (m, 2H), 2.53-2.31 (m, 6H), 1.95 (m, 2H), 1.57 (m, 6H) ppm; MS (ES)
517.23 (M+H), 515.38 (M-H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-methylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #123; 1H NMR (DMSOd6, 300 MHz) 10.00 (s, 1 H), 8.91 (s, 2H), 8.36-8.03 (m, 4H), 7.68 (d, 1 H), 6.81 (m, 1 H), 6.59 (m, 1 H), 3.73 (m, 2H), 2.82 (m, 4H), 2.56-
2.33 (m, 10H) ppm; MS (ES) 463.21 (M+H), 461.35 (M-H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(4-isopropylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #124; 1H NMR (DMSOd6, 300 MHz) 9.86 (s, 1 H), 8.781 (s, 2H), 8.39-8.12 (m, 4H), 7.62 (d, 1 H), 6.79 (m, 1 H), 6.55 (m, 1 H), 3.70 (m, 2H), 2.81 (m, 2H), 2.56-
2.39 (m, 10H), 1.05 (d, 6H) ppm; MS (ES) 491.23 (M+H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-cyclopentylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #125; 1H NMR (DMSO-d6, 300 MHz) 10.43 (s, 1H), 8.91 (s, 2H), 8.43 (m, 1 H), 8.35-8.10 (m, 3H), 7.64 (d, 1 H), 6.82 (d, 1 H), 6.61 (m, 1 H), 3.76 (m, 2H), 3.51 (m,
2H), 3.06 (m, 2H), 2.55-2.33 (m, 6H), 1.99 (m, 2H), 1.59 (m, 6H) ppm; MS (ES) 517.29 (M+H), 515.53 (M-H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(morpholin-4-yl)propen-1-yl)pyridin-5-yl)- 1/-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #126; 1H NMR (DMSOd6, 300 MHz) 9.89 (s, 1 H), 8.88 (s, 2H), 8.35-8.11 (m, 4H), 7.78 (d, 1 H),
6.79 (m, 1 H), 6.57 (m, 1H), 3.74 (m, 2H), 3,62 (m, 4H), 2.56-2.29 (m, 7H) ppm; MS (ES) 450.17 (M+H), 448.26 (M-H); -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(piperidin-1 -yl)propen-1 -yl)pyridin-5-yl)-
1/-/-1,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #127; 1H NMR (DMSOd6, 300 MHz) 9.94 (s, 1 H), 8.45 (s br, 1 H), 8.91 (s, 2H), 8.25-8.15 (m, 4H), 7.63 (d, 1 H), 6.84 (d, 1 H), 6.60 (m, 1H), 3.90 (m, 2H), 3.42 (m, 2H), 2.92 (m, 2H), 2.52-2.43 (m, 6H), 1.81-1.25 (m, 3H) ppm; MS (ES) 446.30 (M+H); 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 - yl)propen-1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #128; 1H NMR (DMSOd6, 300 MHz) 9.72 (s, 1 H), 8.98 (m, 2H), 8.17
(m, 2H), 8.17-8.05 (m, 4H), 7.45 (d, 1 H), 6.65 (d, 2H), 3.21 (m, 3H), 2.98 (s, 3H), 2.60-2.07 (m, 12H), 1.79 (m, 2H), 1.46 (m, 3H), 1.13-1.04 (m, 2H) ppm; MS (ES) 546.26 (M+H), 544.37 (M-H); 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-piperidin-1 -ylpiperidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #129;
1H NMR (DMSOd6, 300 MHz) 9.68 (s, 1 H), 8.85 (m, 2H), 8.23 (m, 2H), 8.11-8.01 (m, 4H), 7.39 (d, 1 H), 6.65 (d, 2H), 3.26 (m, 3H), 2.64-2.05 (m, 12H), 1.81 (m, 2H), 1.43 (m, 3H), 1.15-1.07 (m, 4H) ppm; MS (ES) 531.27 (M+H), 529.24 (M-H); 1 -(6-phenylpyrimidine -4-yl)-Λ/3-(3-methyl-2-(4-pyrrolidin-1 -ylpiperidin-1 -yl)pyridin-5-yl)- 1 /-/-1 ,2,4-triazole-3,5-diamine (trifluoroacetic acid salt), compound #130; 1H-NMR
(DMSO-de, 300 MHz) 9.30 (br. s, 1 H), 9.00 (s, 1 H), 8.46 (s, 1 H), 8.16-8.14 (m, 2H), 7.96 (s, 1 H), 7.93 (br. s, 2H), 7.79 (s, 1 H), 7.60-7.57 (m, 3H), 3.37 (m, 4H), 3.12-3.08 (m, 4H), 2.75 (t, 1 H), 2.15-2.02 (m, 4H), 1.86-1.73 (m, 4H) ppm; MS (ES) 497.22 (M+H); 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(piperidin-1-ylmethyl)piperidin-1- yl)pyrimidin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (bis trifluoroacetic acid salt), compound #131 ; 1H NMR (CDCI3+CD3OD, 300 MHz) 7.86 (s, 1 H), 7.44 (m, 4H), 4.70 (m, 2H), 3.60 (m, 2H), 2.96 (m, 4H), 2.80 (m, 2H), 2.48 (s, 3H), 2.14 (m, 1 H), 1.93 (m, 6H), 1.33 (m, 4H); MS (ES) 540.14 (M+H); and 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(dimethylaminomethyl)carbonyl- 5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine, compound #134.
SYNTHETIC EXAMPLE 3 In a similar manner as described above utilizing the appropriately substituted starting materials and reagents, the following compounds of formula (Ib) were prepared: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine, compound #92; 1H-NMR (DMSO-dβ, 300 MHz) 10.32 (s, 1 H), 8.37 (s, 1 H), 8.22 (s, 1 H), 7.89 (s, 1 H), 6.27 (br. s, 2H), 3.55 (m, 2H), 3.41-3.37 (m, 2H), 3.26 (m, 1 H), 3.11-3.08 (m, 2H), 2.76-2.71 (m, 2H), 2.36 (s, 3H), 2.28 (s, 3H), 2.15-2.11 (m, 2H), 2.02 (m, 2H), 1.86-1.73 (m, 4H) ppm; MS (ES) 525.20 (M);
1-(4-methylthieno[2,3-d]pyridazin-7-yl)-Λ/5-(2-(4-(1S,2S,4/?)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H- 1 ,2,4-triazole-3,5-diamine
(trifluoroacetic acid salt), compound #132; 1H-NMR (DMSO-d6, 300 MHz) 10.94 (s, 1 H, exchanges with D2O), 9.00 (broad s, 1H, exchanges with D2O), 8.55 (s, 1 H), 8.40 (d, 1 H), 8.00 (s, 1 H), 7.79 (d, 1 H), 3.51 (m, 6H), 3.20 (m, 4H), 2.86 (s, 3H), 2.61 (m, 1 H), 2.52 (m, 2H), 2.29 (s, 3H), 1.99 (m, 1 H), 1.59 (m, 2H), 1.41 (m, 2H), 1.22 (m, 1 H); MS (ES) 517.13 (M+H); and
1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(2-(3-(4-(4-methylpiperazin-1-yl)piperidin-1- yl)propen-1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine (formic acid salt), compound #133; MS (ES) 546.29 (M+H), 544.52 (M-H).
TESTING OF THE COMPOUNDS OF THE INVENTION
The compounds of the invention were tested in the following assay for their ability to inhibit AxI activity.
PHOSPHO-AKT IN-CELL WESTERN ASSAY
REAGENTS AND BUFFERS: Cell culture plate: 96 well assay plate (Corning 3610), white, clear bottom, tissue- culture treated. Cells: HeIa cells. Starvation medium: For AxI stimulation: 0.5% FCS (fetal calf serum) in DMEM, plus
Axl/Fc (extracellular domain of AXL fused to imunoglobulin Fc region) (R&D, 154-AL) 500ng/mL
For EGF (epidermal growth factor) stimulation: 0.5% FCS in DMEM (Dulbecco's modified Eagles medium). Poly-L-Lysine 0.01% solution (the working solution): 10μg/ml, dilute In PBS (phosphate buffered saline). AxI antibody cross-linking:
1 st: Mouse anti-Axl (R&D, MAB154).
2nd: Biotin-SP-conjugated AffiniPure goat anti-mouse IgG (H+L) (Jackson ImmunoResearch #115-065-003 ). Fixing buffer: 4% formaldehyde in PBS. Wash buffer: 0.1 % TritonX-100 in PBS.
Quenching buffer: 3% H2O2, 0.1% Azide in wash buffer, Azide and hydrogen peroxide (H2O2) are added fresh.
Blocking buffer: 5% BSA in TBST (tris buffered saline plus 0.1% Tween 20).
Primary antibody: Rabbit anti-human Phospho-Akt antibody (Cell Signaling 9271 ):
1x250 diluted in blocking buffer.
Secondary antibody: HRP (horse radish peroxidase)-conjugated Goat anti-Rabbit secondary, stock solution: Jackson ImmunoResearch (Goat anti-Rabbit HRP,
#111-035-144 ) 1 :1 diluted in glycerol, store at -20° C. The working solution: 1x 2000 dilution of stock in blocking buffer. Chemiluminescent working solution (Pierce, 37030): SuperSignal ELISA (enzyme linked immunosorbant assay) Pico Chemiluminescent substrate. Crystal Violet solution: Stock : 2.5% Crystal violet in methanol, filtered and kept at ambient temperature. The working solution: dilute the stock 1 :20 with PBS immediately before use. 10% SDS: working solution: 5% SDS (sodium dodecylsulfate), diluted in PBS
METHODS: Dav 1 :
A 96 well TC (tissue culture treated) plate was coated with 10μg/ml_ poly-L- Lysine at 37°C for 30 min, washed twice with PBS, and air-dried for 5 minutes before cells were added. HeIa cells were seeded at 10,000 cells/well and the cells were starved in 100 μl_ starvation medium containing Axl/Fc for 24 hrs. Day 2:
The cells were pre-treated with test compounds by adding 100 μl_ of 2X test compound to the starvation medium on the cells. The cells were incubated at 370C for 1 hr before stimulation.
The cells were stimulated by Axl-antibody cross-linking as follows: A 5X ist/2nd AxI antibody mixture was made (37.5μg/mL 1st/ 100μg/ml_ 2nd) in starvation medium and nutated at 4°C with thorough mixing for 1-2 hours for clustering. The resulting mix was warmed to 370C. 50μl_ of 5X AxI 1st /2nd of antibody cluster was added to the cells and the cells were incubated at 37°C for 5 min. After 5 minutes stimulation, the plate was flicked to remove medium and the plate was tapped onto paper towels. Formaldehyde (4.0% in PBS, 100 μl_) was added to fix the cells and the cells were incubated at ambient temperature for 20 min without shaking. The cells were washed with a plate washer buffer to remove the formaldehyde solution. The plate was flicked to removed excess wash buffer and tapped onto paper towels. Quenching buffer (100 μl_) was added to each well and the cells were incubated at ambient temperature for 20 minutes without shaking.
The cells were washed with a plate washer buffer to remove the quenching buffer. Blocking buffer (100 μL) was added and the cells were incubated at ambient temperature for at least an hour with gentle shaking.
The cells were washed with a plate washer buffer and diluted primary antibody (50 μL) was added to each well (blocking buffer was added to the negative control wells instead). The plates were incubated overnight at 4° C with gentle shaking. Day 3:
The wash buffer was removed, diluted secondary antibody (100 μL) was added, and the cells were incubated at ambient temperature for 1 hour with gentle shaking. During the incubation, the chemiluminescent reagent was brought to ambient temperature. The secondary antibody was removed by washing the cells 1X with wash buffer,
1X with PBS by plate washer. The PBS was removed from the plate and the chemiluminescent reagent (80 μL: 40 μL A and 40 μL B) was added to each well at ambient temperature.
The resulting chemiluminescence was read with a Luminomitor within 10 minutes to minimize changes in signal intensity. After reading the chemiluminescence, the cells were washed 1X with wash buffer and 1X with PBS by plate washer. The plate was tapped onto paper towels to remove excess liquid from wells and air-dried at ambient temperature for 5 minutes.
Crystal Violet working solution (60 μL) was added to each well and the cells were incubated at ambient temperature for 30 min. The crystal violet solution was removed, and the wells were rinsed with PBS, then washed 3X with PBS (200 μL) for 5 minutes each.
5% SDS solution (70 μL) was added to each well and the cells were incubated on a shaker for 30 min at ambient temperature. The absorbance was read at 590 nM on a Wallac photospec. The 59OnM readings indicated the relative cell number in each well. This relative cell number was then used to normalize each luminescence reading.
The results of the ability of the compounds of the invention to inhibit AxI activity, when tested in the above assay, are shown in the following Tables 1-2 wherein the level of activity {i.e., the IC50) for each compound is indicated in each Table. The compound numbers in the Tables referred to the compounds disclosed herein as being prepared by the methods disclosed herein:
Compound
Figure imgf000103_0001
Figure imgf000104_0001
Figure imgf000105_0001
Figure imgf000106_0001
Figure imgf000107_0001
Figure imgf000108_0001
Figure imgf000109_0001
Figure imgf000110_0001
Figure imgf000111_0001
Figure imgf000112_0001
Figure imgf000113_0001
Figure imgf000114_0001
Figure imgf000115_0001
Figure imgf000116_0001
Figure imgf000117_0001
Figure imgf000118_0001
Figure imgf000119_0001
Figure imgf000120_0001
Figure imgf000121_0001
Figure imgf000122_0001
Figure imgf000123_0001
Figure imgf000124_0001
Figure imgf000125_0001
Figure imgf000126_0001
Figure imgf000127_0001
Figure imgf000128_0001
Figure imgf000129_0001
Figure imgf000130_0001
Figure imgf000131_0001
Figure imgf000132_0001
Figure imgf000133_0001
Figure imgf000134_0001
Figure imgf000135_0001
Figure imgf000136_0001
* * * * *
All of the U.S. patents, U.S. patent application publications, U.S. patent applications, foreign patents, foreign patent applications and non-patent publications referred to in this specification and/or listed in the Application Data Sheet are incorporated herein by reference, in their entireties.
Although the foregoing invention has been described in some detail to facilitate understanding, it will be apparent that certain changes and modifications may be practiced within the scope of the appended claims. Accordingly, the described embodiments are to be considered as illustrative and not restrictive, and the invention is not to be limited to the details given herein, but may be modified within the scope and equivalents of the appended claims.

Claims

WHAT IS CLAIMED IS:
1. A compound of formula (I):
Figure imgf000138_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
2. The compound of Claim 1 , which is a compound of formula (Ia):
Figure imgf000140_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain.
3. The compound of Claim 2, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
4. The compound of Claim 3, wherein: R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[fe][1 ,4]dioxinyl,
4,5-dihydro-1/-/-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl,
5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-jb]pyridinyl, benzo[jb]thiophenyl,
7',8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl,
4b,5,6,7,7a,8-hexahydropentaleno[2,1-jfc»]pyhdinyl, and
6,7,8,9-tetrahydro-5H-cyclohepta[ιb]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is aryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
5. The compound of Claim 4, wherein:
R1, R4 and R5 are each hydrogen;
R2 is 2,3-dihydrobenzo[/)][1 ,4]dioxinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2l -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
6. The compound of Claim 5, which is Λ/3-(2,3-dihydrobenzo[ύ][1 ,4]dioxin-6- yl)-1 -phenyl-1 /-/-1 ,2,4-triazole-3,5-diamine.
7. The compound of Claim 3, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[fo][1 ,4]dioxinyl,
4,5-dihydro-1H-benzo[b]azepin-2(3/-/)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-φzepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-jb]pyridinyl, benzo[b]thiophenyl, 7\8'-dihydro-5'H-spiro[[1,3]dioxolane-2,6'-quinoline]-3l-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-ιb]pyridinyl, and 6,7,8,9-tetrahydro-5H-cyclohepta[/?]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is heteroaryl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted /V-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
8. The compound of Claim 7, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[6][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3W)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-t>]pyridinyl, benzo[b]thiophenyl, 7',8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-t)]pyridinyl, and 6,7,8,9-tetrahydrocyclohepta[ιb]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is O1 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of pyridinyl, pyrimidinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-c/]pyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5H-cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
9. The compound of Claim 8, wherein:
R1, R4 and R5 are each hydrogen;
R2 is selected from the group consisting of benzo[ιb]thiophenyl,
4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl, 2,3-dihydrobenzo[fo][1 ,4]dioxinyl and benzoxazolyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of isoquinolinyl, quinazolinyl and thieno[3,2- c/]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
10. The compound of Claim 9 selected from the group consisting of: 1-(isoquinolin-1-yl)-/V3-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1H-1 ,2,4-triazole- 3,5-diamine; 1-(6-chloroquinazolin-4-yl)-Λ/3-(2-(pyrrolidin-1-ylmethyl)benzo[d]oxazol-5-yl)-1/-/-1 ,2,4- triazole-3,5-diamine; /V3-(2,3-dihydrobenzo[/?][1 ,4]dioxin-6-yl)-1 -(isoquinolin-1 -yl)-1 H- 1 ,2,4-triazole-3,5- diamine; /V3-(2,3-dihydrobenzo[£»][1 ,4]dioxin-6-yl)-1 -(6,7-dimethoxyquinazolin-4-yl)-1 H- 1 ,2,4- triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(4,5-dihydro-1/-/-benzo[b]azepin-2(3H)-on-8-yl)-1/-/-
1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(1-(4-(2-(dimethylamino)ethyl)piperazin-1- yl)oxomethyl)benzo[b]thiophen-5-yl)-1/-/-1 ,2,4-triazole-3,5-diamine;
11. The compound of Claim 8, wherein:
R1, R4 and R5 are each hydrogen;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of pyridinyl and pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
12. The compound of Claim 11 selected from the group consisting of:
1 -(5-trifluoromethylpyridin-2-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1 -yl)pyridin-3-yl)-1 H-
1 ,2,4-triazole-3,5-diamine; and 1 -(6-phenylpyrimidine ^-yO-Λ/^S-methyl^-^-pyrrolidin-i -yl pi perid i n- 1 -y! )pyrid in-5-yl )-
1 H- 1 ,2,4-triazole-3,5-diamine.
13. The compound of Claim 8, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is quinazolinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
14. The compound of Claim 13 selected from the group consisting of: 1 -(ΘJ-dimethoxyquinazoline-ΦyO-Λ/^θ-^bicycloβ^.1 ]heptan-2-yl)piperazin-1 - yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(4-(4-methylpiperazin-1-yl)piperidin-1-yl)pyridin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-cyclopentyl-1 ,4-diazepan-1 -yl)pyridin-3-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1 -(ΘJ-dimethoxyquinazoline^-yO-ΛΛ-CΘ-^-pyrrolidin-i -ylpiperidin-1 -yl)pyridine-3-yl)-1 H-
1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(4-piperidin-1 -ylpiperidin-1 -yl)pyridine-3-yl)-1 H-
1 ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -ylmethyl)piperidin-1 -yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; i^β^-dimethoxyquinazoline^-yO-Λ^^δ^diethylaminoethylmethylaminoJpyridin-S-yO-IH-
1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1-yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; i-CβJ-dimethoxyquinazoline^-yO-Λ^^β-CS-diethylaminopyrrolidin-i-y^pyridin-S-yO-IH-
1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4-diazepan-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-methylquinazolin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -y I )-5-methyl pyrid in-3-yl )-
1 H-1 ,2,4-triazole-3,5-diamine; 1-(6-fluoroquinazolin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5-methylpyridin-3-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-/V3-(6-bromopyridin-3-yl)-5-(3-(6-bromopyridin-3-yl)-2- cyanoguanadino)-1 H-1 ,2,4-triazole-3-amine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-bromopyridin-3-yl)-1 H-1 ,2,4-triazole-3,5- diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-(4-methylpiperazin-1-yl)piperidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-piperidin-1-ylpiperidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-dimethylaminopiperidin-1- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; I^ΘJ-dimethoxyquinazoline^-yO-Λ/^θ-^S^diethylaminotøyrrolidin-i- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; I^ΘJ-dimethoxyquinazoline^-yO-Λ/^θ-^S^dimethylaminoJpyrrolidin-i- yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(ey-dimethoxyquinazoline^-yO-Λ^^Θ-CS-piperidin-i -ylpropenyl)pyridin-3-yl)-1 H-1 ,2,4- triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-pyrrolidin-1 -ylpiperidin-1 - yl)propenyl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(6-(3-(4-cyclopentylpiperazin-1-yl)propenyl)pyridin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(3-(4-isopropylpiperazin-1-yl)propen-1- yl)pyridine-5-yl)-1H-1 ,2,4-triazole-3,5-diamine; and 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin-1- yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
15. The compound of Claim 8, wherein: R1, R4 and R5 are each hydrogen; R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of isoquinolinyl and phenanthridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
16. The compound of Claim 15 selected from the group consisting of: 1-(isoquinolin-1-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)piperazin-1-yl)pyridin-3-yl)-1H-
1 ,2,4-triazole-3,5-diamine; 1 -(isoquinolin-1 -yO-Λ/^θ-^-methylpiperazin-i -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5- diamine; and 1 -(phenanthridin-6-yl)-/V3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 -yl )-5-methylpyrid in-3-yl )-1 H-
1 ,2,4-triazole-3,5-diamine.
17. The compound of Claim 8, wherein: R1, R4 and R5 are each hydrogen;
R2 is selected from the group consisting of pyridinyl and 1 /-/-pyrrolo[2,3-£>]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of thieno[3,2-c/]pyrimidinyl and thieno[3,2- d]pyridazinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is O1 1 or 2), and -R13-S(O)»N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
18. The compound of Claim 17 selected from the group consisting of: -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-cyclopentyl-1 ,4-diazepan-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-methylpiperazin-1-yl)pyridin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(4-(pyrrolidin-1 -yl)piperidin-1 - yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(4-(4-methylpiperazin-1- yl)piperidin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1 ]heptan-2- yl)piperazin-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-piperidin-1 -ylpiperidin-1 - yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(1 H-pyrrolo[2,3-b]pyridin-5-yl)-1H-
1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1-ylmethyl)piperidin-
1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(azepan-1 -yl)piperidin-1 - yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-
(diethylaminoethylmethylamino)pyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(2-diethylaminomethylpyrrolidin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-tπ'azole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(3-diethylaminopyrrolidin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-(bicyclo[2.2.1]heptan-2-yl)-1 ,4- diazepan-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylmethylpiperazin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(5-bicyclo[2.2.1]heptan-2- yloctahydropyrrol[3,4-c]pyrrolyl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine;-(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(4-cyclopropylpiperazin-1- yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1]heptan-
2-ylpiperazin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5-methyl-6-(4-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(4-((1S,2S,4R)-bicyclo[2.2.1]heptan-2- yl)piperazin-1 -yl)pyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-bicyclo[2.2.1]heptan-2- ylpiperidin-4-yl)pyridine-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-bicyclo[2.2.1]heptan-2-ylpiperidin-4- yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(1-(bicyclo[2.2.1]heptan-2-yl)-5- methylpiperidin-4-yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1- yl)pyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(4-(cyclopropylmethyl)piperazin-1-yl)-5- methylpyridine-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-(4-(cyclopropylmethyl)piperazin-1- yl)-5-methylpyridin-3-yl)-1 H-1 ,2,4-tιϊazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(S)-methyl-4-(1 S,2S,4R)- bicyclo[2.2.1 ]heptan-2-ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ,2,4-triazole-
3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(S)-methyl-4-(2S)- bicyclo^^.ilheptan^-ylpiperazin-i-yO-S-methylpyridin-S-yO-IH-i ^^-triazole-
3,5-diamine; -(thieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(S)-methyl-4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ,2,4-tιϊazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-chloropyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrirnidin-4-yl)-/V3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin-
1 -yl)-3-chloropyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(4-(2S)-bicyclo[2.2.1]heptan-2-ylpiperazin-
1 -yl )-3-methyl pyrid in-5-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; -(4-methylthieno[3,2-d]pyridazine -7-yl)-/V3-(2-(4-(1 S,2S,4R)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1 -y I )py ri d i n-5-y I )- 1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)-methylpiperazin-
1 -yl )pyrid in-5-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(4-cyclopropylmethyl-3-(S)- methylpiperazin-1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-bromopyridin-5-yl)-1 H-1 ,2,4-triazole-3,5- diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(pyrrolidin-1 -yl)propen-1 -yl)pyridin-5-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(3-dimethylaminopyrrolidin-1-yl)propen-
1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(3-diethylaminopyrrolidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3, 2-d]pyrimidin-4-yl)- /^-(2-(3-(4-PyPrOUdJn-I -yl-piperidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-methylpiperazin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-thazole-3,5-diainine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-isopropylpiperazin-1-yl)propen-1- yl )pyrid in-5-yl )- 1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-cyclopentylpiperazin-1-yl)propen-1- yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(morpholin-4-yl)propen-1-yl)pyridin-5-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(piperidin-1 -yl)propen-1 -yl)pyrid in-5-yl )-
1 H-1 ,2,4-triazole-3,5-diamine; 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 - yl)propen-1-yl)pyridin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine; and 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(2-(3-(4-piperidin-1 -ylpiperidin-1 -yl)propen-1 - yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
19. The compound of Claim 8, wherein: R1, R4 and R5 are each hydrogen; R2 is pyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of furo[3,2-c]pyridinyl and 6,7-dihydro-5H- cyclopenta[4,5]thieno[2,3-cdpyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
20. The compound of Claim 19 selected from the group consisting of: i^furotS^-cjpyridine-ΦyO-Λ^^e-C^pyrrolidin-i-yOpiperidin-i-yO-δ-methylpyridin-S-yl)-
1 H-1 ,2,4-triazole-3,5-diamine; and
1-(6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-c/]pyrimidin-4-yl)-Λ/3-(6-(4-(pyrrolidin-1- yl)piperidin-1 -yl)-5-methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
21. The compound of Claim 8, wherein: R1, R4 and R5 are each hydrogen;
R2 is 6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of thieno[3,2-cf]pyrimidinyl and quinazolinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
22. The compound of Claim 21 selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(7-cyclopentyl-6,7,8,9-tetrahydro- 5H-pyrido[3,2-d]azepin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(7-cyclopentyl-6,7,8,9-tetrahydro-5H-pyrido[3,2- d]azepin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine.
23. The compound of Claim 8, wherein:
R1, R4 and R5 are each hydrogen;
R2 is 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of isoquinolinyl and thieno[3,2-c/]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted /V-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
24. The compound of Claim 23 selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-methyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(isoquinolin-1 -yO-Λ^-Cβ-methyl-δ.θJ.δ-tetrahydro-i ,6-naphthyridin-3-yl)-1 H-1 ,2,4- triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-benzyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(6-(ethylcarboxy)-5,6,7,8-tetrahydro-
1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)-
5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(5,6,7,8-tetrahydro-1 ,6-naphthyridin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(dimethylaminomethylcarbonyl)-
5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(2-dimethylaminoethyl)- 5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-cyclopentyl-5,6,7,8-tetrahydro-
1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-c(]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylcarbonyl)-
5,6,7,8-tetrahydro-i ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3I2-d]pyrimidin-4-yl)-/\/3-(6-(piperidin-4-ylcarbonyl)-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-cyclopentyl-5,6,7,8-tetrahydro-1 ,6- naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclopropylmethyl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-bicyclo[2.2.1]heptan-2-yl-5,6,7,8- tetrahydro-1 ,6-naphthyridin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; and 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(dimethylaminomethyl)carbonyl-
5,6,7,8-tetrahydro-1 ,6-naphthyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
25. The compound of Claim 8, wherein:
R1, R4 and R5 are each hydrogen;
R2 is selected from the group consisting of 6,7,8, 9-tetrahydro-5H-cyclohepta[ό]pyhdinyl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-ιb]pyridinyl, 5,6,7,8-tetrahydroquinolinyl, and 7',8'-dihydro-5'H-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3l-yl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is thieno[3,2-c(]pyrimidinyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
26. The compound of Claim 25 selected from the group consisting of: -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(pyrrolidin-1ylcarbonyl)-5, 6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(2-(dimethylamino)-1- oxyethylamino)-5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine;-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-amino-5,6,7,8-tetrahydroquinolin-
3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylamino)-
5,6,7,8-tetrahydroquinolin-3-yl)-1/-/-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-/V3-(7I,8'-dihydro-5'H- spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(pyrrolidin-1-yl)-4b,5,6,7,7a,8- hexahydropentaleno[2, 1 -£>] py rid i n-3-yi )- 1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-of]pyrimidin-4-yl)-Λ/3-(6-(4-methylpiperazin-1-yl)-5,6)7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-cyclopentylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidine-4-yl)-/V3-(7-(pyrrolidin-1-yl)-6,7,8,9- tetrahydro-δH-cycloheptafblpyridin-S-yO-IH-i ^^-triazole-S^-diamine; -(2-chloro-7-methylthieno[3,2-c/]pyπmidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8- tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-ylamino)-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-c/]pyrimidin-4-yl)-Λ/3-(6-pyrrolidin-1-yl-5,6,7,8-tetrahydroquinolin-3- yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-(1-methylpiperidin-4-yl)carbonylamino-
5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclopentylamino-5,6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/3-(6-cyclohexylamino-5, 6,7,8- tetrahydroquinolin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-bicyclo[2.2.1]heptan-2-yl-amino- 5,6,7,8-tetrahydroquinolin-3-yl)-1H-1 ,2,4-triazole-3,5-diamine; 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(6-bis-(cyclopropylmethyl)amino-
5,6,7>8-tetrahydroquinolin-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine; and 1-(7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(7-(pyrrolidin-1-yl)-6,7>8,9-tetrahydro-5H- cyclohepta[b]pyrϊdine-3-yl)-1 H- 1 ,2,4-triazole-3,5-diamine.
27. The compound of Claim 8, wherein:
R1, R4 and R5 are each hydrogen;
R2 is pyrimidinyl optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of quinazolinyl and thieno[3,2-cf]pyrimidinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
28. The compound of Claim 27 selected from the group consisting of: 1-(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-pyrrolidin-1-ylpiperidin-1-yl)pyrimidin-5-yl)-1H-
1 ,2,4-triazole-3,5-diamine; 1 -(6,7-dimethoxyquinazoline-4-yl)-Λ/3-(2-(4-piperidin-1 -ylmethylpiperidin-1 -yl)pyrimidin-5- yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1 -(2-chloro-7-methylthieno[3,2-cf]pyrimidin-4-yl)-Λ/3-(2-(4-pyrrolidin-1 ylpiperidin-1 - yl)pyrimidin-5-yl)-1H-1 ,2,4-triazole-3,5-diamine; and 1 -(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-/V3-(2-(4-(piperidin-1 -ylmethyl)piperidin-1 - yl)pyrimidin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
29. The compound of Claim 1 , which is a compound of formula (Ib):
N — N
R1 R*
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain.
30. The compound of Claim 29, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)PR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; and each R14 is independently an optionally substituted straight or branched alkylene chain.
31. The compound of Claim 30, wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[jb][1 ,4]dioxinyl, 4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-G(]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl, 5,6,7,8-tetrahydroquinolinyl, 1 /-/-pyrrolo[2,3-έ)]pyridinyl, benzo[£»]thiophenyl, 7\8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3'-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2, 1 -b]pyridinyl, and
6,7,8,9-tetrahydro-5H-cyclohepta[ib]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O),N(R6)R7 (where t is 1 or 2);
R3 is phenyl optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alky], alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted Λ/-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
32. The compound of Claim 30, wherein: R1, R4 and R5 are each independently selected from the group consisting of hydrogen,
-C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl selected from the group consisting of benzoxazolyl, pyridinyl, isoquinolinyl, pyrimidinyl, 2,3-dihydrobenzo[ιb][1 ,4]dioxinyl,
4,5-dihydro-1H-benzo[b]azepin-2(3H)-onyl,
6,7,8,9-tetrahydro-5H-pyrido[3,2-c/]azepinyl, 5,6,7,8-tetrahydro-1 ,6-naphthyridinyl,
5,6,7,8-tetrahydroquinolinyl, 1 H-pyrrolo[2,3-ib]pyridinyl, benzo[fc>]thiophenyl,
7I,8'-dihydro-5'/-/-spiro[[1 ,3]dioxolane-2,6'-quinoline]-3l-yl, 4b,5,6,7,7a,8-hexahydropentaleno[2,1-ιb]pyridinyl, and
6,7,8,9-tetrahydro-5H-cyclohepta[t»]pyridinyl, each optionally substituted by one or more substituents selected from the group consisting of cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is a heteroaryl selected from the group consisting of pyridinyl, isoquinolinyl, quinazolinyl, phenanthridinyl, thieno[3,2-c(]pyrimidinyl, thieno[3,2-d]pyridazinyl, 6,7-dihydro-5/-/-cyclopenta[4,5]thieno[2,3-c/]pyrimidinyl, and furo[3,2-c]pyridinyl, each optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, halo, haloalkyl, haloalkenyl, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R13-OR12, -R13-OC(O)-R12, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O),N(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heteroaryl or an optionally substituted /V-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, haloalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl, and optionally substituted heteroarylalkyl; each R9 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain; each R10 is independently an optionally substituted straight or branched alkylene chain; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, may optionally form an optionally substituted /V-heterocyclyl or an optionally substituted /V-heteroaryl; and each R13 is independently selected from the group consisting of a direct bond and an optionally substituted straight or branched alkylene chain.
33. The compound of Claim 32 selected from the group consisting of: 1-(2-chloro-7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(6-(4-(pyrrolidin-1-yl)piperidin-1-yl)-5- methylpyridin-3-yl)-1 H-1 ,2,4-triazole-3,5-diamine; 1-(4-methylthieno[2,3-d]pyridazin-7-yl)-/V5-(2-(4-(1S,2S,4R)-bicyclo[2.2.1]heptan-2- ylpiperazin-1 -yl)-3-methylpyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine; and 1 -(7-methylthieno[3,2-d]pyrimidin-4-yl)-Λ/5-(2-(3-(4-(4-methylpiperazin-1 -yl)piperidin-1 - yl)propen-1 -yl)pyridin-5-yl)-1 H-1 ,2,4-triazole-3,5-diamine.
34. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of formula (I):
Figure imgf000181_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7; R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O),R8 (where t is 1 or 2), -R9-S(O)tOR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O)tR12 (where t is 1 or 2), -R13-S(O),OR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is 0, 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2l or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
35. A method of treating a disease or condition associated with AxI activity in a mammal, wherein the method comprises administering to the mammal a therapeutically effective amount of a compound of formula (I):
Figure imgf000184_0001
wherein:
R1, R4 and R5 are each independently selected from the group consisting of hydrogen, alkyl, aryl, aralkyl, -C(O)R8, -C(O)N(R6)R7, and -C(=NR6)N(R6)R7;
R2 is a heteroaryl optionally substituted by one or more substituents selected from the group consisting of oxo, thioxo, cyano, nitro, halo, haloalkyl, alkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, -R9-OR8, -R9-O-R10-OR8, -R9-O-R10-O-R10-OR8, -R9-O-R10-CN, -R9-O-R10-C(O)OR8, -R9-O-R10-C(O)N(R6)R7, -R9-O-R10-S(O)pR8 (where p is 0, 1 or 2), -R9-O-R10-N(R6)R7, -R9-O-R10-C(NR11)N(R11)H, -R9-OC(O)-R8, -R9-C(O)R8, -R9-C(O)OR8, -R9-C(O)N(R6)R7, -R9-C(O)-R10-N(R6)R7, -R9-N(R6)R7, -R9-N(R6)-R10-N(R6)R7, -R9-N(R6)C(O)OR8, -R9-N(R6)C(O)-R10-N(R6)R7, -R9-N(R6)C(O)R8, -R9-N(R6)S(O)tR8 (where t is 1 or 2), -R9-S(O),OR8 (where t is 1 or 2), -R9-S(O)PR8 (where p is 0, 1 or 2), and -R9-S(O)tN(R6)R7 (where t is 1 or 2);
R3 is selected from the group consisting of aryl and heteroaryl, where the aryl and the heteroaryl are each independently optionally substituted by one or more substitutents selected from the group consisting of alkyl, alkenyl, alkynyl, halo, haloalkyl, haloalkenyl, haloalkynyl, oxo, thioxo, cyano, nitro, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted hβteroarylalkynyl, -R13-OR12, -R13-OC(O)-R12, -R13-O-R14-N(R12)2, -R13-N(R12)2, -R13-C(O)R12, -R13-C(O)OR12, -R13-C(O)N(R12)2, -R13-C(O)N(R12)-R14-N(R12)R13, -R13-C(O)N(R12)-R14-OR12, -R13-N(R12)C(O)OR12, -R13-N(R12)C(O)R12, -R13-N(R12)S(O),R12 (where t is 1 or 2), -R13-S(O)tOR12 (where t is 1 or 2), -R13-S(O)pR12 (where p is O1 1 or 2), and -R13-S(O)tN(R12)2 (where t is 1 or 2); each R6 and R7 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, hydroxyalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl, -R10-OR8, -R10-CN, -R10-NO2, -R10-N(R8)2, -R10-C(O)OR8 and -R10-C(O)N(R8)2, or any R6 and R7, together with the common nitrogen to which they are both attached, form an optionally substituted N- heteroaryl or an optionally substituted Λ/-heterocyclyl; each R8 is independently selected from the group consisting of hydrogen, alkyl, alkenyl, alkynyl, haloalkyl, haloalkenyl, haloalkynyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted aralkenyl, optionally substituted aralkynyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted cycloalkylalkenyl, optionally substituted cycloalkylalkynyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heterocyclylalkenyl, optionally substituted heterocyclylalkynyl, optionally substituted heteroaryl, optionally substituted heteroarylalkyl, optionally substituted heteroarylalkenyl, optionally substituted heteroarylalkynyl; each R9 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R10 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain, an optionally substituted straight or branched alkenylene chain and an optionally substituted straight or branched alkynylene chain; each R11 is hydrogen, alkyl, cyano, nitro or -OR8; each R12 is independently selected from the group consisting of hydrogen, alkyl, haloalkyl, optionally substituted cycloalkyl, optionally substituted cycloalkylalkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heterocyclyl, optionally substituted heterocyclylalkyl, optionally substituted heteroaryl and optionally substituted heteroarylalkyl, or two R12 s, together with the common nitrogen to which they are both attached, form an optionally substituted Λ/-heterocyclyl or an optionally substituted Λ/-heteroaryl; each R13 is independently selected from the group consisting of a direct bond, an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; and each R14 is independently selected from the group consisting of an optionally substituted straight or branched alkylene chain and an optionally substituted straight or branched alkenylene chain; as an isolated stereoisomer or mixture thereof, or a pharmaceutically acceptable salt thereof.
36. The method of Claim 35 wherein the disease or condition is alleviated by the modulation of AxI activity.
37. The method of Claim 35 wherein the disease of condition is alleviated by a increase in AxI activity.
38. The method of Claim 35 wherein the disease of condition is alleviated by a decrease in AxI activity.
39. The method of Claim 38 wherein the disease or condition is selected from the group consisting of rheumatoid arthritis, vascular disease, vascular injury, psoriasis, visual impairment due to macular degeneration, diabetic retinopathy, retinopathy of prematurity, kidney disease, osteoporosis, osteoarthritis and cataracts.
40. The method of claim 38, wherein a manifestation of the disease or condition is solid tumor formation in said mammal.
41. The method of Claim 40, wherein the disease or condition is selected from the group consisting of breast carcinoma, renal carcinoma, endometrial carcinoma, ovarian carcinoma, thyroid carcinoma, non-small cell lung carcinoma, melanoma, prostate carcinoma, sarcoma, gastric cancer and uveal melanoma.
42. The method of claim 38, wherein a manifestation of the disease or condition is liquid tumor formation in said mammal.
43. The method of claim 42, wherein the disease or condition is myeloid leukemia or lymphoma.
44. The method of Claim 38 wherein the disease or condition is endometriosis.
PCT/US2007/089153 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors WO2008083354A1 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU2007342005A AU2007342005A1 (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
EP07866122.0A EP2074115B1 (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
CA2710046A CA2710046C (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
ES07866122.0T ES2672172T3 (en) 2006-12-29 2007-12-28 N3-heteroarylsubstituted triazoles and N5-heteroarylsubstituted triazoles useful as Axl inhibitors
JP2009544313A JP5567837B2 (en) 2006-12-29 2007-12-28 N3-heteroaryl-substituted triazoles and N5-heteroaryl-substituted triazoles useful as Axl inhibitors
CN2007800489092A CN101622248B (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as AXL inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US88287506P 2006-12-29 2006-12-29
US60/882,875 2006-12-29
US97544307P 2007-09-26 2007-09-26
US60/975,443 2007-09-26

Publications (1)

Publication Number Publication Date
WO2008083354A1 true WO2008083354A1 (en) 2008-07-10

Family

ID=39203174

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/089153 WO2008083354A1 (en) 2006-12-29 2007-12-28 N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors

Country Status (9)

Country Link
US (2) US9650391B2 (en)
EP (2) EP2074115B1 (en)
JP (2) JP5567837B2 (en)
CN (1) CN101622248B (en)
AU (1) AU2007342005A1 (en)
CA (1) CA2710046C (en)
ES (2) ES2672172T3 (en)
HK (1) HK1174631A1 (en)
WO (1) WO2008083354A1 (en)

Cited By (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010083465A1 (en) 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8349838B2 (en) 2008-07-09 2013-01-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
WO2013115280A1 (en) 2012-01-31 2013-08-08 第一三共株式会社 Pyridone derivative
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
WO2015081257A2 (en) 2013-11-27 2015-06-04 Signalchem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
KR20170029495A (en) 2014-07-07 2017-03-15 다이이찌 산쿄 가부시키가이샤 Pyridone derivative having tetrahydropyranyl methyl group
EP3184121A2 (en) 2012-07-25 2017-06-28 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
WO2017146236A1 (en) 2016-02-26 2017-08-31 小野薬品工業株式会社 Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
WO2019039525A1 (en) 2017-08-23 2019-02-28 小野薬品工業株式会社 Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
WO2019074116A1 (en) 2017-10-13 2019-04-18 小野薬品工業株式会社 Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021032883A1 (en) 2019-08-22 2021-02-25 Bergenbio Asa Combination therapy of a patient subgroup
EP3804723A1 (en) 2015-05-29 2021-04-14 BerGenBio ASA Combination therapy
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021191197A1 (en) 2020-03-23 2021-09-30 Bergenbio Asa Combination therapy comprising an axl inhibitor
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
WO2021214492A1 (en) 2020-04-24 2021-10-28 Bergenbio Asa Method of selecting patients for treatment with a combination of an axl inhibitor and an immune checkpoint modulator
WO2022200463A1 (en) 2021-03-23 2022-09-29 Bergenbio Asa Combination of axl antibodies and ace inhibitors in the treatment of fibrosis
WO2023247769A1 (en) 2022-06-24 2023-12-28 Bergenbio Asa Dosage regimen for axl inhibitor
WO2024051667A1 (en) * 2022-09-05 2024-03-14 南京正大天晴制药有限公司 Substituted triazole compound having axl inhibitory activity

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2621503C (en) * 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
ME01832B (en) 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2114955B1 (en) 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2074115B1 (en) * 2006-12-29 2018-03-07 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
EP2079736B1 (en) 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
ES2424259T3 (en) * 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoles substituted with polycyclic aryl and polycyclic heteroaryl, useful as inhibitors of Axl
NZ587589A (en) 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
ES2399319T3 (en) 2008-07-09 2013-03-27 Rigel Pharmaceuticals, Inc. Bicyclic heteroaryl substituted triazoles containing bridges useful as AXL inhibitors
GB201213556D0 (en) 2012-07-31 2012-09-12 Luminectric Ltd Cases for portable electronic devices
US9840503B2 (en) 2015-05-11 2017-12-12 Incyte Corporation Heterocyclic compounds and uses thereof
WO2017027717A1 (en) 2015-08-12 2017-02-16 Incyte Corporation Bicyclic fused pyrimidine compounds as tam inhibitors
US10053465B2 (en) 2015-08-26 2018-08-21 Incyte Corporation Pyrrolopyrimidine derivatives as TAM inhibitors
CA3019145A1 (en) 2016-03-28 2017-10-05 Incyte Corporation Pyrrolotriazine compounds as tam inhibitors
RS62872B1 (en) 2017-09-27 2022-02-28 Incyte Corp Salts of pyrrolotriazine derivatives useful as tam inhibitors
JP2021529765A (en) 2018-06-29 2021-11-04 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ Formulation of AXL / MER inhibitor

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2002057240A1 (en) * 2000-12-22 2002-07-25 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
WO2004046120A2 (en) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1403866A (en) 1971-12-06 1975-08-28 Wyeth John & Brother Ltd Derivatives of 3-amino-1,2,4-triazoles
EP0710654A4 (en) 1993-07-23 1996-08-28 Green Cross Corp Triazole derivative and pharmaceutical use thereof
JP2002241368A (en) * 1997-02-18 2002-08-28 Shionogi & Co Ltd New benzolactam derivative and pharmaceutical composition containing the same
TWI335221B (en) 2001-09-27 2011-01-01 Alcon Inc Inhibtors of glycogen synthase kinase-3 (gsk-3) for treating glaucoma
WO2003093344A1 (en) 2002-05-03 2003-11-13 Janssen Pharmaceutica N.V. Polymeric microemulsions
CA2501719C (en) * 2002-08-06 2013-02-05 Toray Industries, Inc. Remedy or preventive for kidney disease and method of diagnosing kidney disease
AU2003286746A1 (en) 2002-10-29 2004-05-25 Rigel Pharmaceuticals, Inc. Modulators of angiogenesis and tumorigenesis
CA2534921C (en) 2003-08-06 2011-06-14 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
KR20070036025A (en) 2004-02-11 2007-04-02 얀센 파마슈티카 엔.브이. Process for the preparation of substituted triazole compounds
CN101039933B (en) * 2004-09-17 2012-06-06 沃泰克斯药物股份有限公司 Diaminotriazole compounds useful as protein kinase inhibitors
DE602005024293D1 (en) 2004-10-21 2010-12-02 Vertex Pharma TRIAZOLE AS AN INHIBITOR OF PROTEIN KINASES
CA2621503C (en) * 2005-09-07 2014-05-20 Rigel Pharmaceuticals, Inc. Triazole derivatives useful as axl inhibitors
US8097630B2 (en) * 2006-10-10 2012-01-17 Rigel Pharmaceuticals, Inc. Pinane-substituted pyrimidinediamine derivatives useful as Axl inhibitors
EP2079736B1 (en) * 2006-12-29 2017-10-18 Rigel Pharmaceuticals, Inc. Substituted triazoles useful as axl inhibitors
ME01832B (en) * 2006-12-29 2014-12-20 Rigel Pharmaceuticals Inc Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
CA2710043C (en) * 2006-12-29 2016-02-09 Rigel Pharmaceuticals, Inc. Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2114955B1 (en) * 2006-12-29 2013-02-13 Rigel Pharmaceuticals, Inc. Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2074115B1 (en) * 2006-12-29 2018-03-07 Rigel Pharmaceuticals, Inc. N3-heteroaryl substituted triazoles and n5-heteroaryl substituted triazoles useful as axl inhibitors
CA2681516A1 (en) * 2007-03-22 2008-09-25 Vertex Pharmaceuticals Incorporated Compounds useful as inhibitors of janus kinases
CN101707863A (en) 2007-06-15 2010-05-12 Irm责任有限公司 protein kinase inhibitors and methods for using thereof
ES2424259T3 (en) * 2007-10-26 2013-09-30 Rigel Pharmaceuticals, Inc. Triazoles substituted with polycyclic aryl and polycyclic heteroaryl, useful as inhibitors of Axl
NZ587589A (en) * 2008-02-15 2012-10-26 Rigel Pharmaceuticals Inc Pyrimidine-2-amine compounds and their use as inhibitors of jak kinases
ES2399319T3 (en) * 2008-07-09 2013-03-27 Rigel Pharmaceuticals, Inc. Bicyclic heteroaryl substituted triazoles containing bridges useful as AXL inhibitors
ES2537480T3 (en) * 2008-07-09 2015-06-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
US8546433B2 (en) * 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001009106A1 (en) * 1999-08-02 2001-02-08 Smithkline Beecham P.L.C. Diamino-1,2,4-triazole-carboxylic and derivatives as gsk-3 inhibitors
WO2002057240A1 (en) * 2000-12-22 2002-07-25 Ortho Mc Neil Pharmaceutical, Inc. Substituted triazole diamine derivatives as kinase inhibitors
WO2002094814A1 (en) * 2001-05-08 2002-11-28 Schering Aktiengesellschaft 3,5-diamino-1,2,4-triazoles as kinase inhibitors
WO2004046120A2 (en) * 2002-11-15 2004-06-03 Vertex Pharmaceuticals Incorporated Diaminotriazoles useful as inhibitors of protein kinases

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; FAHMY, SHERIEF MAHMOUD ET AL: "Reactions with heterocyclic amidines. X: Synthesis of some new azolylthioureas derivatives", XP002474695, retrieved from STN Database accession no. 1984:68229 *
IRAQI JOURNAL OF SCIENCE , 23(1), 28-41 CODEN: IRJSD5; ISSN: 0067-2904, 1982 *

Cited By (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9079898B2 (en) 2008-07-09 2015-07-14 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
US8349838B2 (en) 2008-07-09 2013-01-08 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
US9173882B2 (en) 2008-07-09 2015-11-03 Rigel Pharmaceuticals, Inc. Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors
CN102281875A (en) * 2009-01-16 2011-12-14 里格尔药品股份有限公司 Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
WO2010083465A1 (en) 2009-01-16 2010-07-22 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
US8546433B2 (en) 2009-01-16 2013-10-01 Rigel Pharmaceuticals, Inc. Axl inhibitors for use in combination therapy for preventing, treating or managing metastatic cancer
CN102281875B (en) * 2009-01-16 2017-09-22 里格尔药品股份有限公司 The combination treatment of the use AXL inhibitor of prevention, treatment or reply metastatic carcinoma
KR20140117439A (en) 2012-01-31 2014-10-07 다이이찌 산쿄 가부시키가이샤 Pyridone derivative
US8933103B2 (en) 2012-01-31 2015-01-13 Daiichi Sankyo Company, Limited Pyridone derivatives
WO2013115280A1 (en) 2012-01-31 2013-08-08 第一三共株式会社 Pyridone derivative
EP3184121A2 (en) 2012-07-25 2017-06-28 Salk Institute For Biological Studies Lipid membranes with exposed phosphatidylserine as tam ligands, use for treating autoimmune diseases
WO2015077375A1 (en) 2013-11-20 2015-05-28 Signalchem Lifesciences Corp. Quinazoline derivatives as tam family kinase inhibitors
WO2015081257A2 (en) 2013-11-27 2015-06-04 Signalchem Lifesciences Corporation Aminopyridine derivatives as tam family kinase inhibitors
EP3868757A1 (en) 2014-07-07 2021-08-25 Daiichi Sankyo Company, Limited Pyridone derivative having tetrahydropyranylmethyl group
KR20170029495A (en) 2014-07-07 2017-03-15 다이이찌 산쿄 가부시키가이샤 Pyridone derivative having tetrahydropyranyl methyl group
US10442797B2 (en) 2014-07-07 2019-10-15 Daiichi Sankyo Company, Limited Pyridone derivatives having tetrahydropyranylmethyl groups
US11208403B2 (en) 2014-07-07 2021-12-28 Daiichi Sankyo Company, Limited Pyridone derivatives having tetrahydropyranylmethyl groups
US11534440B2 (en) 2015-05-29 2022-12-27 Bergenbio Asa Combination therapy with Axl inhibitor and immune checkpoint modulator or oncolytic virus
EP3804723A1 (en) 2015-05-29 2021-04-14 BerGenBio ASA Combination therapy
WO2017146236A1 (en) 2016-02-26 2017-08-31 小野薬品工業株式会社 Drug for cancer therapy characterized by administering combination between axl inhibitor and immune checkpoint inhibitor
WO2019039525A1 (en) 2017-08-23 2019-02-28 小野薬品工業株式会社 Pharmaceutical for cancer treatment including ax1 inhibitor as an effective component
WO2019074116A1 (en) 2017-10-13 2019-04-18 小野薬品工業株式会社 Therapeutic agent for solid cancers, which contains axl inhibitor as active ingredient
WO2020188015A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2021032883A1 (en) 2019-08-22 2021-02-25 Bergenbio Asa Combination therapy of a patient subgroup
WO2021089791A1 (en) 2019-11-08 2021-05-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
WO2021191197A1 (en) 2020-03-23 2021-09-30 Bergenbio Asa Combination therapy comprising an axl inhibitor
WO2021204713A1 (en) 2020-04-08 2021-10-14 Bergenbio Asa Axl inhibitors for antiviral therapy
WO2021214492A1 (en) 2020-04-24 2021-10-28 Bergenbio Asa Method of selecting patients for treatment with a combination of an axl inhibitor and an immune checkpoint modulator
WO2022200463A1 (en) 2021-03-23 2022-09-29 Bergenbio Asa Combination of axl antibodies and ace inhibitors in the treatment of fibrosis
WO2023247769A1 (en) 2022-06-24 2023-12-28 Bergenbio Asa Dosage regimen for axl inhibitor
WO2024051667A1 (en) * 2022-09-05 2024-03-14 南京正大天晴制药有限公司 Substituted triazole compound having axl inhibitory activity

Also Published As

Publication number Publication date
EP2484679A3 (en) 2012-10-10
JP5567837B2 (en) 2014-08-06
US9650391B2 (en) 2017-05-16
ES2672172T3 (en) 2018-06-12
EP2074115B1 (en) 2018-03-07
US20130090330A1 (en) 2013-04-11
HK1174631A1 (en) 2013-06-14
CN101622248A (en) 2010-01-06
CA2710046C (en) 2016-02-09
JP2010514809A (en) 2010-05-06
AU2007342005A1 (en) 2008-07-10
US8796259B2 (en) 2014-08-05
US20080182862A1 (en) 2008-07-31
EP2484679A2 (en) 2012-08-08
JP5890445B2 (en) 2016-03-22
JP2014111641A (en) 2014-06-19
CN101622248B (en) 2013-04-17
EP2074115A1 (en) 2009-07-01
EP2484679B1 (en) 2016-09-28
CA2710046A1 (en) 2008-07-10
ES2607065T3 (en) 2017-03-29

Similar Documents

Publication Publication Date Title
EP2484679B1 (en) N3-heteroaryl substituted triazoles and n5-heteroaryl substitued triazoles useful as axl inhibitors
EP2205592B1 (en) Polycyclic aryl substituted triazoles and polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2078010B1 (en) Polycyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2476679B1 (en) Substituted triazoles useful as AXL inhibitors
EP2114954B1 (en) Bicyclic aryl and bicyclic heteroaryl substituted triazoles useful as axl inhibitors
EP2114955B1 (en) Bridged bicyclic aryl and bridged bicyclic heteroaryl substituted triazoles useful as axl inhibitors
WO2008045978A1 (en) Pinane-substituted pyrimidinediamine derivatives useful as axl inhibitors
JP2010514809A5 (en)
AU2014200825B2 (en) N3-heteroaryl substituted triazoles and N5-heteroaryl substituted triazoles useful as Axl inhibitors
AU2014200824B2 (en) Substituted triazoles useful as Axl inhibitors

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780048909.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07866122

Country of ref document: EP

Kind code of ref document: A1

WWE Wipo information: entry into national phase

Ref document number: 2007866122

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2009544313

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007342005

Country of ref document: AU

Ref document number: 4864/DELNP/2009

Country of ref document: IN

ENP Entry into the national phase

Ref document number: 2007342005

Country of ref document: AU

Date of ref document: 20071228

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2710046

Country of ref document: CA